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INTRODUCTION 
In recent years, colonic health has been increasingly linked to maintain the well being and to 
reduce the risk of various diseases due to changes in diet and lifestyle. At the forefront it has been 
considered the functional foods, such as ‘‘prebiotics’’ and ‘‘probiotics,’’ dietary fibers, and other 
dietary components that target the colon and affect its environment, enhancing short chain fatty 
acids (SCFAs) production, and the conversion of bioactive substances such as phytoestrogens to 
promote or retard their absorption from the colon. This is far from the classic view that the role of 
the human colon is to absorb salt and water and to provide a mechanism of the disposal of waste 
products. The development of the intestinal ecosystem is crucial for gastrointestinal functions and 
body health. The intestinal ecosystem essentially comprises the epithelium, immune cells, enteric 
neurons, intestinal microflora, and nutrients. The coordinate interplay between all these components 
has been the object of intensive research efforts to design new strategies for many intestinal and 
extraintestinal diseases. In the gut live about 10
14
 bacterial cells, including up 2000 species 
dominated by anaerobic bacteria . 
Intestinal microflora benefit from constant nutrient flow, stable temperature and niches for 
various metabolic requirements provided by the intestinal environment. Likewise, the host benefits 
from the ability of the intestinal microflora to synthesize vitamin K, exert trophic effects on 
intestinal epithelial cells, saving energy from unabsorbed food, producing SCFAs, inhibiting the 
growth of pathogens, sustaining intestinal barrier integrity, maintaining mucosal immune 
homeostasis, and participating to the xenobiotic metabolism system [1,2]. 
Probiotics are live microbes able to modulate the intestinal microflora and enhance body 
heath. At birth, the gastrointestinal tract is a sterile environment. Within a few months after birth, a 
relatively stable microbial population is established [2,3]. This abundant, diverse and dynamic 
microflora normally lives in a complex, synbiotic relationship with the eukaryotic cells of the 
intestinal mucosa. Firmicutes are the most representative bacteria among phyla found in the human 
colon, and include Clostridiales and lactic bacteria (LAB), and Bacteroidetes [4]. However, several 
factors, such as age, diet, hygienic habit, infection and antibiotic therapy can modify microbiota 
composition. Recently, gut microbiota has been considered as a regulator of energy homeostasis 
and ectopic fat deposition, evidencing its implications for metabolic diseases [5,6]. In particular, 
obese people were shown to have lower Bacteroidetes and more Firmicutes in their distal gut 
compared to lean control and this alteration was abolished after diet-induced weight loss [7]. 
Moreover, high–fat fed animals present gut microbiome with increased transport proteins and 
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enzymes involved in import and fermentation of simple sugars and host glycans. In return, these 
substances can be more utilized for hepatic lipogenesis increasing the capability of hosts to harvest 
energy from diet [8]. Moreover, in healthy subject the microbiota suppresses expression of fasting-
induced adipocyte factor (Fiaf, also known as angiopoietin-like protein 4), a lipoprotein lipase 
inhibitor (LPL), produced not only by the intestine but also by liver and adipose tissue, and 
therefore is an important regulator of peripheral fat storage [9]. So it has become clear that 
overnutrition alters the immune system and functions. Chronic overnutrition leads to accumulation 
of fat in adipose tissue, in which subsequently immune cells infiltrate. This gives rise to a mild and 
sustained increase in inflammatory mediators in the systemic circulation, for example, the acute-
phase response marker C-reactive protein (CRP) and its major regulators interleukin IL-6 and tumor 
necrosis factor TNF- [10]. In addition, repeated exposure to increased concentrations of 
proinflammatory cytokines in the postprandial period after high-fat meals or rapidly digestible 
carbohydrates has recently postulated to be involved in the development of low-grade inflammation 
in susceptible persons [11,12]. Chronic low-grade inflammation is associated with an increased risk 
of, among others, insulin resistance (IR), diabetes type 2, and atherosclerosis [13]. For this reason, 
strategies to suppress low-grade inflammation as a preventive measure for these chronic diseases 
are intensively investigate. 
Food and food-derived substances receive increasing attention as potential factors that can 
modulate cells or cell functions that play a role in immunological processes. Dietary fiber intake has 
been shown in prospective studies to be inversely related to plasma concentrations of CRP [14,15] 
and the proinflammatory cytokine IL-6 [16]. In a human study on healthy elderly, 
immunomodulatory effects of the prebiotic B-galactooligosaccharides (B-GOSs) were demonstrated 
[17]. B-GOS significantly increased the production of the anti-inflammatory cytokine IL-10 and 
significantly reduced production of IL-6, IL-1, and TNF-[17]. Another intervention study on 
fructooligosaccharides in older persons resulted in decreased IL-6 mRNA expression in peripheral 
blood monocytes [18]. In healthy young individuals, an evening meal rich in nondigestible 
carbohydrate prevented the glucose-induced postprandial rise in plasma IL-6 and TNF- 
concentrations [19]. One of the proposed factors that could explain these effects is the increase in 
short-chain fatty acids acetate, propionate, and butyrate, which are produced by the colonic 
microbiota when dietary fiber are fermented [20,21]. SCFAs are rapidly absorbed from the colonic 
lumen and partly metabolized by colonic epithelial cells. A fraction also enters the portal and 
peripheral circulation. In six nonfasted sudden death victims, portal concentrations of acetate, 
propionate, and butyrate lay between 108 and 404 mmol/l, 17 and 194 mmol/l, and 14 and 64 
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mmol/l, respectively and peripheral concentrations between 19 and 146 mmol/l, 1 and 13 mmol/l, 
and 1–12 mmol/l, respectively [22]. SCFAs, and especially butyrate, have been for long time, at the 
center of interest for modulating inflammatory response in the colonic epithelial cells and results of 
these studies indicate beneficial effects. Therefore, it seems worthwhile to explore whether SCFAs 
could also affect systemic inflammation. This is especially interesting because, as discussed below, 
recent studies suggest that obesity induced inflammation is partly antigen-dependent. Information 
about, for instance, the capacity of SCFAs to reduce activation of T cells by monocyte-presented 
antigens is, thus, highly relevant in this context. Butyrate irrigation (enema) has also been suggested 
in the treatment of colitis. More human studies are now needed, especially, given the diverse nature 
of carbohydrate substrates and the SCFA patterns resulting from their fermentation. Short-term and 
long-term human studies are particularly required on SCFAs in relation to markers of cancer risk. 
Taken togrther these considerations, probiotics and SCFAs have been proposed in the treatment and 
prevention of many conditions. The mechanisms of these effects are multiple, the vast majority are 
related to the regulation of immune system. Given the close anatomical and functional correlation 
between the bowel and the liver, and the immunoregulatory effects elicited by these compounds, the 
aim of this study is evaluate the effects of probiotics and short chain fatty acids in some 
gastrointestinal disease like non-alcoholic fatty liver disease (NAFLD) and ulcerative colitis (UC), 
focusing their molecular and biochemical mechanisms and highlighting their efficacy as emerging 
therapeutic strategy to treat or prevent these conditions.  
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CHAPTER 1: NALFD 
 
Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of diseases ranging from 
simple steatosis to nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular 
carcinoma [23]. The majority of patients with NAFLD are overweight or even morbidly obese and 
often shows insulin resistance [24,25]. The proportion of patients with NAFLD who develops 
NASH is still not entirely clear but might range from 10%-20%. This is relevant because 
inflammation and/or fibrosis determine the long-term prognosis of this disease, whereas steatosis 
per se might not adversely affect outcome [26,27]. Most studies indicate that 1%-3% of the Western 
population might have NASH. 
The natural history of NAFLD is still poorly understood, and in particular, it is not known 
why any patients progress toward inflammation, fibrosis, and cirrhosis and why others do not. One 
of the burning questions in NAFLD remains the identification of those factors that drive forces 
toward a more progressive, inflammatory disease phenotype. Day and colleagues presented more 
than a decade ago the so-called ‘‘two hit’’ model, suggesting that after a first hit (i.e., hepatic 
steatosis) another hit (e.g., gut-derived endotoxin) is needed to develop NASH [28]. Because simple 
hepatic steatosis is a benign process in the majority of patients, NASH might be a separate disease 
with a different pathogenesis. Later, Tilg and Moschen propose a new model suggesting that many 
hits may act in parallel, finally resulting in liver inflammation and that especially gut-derived and 
adipose tissue–derived factors may play a central role in steatosis progression. Inflammation may 
also precede steatosis in NASH, as inflammatory events may lead to subsequent steatosis. 
Furthermore, the authors highlight the potential importance of endoplasmic reticulum (ER) stress in 
various aspects of this disease [29]. 
The majority of patients with NAFLD is overweight or obese, and there is convincing 
evidence that NAFLD is a component of the metabolic syndrome [30]. NAFLD is currently the 
most common liver disease worldwide, both in adults and children. NAFLD is characterized by 
aberrant lipid storage in hepatocytes (hepatic steatosis), and inflammatory progression to non 
alcoholic steatohepatitis (NASH). Even if pathologically, several patterns of disease exist which 
resemble alcoholic liver disease, the sine qua non condition for NAFLD recognition is hepatic 
macrovesicular steatosis or fatty liver. Simple steatosis remains a benign process in most affected 
persons and seem to be well tolerated [26,31]. However, some patients develop superimposed 
necroinflammatory activity with a nonspecific inflammatory infiltrate, hepatocyte ballooning with 
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Mallory’s hyaline which are the driving force for the development of fibrosis, observed in 
nonalcoholic steatohepatitis (NASH) [32]. Likely a minority of these patients develops cirrhosis, 
which may become complicated by hepatocellular carcinoma.  
 
Beginning of hepatic steatosis 
A fatty liver is the result of the accumulation of various lipids [33]. Several mechanisms may 
lead to a fatty liver: (1) increased free fatty acids (FFAs) supply due to increased lipolysis from both 
visceral/subcutaneous adipose tissue and/or increased intake of dietary fat; (2) decreased free fatty 
oxidation; (3) increased de novo hepatic lipogenesis (DNL) and (4) decreased hepatic very low 
density lipoprotein–triglyceride secretion [34]. Free fatty acid delivery to the liver accounts for 
almost two-thirds of its lipid accumulation [35]. Elevated peripheral fatty acids and DNL therefore 
predominantly contribute to the accumulation of hepatic fat in NAFLD. Besides the well-
established lipogenesis-controlling factors such as sterol regulatory element- binding protein 
(SREBP) or carbohydrate response element-binding protein (ChREBP), X-box binding protein 1 
(XBP1), known as a key regulator of the unfolded protein response (UPR) secondary to ER stress, 
is a only recently characterized regulator of hepatic lipogenesis [36]. Triglycerides are the main 
lipids stored in the liver of patients with NAFLD. Although large epidemiological studies suggest 
triglyceride-mediated pathways might negatively affect disease [37], recent evidence indicates that 
trigylcerides might exert protective functions. Diacylglycerol acyltransferase 1 and 2 (DGAT1/2) 
catalyze the final step in triglyceride synthesis. In a model of diet induced obesity, mice with 
overexpression of adipocyte and macrophage DGAT1 are protected from systemic inflammation 
and insulin resistance by the prevention of macrophage activation and their accumulation in white 
adipose tissue [38]. Inhibition of triglyceride synthesis via DGAT2 antisense oligonucleotides 
improves liver steatosis but worsens liver damage, also suggesting that accumulation of liver 
triglycerides could be a protective mechanism [39]. 
Hepatic steatosis (i.e., triglyceride accumulation) is dissociated from insulin resistance in 
patients with familial hypobetalipoproteinemia, providing further evidence that increased 
intrahepatic triglyceride content might be more a marker rather than a cause of insulin resistance. In 
summary, triglyceride synthesis seems to be an adaptive, beneficial response in situations where 
hepatocytes are exposed to potentially toxic triglyceride metabolites. Thus, evidence is increasing 
that accumulation of fat in the liver in many instances cannot be regarded as a pathology or disease, 
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but rather as a physiologic response to increased caloric consumption [40]. Free fatty acids and 
cholesterol, especially when accumulated in mitochondria, are considered the ‘‘aggressive’’ lipids 
leading to TNF-α mediated liver damage and reactive oxygen species (ROS) [41,42]. These lipids 
could also be present in a nonsteatotic liver and act as early ‘‘inflammatory’’ hits leading to the 
wide spectrum of NAFLD pathologies. The concept of lipotoxicity and involved lipid species has 
been introduced and discussed in several excellent review articles [43,44]. 
 
Inflammation Preceding Steatosis 
Simple hepatic steatosis, which is benign and nonprogressive in the majority of patients, and 
NASH may reflect different disease entities. Inflammation results in a stress response of 
hepatocytes, may lead to lipid accumulation, and therefore could precede steatosis in NASH. 
Patients with NASH may present without any or much steatosis, suggesting that inflammation could 
take place first [23]. Anti-TNF antibody treatment and metformin, an antidiabetic drug that inhibits 
hepatic TNF-α expression, improve steatosis in ob/ob mice [45,46]. Other proinflammatory 
mediators might also contribute to the development of steatosis because in some studies hepatic 
steatosis was not dependent on TNF-α [47]. In patients with severe alcoholic hepatitis, treatment 
with infliximab, an anti-TNF antibody, primarily improves hepatic steatosis [48]. Loss of Kupffer 
cells also leads to hepatic steatosis probably via decreased interleukin-10 (IL-10) release from 
Kupffer cells [49]. Other cell types might also promote hepatic steatosis because obesity leads to the 
hepatic recruitment of a myeloid cell population that further promotes hepatic lipid storage [50]. In 
all these situations, hepatic steatosis may be considered as ‘‘bystander phenomenon’’ subsequent to 
inflammatory attacks. Very diverse processes including toxic lipids, nutrients, and other gut-derived 
and adipose-derived signals may represent such inflammatory insults. 
 
Key features of NAFLD: insulin resistance and inflammation 
Insulin resistance (IR) plays a crucial pathophysiological role in the development and 
progression of NAFLD. It is increasingly recognized that free fatty acids and soluble mediators, 
synthesized from immune cells and adipose tissue, are crucially involved in regulating insulin 
action and NAFLD occurrence [51,52]. The central role of IR in liver disease is further suggested 
by evidence that it is present also in non-obese, non-diabetic subjects with NAFLD [53]. Subjects 
with NAFLD and IR, present an impairment in muscle glucose uptake, an alteration in suppression 
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of hepatic endogenous glucose production induced by insulin [53,54], and a high lipolytic effect in 
adipose tissue resulting in an increased FFAs release [55]. The importance of visceral fat in the 
pathogenesis of hepatic IR and steatosis has been widely demonstrated in preclinical and clinical 
studies [56]. In particular, in an animal model of inherited leptin resistance using leptin-receptor-
deficient Zucker (fa/fa) rat, the surgical resection of intra-abdominal fat depots reverses both 
hepatic IR and steatosis [57]. In humans, a clear relationship exists between hepatic IR and visceral 
fat leading to altered adipokine production and increased FFAs [58,59]. The enlargement of adipose 
tissue and in particular visceral fat has been associated with tissue inflammation characterized by a 
decreased release of insulin-sensitizing and anti-inflammatory cytokines and increased expression 
of pro-inflammatory molecules, which modify adipokine secretion [59]. Subjects with NAFLD 
exhibit decreased adiponectin levels [60], which are correlated negatively with hepatic triglyceride 
(TG) content. Interestingly, although the three-dimensional structure of adiponectin closely 
resembles that of TNF-α, these two proteins have completely opposite effects [61]. Both in vivo and 
in vitro experiments demonstrated that the production and function of adiponectin and TNF-α are 
inversely correlated in their target tissues [62]. Administration of adiponectin into mice has been 
shown to produce beneficial effects on lipid metabolism, such as enhancing lipid clearance from 
plasma and increasing fatty acid β oxidation in muscle, whereas gluconeogenesis and de novo 
lipogenesis are decreased in the liver [63]. It has been demonstrated that the insulin-sensitizing 
effect of adiponectin is mediated by an increase in fatty-acid oxidation through sequential activation 
of AMP kinase (AMPK), p38 mitogen-activated protein kinase (p38 MAPK) and peroxisome 
proliferator-activated receptors  (PPAR- [64]. Other adipokines, such as leptin, visfatin and 
resistin, have also been reported to be involved in hepatic TG accumulation and inflammation. 
However, the role of these factors and their interplay is still to be elucidated [59]. It is well known 
that steatosis may interfere with sinusoid microcirculation and hepatocellular clearance of microbial 
and host-derived danger signals, enhancing responsiveness of Kupffer cells, which critically 
contribute to progression of NAFLD [65]. Altered lipid homeostasis in NAFLD negatively affects 
Toll-like receptor 4 (TLR4) complex assembly and sorting, leading alternative signalling pathways 
activation, such as NF-kB/AP1 (Nuclear factor-kB/ Activator protein 1), interferon regulatory factor 
3 and promoting differential gene transcription. These differential pathways were similar not only in 
Kupffer cells and hepatic stellate cells, but also in other hepatic non-immune cell populations, 
including hepatocytes, biliary epithelial and endothelial cells [66,67]. Additional factors appear to 
interact with adiponectin to regulate hepatic triglyceride content. Among these, PPARs, belonging 
to the nuclear receptor superfamily, impact on multiple processes involved in lipid trafficking and 
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metabolism, and fuel partitioning [68]. In particular PPAR-regulates mitochondrial and 
peroxisomal fatty acid -oxidation pathways modulating many genes encoding enzymes involved in 
these processes (i.e., acyl-CoA synthetase, carnitine palmitoyl transferase I, and very long-chain 
acyl-CoA dehydrogenase). Loss or reduction of PPAR-α expression, in KO mice or in animal fed a 
methionine- choline deficient diet (MCD) or a high fat diet (HFD), results in hepatic steatosis 
[69,70]. In nutritional NAFLD models the administration of a potent PPAR agonist or probiotics 
results in an improvement of hepatic steatosis. These findings suggest that under conditions of 
increased hepatic fatty acid influx or decreased hepatic fatty acid efflux, PPAR-α activation 
prevents the accumulation of TG by increasing the rate of fatty acid catabolism [70,71].  
A growing body of literature implicate PPARs in the pathogenesis and in the treatment of 
NAFLD, linking PPAR- and PPAR- to NAFLD/NASH [72]. In fact, PPAR-γ are expressed at 
high levels in adipose tissue and play a role in increasing insulin sensitivity, as well as in promoting 
fatty acid uptake into adipocytes [73]. The net effect of PPAR- activation is the increase in 
adipocyte TG storage, reducing delivery of fatty acids to the liver. Moreover, PPAR-γ increases 
insulin sensitivity by up-regulating GLUT4, an insulin dependent glucose transporter in adipose 
tissue and striated muscle, and by inducing expression of the c-Cbl (named after Casitas B-lineage 
Lymphoma) associated protein, which is involved in insulin signalling [74]. Additionally, in mouse 
models of insulin resistance, PPAR-γ activation attenuated induction of suppressor of cytokine 
signalling 3 (SOCS3), which is involved in the development of insulin resistance [75]. PPAR-γ 
expression also might reduce hepatic inflammation by decreasing expression of proinflammatory 
cytokines, such as TNF-α [76]. Moreover, adiponectin is up-regulated by PPAR-γ, providing a 
connection between the two receptor isotypes [77]. The complexity and the chronology of 
pathophysiological events leading to development of NAFLD/NASH are not fully understood. The 
increased intrahepatic levels of FFAs provide a source of oxidative stress, which are in part 
responsible for the progression from steatosis to steatohepatitis and cirrhosis. FFAs may elicit 
hepatotoxicity by several mechanisms: direct cytotoxic effect [78], increased lysosomal 
permeability and TNF- synthesis by hepatocytes [79]. 
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Adipose Tissue-Derived Signals: The Adipose Tissue Factors Attack 
the Liver 
Adipose tissue has appeared in the last decade as a highly active endocrine and immune organ 
with the capability of producing various mediators including adipocytokines and cytokines both in 
health and disease. The balance/imbalance of an adipose tissue ‘‘mediator cocktail’’ may 
profoundly affect not only the functions in the adipose tissue but also in other important target 
organs such as liver (Figure 1.1). 
 
 
 
Fig. 1.1. The multiple parallel hits model. Lipotoxicity: (1) A liver loaded with lipids consisting primarily of trigylcerides might reflect a benign 
process because trigylcerides might exert mostly protective effects. Furthermore, hyperleptinemia leads to oxidation of hepatic lipids, thereby also 
protecting this organ from lipotoxicity. When the capacity of peripheral and central organs of detoxifying ‘‘aggressive lipids’’ fails, lipotoxic attack of 
the liver might begin. Inflammation may precede steatosis in NASH. Gut-derived signals: Many signals beyond endotoxin might affect hepatic 
steatosis and inflammation. Several pathways have been identified how the gut microbiota might influence host energy metabolism: (2) Absence of 
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the microbiota in germ-free mice correlates with increased activity of phosphorylated AMPK in the liver and the muscle (not shown). (3) Some of the 
breakdown products of polysaccharides are metabolized to SCFAs. SCFAs such as propionate and acetate are ligands for the G protein–coupled 
receptors Gpr41 and Gpr43. Shortage of SCFAs might allow the evolution of systemic inflammatory events. Such mechanisms elegantly combine 
diet, microbiota, and the epithelial cell as ‘‘nutrient sensor.’’ (4) The microbiota decreases epithelial expression of fasting-induced adipocyte factor 
(Fiaf), which functions as a circulating lipoprotein lipase (LPL) inhibitor and therefore is an important regulator of peripheral fat storage. (5) Several 
TLRs, such as TLR5 or TLR9, are not only able to affect microbiota but also to regulate metabolism, systemic inflammation, and insulin resistance, 
thus highlighting the role of the innate immune system in metabolic inflammation as observed in NASH. (6) Various nutrients such as trans fatty 
acids (TFAs), fructose or aryl hydrocarbon receptor (AhR) ligands such as 2,3,7,8-tetrachlorodibenzodioxin (TCDD) may directly lead to 
steatosis/liver inflammation. Adipose tissue–derived signals: Signals derived from the adipose tissue beyond toxic lipids might play a central role in 
NAFLD/NASH. (7) Here, adipocytokines such as adiponectin and leptin, certain proinflammatory cytokines such as TNF- or IL-6, and others (the 
death receptor Fas, PPAR-) are of key relevance. The cytokine/adipocytokine milieu might be critical because ob/ob-adiponectin tg mice, although 
becoming severely obese, are not insulin-resistant. This suggests that in the hierarchy of processes soluble mediators play the central role. Adipose-
derived mediators might indeed affect target organs such as the liver, because JNK1 adipose-deficient mice are protected from diet-induced obesity, 
and experiments have demonstrated that this effect is mediated mainly by IL-6 (a cytokine), which is of key importance in human obesity. 
Image from Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 
2010 Nov;52(5):1836-46. doi: 10.1002/hep.24001. 
 
Adiponectin: Prototypic Adipocytokine in Health and Disease 
Adiponectin is an anti-inflammatory adipocytokine that signals through two receptors [80,81]. 
Obesity is associated with hypoadiponectinemia, and adiponectin levels increase after weight loss 
[80]. Adiponectin induces extracellular Ca
2+
 influx by adiponectin receptor 1, which is necessary 
for activation of AMPK and Sirtuin 1 (Sirt1) [82]. Hepatocyte-specific deletion of Sirt1 leads not 
only to hepatic steatosis but also to ER stress and liver inflammation [83]. Genetically obese leptin- 
deficient ob/ob mice exhibit a reversal of the diabetic phenotype with normalization of glucose and 
insulin levels upon transgenic overexpression of the full-length isoform of adiponectin, despite 
retaining the obese phenotype [84]. Therefore, also in humans, a sufficient production of 
adiponectin might play a central role in susteining homeostasis and establishing a balance when 
local and systemic/ liver inflammation is compromised [85]. 
 
IL-6 and TNF-: Key (Adipo)cytokines 
Expression of IL-6 and TNF-α, two important proinflammatory cytokines, is profoundly 
increased in human fat cells from obese subjects and patients with insulin resistance [86]. IL-6 
serum levels are elevated in obese patients and weight loss results in their reduction [87,88]. 
Enhanced TNF-α expression in adipose tissue of obese subjects decreases following weight loss 
[89]. Insulin resistance is an important feature of NAFLD and it is caused by several factors, 
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including soluble mediators derived from immune cells and/or adipose tissue [90]. Insulin 
resistance may augment inflammation in NASH because patients with type 2 diabetes mellitus are 
often worsen in terms of histopathological changes such as ballooning, apoptosis, and lobular 
and/or portal inflammation [23]. Serine phosphorylation of insulin receptor substrate by 
inflammatory signal transducers such as c-jun N-terminal protein kinase 1 (JNK1) or inhibitor of 
nuclear factor-kB kinase-β (IKK β) is considered one of the key aspects that impairs insulin 
signalling (Figure 1.2). Sabio et al. reported that JNK1 signaling specifically in adipose tissue 
consequent to a high-fat diet causes hyperinsulinemia, hepatic steatosis, and hepatic insulin 
resistance [91]. Importantly, this distal effect of adipose tissue on the liver was mediated via 
increased JNK1-dependent IL-6 secretion from adipocytes, proving that adipose tissue–derived IL-6 
regulates distal metabolic effects in the liver. In this and in other models, a high-fat diet, that can be 
considered ‘‘an inflammatory diet’’, is a prerequisite and a key player in the etiophatogenesis 
including hepatic steatosis and other related pathologies. 
Moschen et al., recently demonstrated that such a mechanism as suggested by Sabio et al. 
might also be operative in human obesity [92]. In this study, IL-6 expression has been more than 
100-fold higher in adipose tissue (subcutaneous and visceral) compared to its liver expression, 
suggesting that in severe obesity, the adipose tissue is indeed the major source of IL-6. Weight loss 
resulted in a dramatic decrease of IL-6 and TNF-α expression with subsequent reduced expression 
of SOCS3 expression and improved insulin sensitivity, evidencing the hepatic consequences of 
adipose tissue alterations. So, the liver can be considered a key target organ for adipose tissue–
derived IL-6 and TNF-α, because continuous IL-6/ TNF-α exposure affects hepatic insulin 
resistance, e.g., via up-regulation of SOCS3 [93]. 
Interestinly, enhanced expression of proinflammatory cytokines in adipose tissue was 
observed, although liver inflammation was still absent, suggesting that adipose tissue inflammation 
could precede liver inflammation [92]. Many human studies suggest that the amount of visceral fat 
directly correlates with degree of hepatic steatosis and inflammation. Hepatic inflammation and 
fibrosis correlate with the amount of visceral fat [94]. Abdominal fat has been shown to be a major 
factor leading to increased serum alanine aminotransferase levels, which might reflect more 
advanced disease such as NASH [95]. This important clinical study further supports the important 
association between adipose tissue and liver disease. Besides certain adipocytokines/immune 
mediators, the cellular infiltrate in the adipose tissue must be also considered. In fact, the reduction 
of adipose macrophages (CD11c+ cells) improves insulin sensitivity and decreases inflammation 
[96]. Importantly, adiponectin and PPAR-γ promote adipose tissue macrophage polarization toward 
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an alternative/anti-inflammatory phenotype [97,98]. Other studies [99] present evidence that 
adipose tissue inflammation is a common event in morbid obesity, and this tissue could be 
considered the major cytokine source in obesity. 
 
 
Fig. 1.2. Regulation of insulin resistance and involved pathways. Several inflammatory pathways involved in the regulation of IR have been 
identified. (i) adiponectin, an important insulin-sensitizing adipocytokine that signals via adiponectin receptors. (ii) TNF- was among the first 
mediators to be defined as an important factor linking inflammation, obesity and IR. Engagement of TNFR by TNF-induces inhibitory 
phosphorylation of serine residues on IRS1 and activates IKK and NF-kB pathways and JNK pathways, two major intracellular regulators of IR. (iii) 
IL-6 is another pro-inflammatory cytokine involved in IR development. This cytokine activates SOCS1 and SOCS3 that initiate ubiquitin-mediated 
degradation of IRS. (iv) IL-1 has been shown to reduce IRS1 expression via ERK1/2 and can also activate the IKK and NF-kB pathway. (v) 
Oxidative stress also regulates inflammation-associated IR.  
Abbreviations: AP-1, activator protein 1; ERK, extracellular receptor kinase; IKK, inhibitor of kappa B kinase ; IL, interleukin; insulinR, insulin 
receptor; IR, insulin resistance; JNK, c-Jun N-terminal kinase; NF-kB, nuclear factor kappa B; PPAR, peroxisome proliferator activated receptor; 
RIP, receptor interacting protein; ROS, reactive oxygen species; SOCS, suppressor-of-cytokine-signaling; STAT, signal transducer and activator of 
transcription; TNF, tumor necrosis factor-; TRADD, TNF receptor-1 associated death domain protein; TRAF2, TNF receptor-associated factor 2; 
Ub, ubiquitin mediated. Image from Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol 
Metab. 2008 Dec;19(10):371-9. doi: 10.1016/j.tem.2008.08.005. Epub 2008 Oct 17. Review. 
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Liver-gut axis 
Due to its anatomical links to the gut, the liver is the major filter organ and a first line defence 
for the host. The liver is constantly exposed to gut-derived bacterial fractions or metabolites, and it 
is an important site for bacterial phagocytosis and clearance, as it hosts more then 80% of the 
body’s macrophages. In particular, Kupffer cells, the resident macrophages of the liver, effectively 
limit the amount of endotoxin and phagocyte bacteria carried through the portal vein, playing a 
pivotal role for the protection in systemic bacterial infection [100]. Toll-like receptors (TLRs) 
recognise pathogen-associated molecular patterns (PAMPs) to detect the presence of pathogens. 
Even low amounts of PAMPs such as lipopolysaccharide (LPS), lipopeptides, unmethylated DNA, 
and double-stranded RNA evoke intense inflammatory reactions. Considering that gut hosts more 
than 99% of the bacterial mass in the body, intestinal microbiota is the principal source of bacterial-
derived PAMPs in health and disease. In addition to their role in innate immunity, TLRs also play a 
major role in the regulation of inflammation. Several TRL endogenous ligands, termed damage-
associated molecular patterns (DAMPs), act as signal of the presence of necrosis and subsequently 
trigger inflammation [66,101]. The healthy liver contains low mRNA levels of TLRs (TLR1, TLR2, 
TLR4, TLR6, TLR7, TLR8, TLR9, TLR10) and signalling molecules (i.e. CD14 cluster of 
differentiation 14, MD-2 or Lymphocyte antigen 96 and MyD88 myeloid differentiation primary 
response 88) in comparison to other organs, suggesting that the low expression of TLR signalling 
molecules may contribute to the high tolerance of the liver to TLR ligands deriving from the 
intestinal microbiota [67,102]. In chronic liver diseases, for instance cirrhosis, structural changes of 
the intestinal mucosa (e.g. loss of tight junctions TJs, widening of intercellular spaces, vascular 
congestion, and defects in the mucosal immune system) promote the loss of barrier function and 
allow translocation of bacteria and bacterial PAMPs [102]. Many proinflammatory effects of 
PAMPs are a consequence of TLR-induced secretion of inflammatory mediators, such as TNF- 
and interleukin (IL)-1 as demonstrated both in vitro and in vivo [103]. 
Gut-liver axis suggests a tight linkage between the health of intestinal tract and that of liver. 
In fact, there is growing evidence of how gut microflora alteration or dysbiosis may affect liver 
pathology. Altered intestinal bacterial flora as a result of stress, or wrong nutritional habits could 
play an important role in the pathogenesis or the development of NAFLD. On the basis that a shift 
in the gut microbiota enteric profile, due to bacterial overgrowth, may contribute to the 
pathogenesis of NAFLD, treatments able to manipulate enteric flora, such as probiotics or 
prebiotics, were proposed. Normally, intestinal anaerobic bacteria outnumber aerobic bacteria, the 
latter are responsible of bacterial translocation. Thus, anaerobic bacteria, suppressing the 
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colonisation and growth of potentially invasive microbes, exert an important role in maintaining 
gastrointestinal health and in reducing the translocation of potentially dangerous microbes. 
Conversely, selective elimination of anaerobic bacteria promotes intestinal bacterial overgrowth and 
translocation. Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, enterococci 
and streptococci not only represent the species that are most proficient at translocation, but also 
cause the large majority of infections in patients with cirrhosis [104]. 
 
Endotoxin and Its Role in Obesity 
Endotoxin (lipopolysaccharide -LPS), a key constituent of many bacteria present in our 
microbiota, plays a central role in innate immune responses and has been considered the so-called 
‘‘second hit’’ in previous NASH models [28]. Manipulation at the gut surface, including dietary 
ingredients, may affect LPS metabolism and result in increased circulating plasma levels. It has 
been demonstrated that intake of a high-fat or a high-carbohydrate diet in humans over only 3 days 
leads to an increase in circulating LPS concentrations [105]. Endotoxemia, however, might not only 
lead to systemic inflammation but might also worsen obesity itself [106]. When endotoxemia was 
induced for 4 weeks in lean mice, liver and adipose tissue weight gain were increased similarly as 
after a high-fat diet. This weight gain was paralleled by hepatic insulin resistance, and could be 
prevented by antibiotic therapy. Patients with NAFLD demonstrate increased gut permeability, 
which importantly has been associated with the severity of liver steatosis but not with the degree of 
inflammation (NASH) [107]. This study therefore suggests that gut derived factors/signals such as 
endotoxin might also affect accumulation of hepatic fat. 
 
Intestinal Epithelium: Linking Nutrients to Metabolic Diseases 
To date it is be recognized that our microbiota might influence systemic immune responses. 
At least in part this effect might take place via the bacterial capacity to digest dietary fiber resulting 
in the production of short-chain fatty acids (SCFA). SCFAs have anti-inflammatory functions in 
various models of colitis and human ulcerative colitis probably via interaction with its receptor, the 
G protein–coupled receptor 43 (Gpr43) [108].  
Gpr43-/- mice show systemic inflammation in various tissues [109], similar to germ-free 
wild-type mice devoid of bacterial fermenting capacity and hence with almost absent SCFAs in the 
gut. Various other pathways (i.e., Fiaf; Gpr41) have been characterized interfering with 
21 
 
metabolism/adiposity, highlighting how the intestinal microbiota and its products might directly 
regulate host gene expression and affect systemic inflammation [110,111]. These pathways involve 
the intestinal epithelium as ‘‘sensor’’ of the microbiota, implicating a major role for the intestinal 
epithelium in determining systemic metabolic functions. Interference with our microbiota via 
probiotics or prebiotics or SCFAs might therefore be beneficial and improve systemic 
inflammation/metabolic function. So far, only a few animal studies have been performed [112,113]. 
 
Toll-Like Receptors and Role of Innate Immunity in Obesity-Related 
Inflammation 
Toll-like receptors (TLRs), also expressed on the gut epithelium, can respond to nutritional 
lipids such as free fatty acids and might thereby have a role in the pathogenesis of obesity-
associated inflammation/insulin resistance [114]. The recognition of fatty acids by TLR4 can induce 
the production of proinflammatory cytokines in macrophages and epithelial cells [115]. TLR-4–
deficient mice are protected from high-fat diet-induced inflammation and insulin resistance [116]. It 
is, however, not universally accepted that saturated free fatty acids are ligands for certain TLRs 
because it has been demonstrated that saturated fatty acids might not directly stimulate TLR-
dependent signalling [117]. Therefore, the in vivo effects observed in the above discussed study 
[115] could also be accounted by gut-derived endotoxin or by endotoxin contamination of the lipids 
employed. 
Other TLRs may also be involved in obesity-related inflammation. TLR9 promotes 
steatohepatitis because TLR9-deficient mice are protected from liver inflammation [118]. The 
importance of the gut as ‘‘metabolic organ’’ has been convincingly demonstrated by a recent report 
indicating that mice deficient in TLR5 develop all features of metabolic syndrome including 
hyperphagia, obesity, insulin resistance, pancreatic inflammation, and hepatic steatosis [119]. TLR5 
deficiency affected the composition of the gut microbiota and, remarkably, transfer of the 
microbiota from TLR5 -/- mice to healthy mice resulted in transfer of disease. There are two major 
implications of this work: (1) the innate immune system plays a critical role in the development of 
the metabolic syndrome and (2) transfer of the gut microbiota to wild-type germ-free mice results in 
several features of de novo disease (i.e., metabolic syndrome), again supporting a major role for our 
microbiota in metabolic inflammation. 
22 
 
Treatment for NAFLD/NASH 
Current therapies for NAFLD and NASH are focused on the various pathways or process 
thought to be central in the pathogenesis of this disease. Treatment regimens targeting insulin 
resistance, oxidative stress, diabetes, hyperlipidemia, obesity, and hepatic fibrosis all warrant 
critical appraisal. Multiple modalities include diet, exercise, surgical interventions, and finally 
pharmacotherapy require evaluation to determine the most effective treatment algorithms. Although 
one panacea has not been found and is unlikely to exist, a multimodality treatment regimen might 
prove effective (Figure 1.3). 
 
 
 
 
Fig. 1.3. Potential pathophysiologic effects of therapies that are under investigation. The development of hepatic steatosis and subsequent 
steatohepatitis is multifaceted. Several therapeutic modalities under investigation such as the TZDs (Thiazolidinediones), diet, and exercise, and 
possibly rimonabant, may have pleiotrophic effects in improving NAFLD. 
*Endocannabinoid receptors have been identified in multiple organs involved in energy homeostasis to include adipocytes, liver, and possibly skeletal 
muscle and the pancreas. Image from: Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitisGastroenterology. 2008 
May;134(6):1682-98. doi: 10.1053/j.gastro.2008.02.077. 
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CHAPTER 2: ULCERATIVE COLITIS 
 
Ulcerative colitis (UC) was first described in the mid-1800s, whereas Crohn’s disease (CD) 
was first reported later, in 1932, as “regional ileitis.” Because Crohn’s disease can involve the colon 
and shares clinical manifestations with ulcerative colitis, these entities have often been conflated 
and diagnosed as inflammatory bowel disease (IBD), although they are clearly distinct 
pathophysiological entities. Ulcerative colitis is the most common form of inflammatory bowel 
disease worldwide. In contrast to Crohn’s disease, ulcerative colitis is a disease of the mucosa that 
is less prone to complications and can be cured by means of colectomy, and in many patients, its 
course is mild [120]. The literature on the pathogenesis and treatment of so-called IBD has tended 
to focus on Crohn’s disease [121,122], and few articles expressly discuss ulcerative colitis 
[123,124]. Ulcerative colitis and Crohn’s disease are disorders of modern society, and their 
frequency in developed countries has been increasing since the mid-20th century. When IBD is 
identified in a new population, ulcerative colitis invariably precedes Crohn’s disease and has a 
higher incidence. Among children, however, ulcerative colitis is less prevalent than Crohn’s disease 
[125]. The highest incidence and prevalence of IBD are seen in the populations of Northern Europe 
and North America and the lowest in continental Asia, where ulcerative colitis is by far the most 
common form of inflammatory bowel disease [126]. A westernized environment and lifestyle is 
linked to the appearance of IBD, which is associated with smoking, diets high in fat and sugar, 
medication use, stress, and high socio-economic status [127]. IBD has also been associated with 
appendectomy [127]. Of these factors, only cigarette smoking and appendectomy are reproducibly 
linked to ulcerative colitis. 
 
Symptoms, Clinical Course, and Assessment of Disease Activity 
Bloody diarrhea with or without mucus is the hallmark of ulcerative colitis. The onset is 
typically gradual, often followed by periods of spontaneous remission and subsequent relapses. 
Active disease is manifested as mucosal inflammation commencing in the rectum (proctitis) and in 
some cases spreading to the rest of the colon (Fig. 2.1A). Although proctitis is frequently associated 
with fecal urgency and the passage of fresh blood, constipation may paradoxically occur.  
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Proctosigmoiditis, leftsided colitis, extensive colitis, or pancolitis (Fig. 2.1B) may lead to 
diarrhea, frequent evacuations of blood and mucus, urgency or tenesmus, abdominal pain, fever, 
malaise, and weight loss, depending on the extent and severity of the disease. The prognosis for 
patients with ulcerative colitis is generally good during the first decade after diagnosis, with a low 
rate of colectomy; over time, remission occurs in most patients [120]. Assessment of the clinical 
activity of ulcerative colitis helps the clinician choose, diagnostic tests and make therapeutic 
decisions. 
 
   A                                                                                      B 
                        
Fig. 2.1. Gross morphological appearance of typical UC specimens. A. Severe inflammation of the rectum, sigmoid, splenic flexure and part of the 
transverse colon, where it stops abruptly and transitions to normal mucosa; B. Severe pancolitis; Pictures taken from: Danese S, Fiocchi C. Ulcerative 
colitis. N Engl J Med. 2011 Nov 3;365(18):1713-25. Doi 10.1056/NEJMra1102942.Review. 
 
Diagnosis 
An accurate diagnosis of ulcerative colitis involves defining the extent and severity of 
inflammation, and this information provides the basis for selecting the most appropriate treatment 
and for predicting the patient’s prognosis. Both endoscopy and biopsy are required to determine 
specific histologic characteristics; radiologic and ultrasonographic examinations are not critical but 
may be useful [128]. All these investigations aid in differentiating ulcerative colitis from other 
conditions that have similar sympthoms. Colonoscopy shows a uniformly inflamed mucosa that 
starts at the anorectal verge and extends proximally, with an abrupt or a gradual transition from 
affected to normal mucosa. In mild ulcerative colitis, the mucosa has a granular, erythematous 
appearance, with friability and loss of the vascular pattern. In moderate disease, erosions or 
microulcerations are evident, whereas in severe ulcerative colitis, shallow ulcerations with 
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spontaneous bleeding are generally seen (Fig. 2.2A and 2.2B). Colonoscopy helps to differentiate 
ulcerative colitis from Crohn’s disease, which is typically characterized by rectal sparing, aphthous 
ulcers, skip lesions (areas of inflammation alternating with normal mucosa), a cobblestone pattern, 
and longitudinal, irregular ulcers. In patients with cycles of inflammation and healing and in those 
with chronic, unremitting inflammation, colonoscopy may reveal pseudopolyps or mucosal 
bridging. Although there is no clear evidence that surveillance prolongs survival [129], biopsy 
specimens should be taken from all colonic segments, regardless of whether they are inflamed, with 
a particular focus on irregular mucosa, polypoid lesions, and any raised, dysplasia-associated lesion 
or mass [130]. 
 
       A                                                                                  B 
                                     
Fig. 2.2. Endoscopic appearance of UC. A. Severe active colitis with ulcerations and spontaneous bleeding; B. Chronic active colitis. Pictures taken 
from: Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011 Nov 3;365(18):1713-25. Doi 10.1056/NEJMra1102942.Review. 
 
Histologic Evaluation 
In ulcerative colitis, inflammation is characteristically restricted to the mucosal layer, with 
infiltrates varying in density and composition during active disease or stages of remission (Fig. 
2.3A and 2.3B). Infiltrates consist primarily of lymphocytes, plasma cells, and granulocytes; the 
last are being particularly prominent during acute flare-ups and accumulate in crypt abscesses [131] 
(Fig. 2.3C). Other typical features include goblet- cell depletion, distorted crypt architecture, 
diminished crypt density, and ulcerations. However, epithelioid granulomas, which are typical of 
Crohn’s disease, are not present. Looking for epithelial dysplasia is critical, given the risk of cancer 
in patients with long-standing ulcerative colitis; however, dysplasia can occur at any stage without 
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indicating malignant transformation There are no exact criteria for the diagnosis of ulcerative 
colitis, but in most cases, the presence of two or three of the aforementioned histologic features will 
suffice [132]. The severity of inflammation on histologic examination and the severity of disease on 
endoscopic examination may not coincide; for instance, histological findings (Figure 2.3) may 
indicate severe disease even in a patient with endoscopically quiescent disease. 
 
 
A                                                   B                                                   C 
               
Fig. 2.3. Histologic appearance of typical UC mucosal tissue. A. Chronic active colitis with dense and diffuse inflammatory infiltrates; B. Chronic 
quiescent colitis with crypt distortion; C. Neutrophil accumulation in a crypt (crypt abscess) in severe colitis with massive leukocyte infiltration of the 
lamina propria. Pictures taken from: Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011 Nov 3;365(18):1713-25. Doi 
10.1056/NEJMra1102942.Review. 
 
Genetic Features 
The discovery that NOD2 (Nucleotide-binding oligomerization domain-containing protein 2) 
variants are associated with susceptibility to Crohn’s disease opened a new era in the study of the 
genetic basis of inflammatory bowel disease [133,134]. In studies of twins, there is stronger 
concordance with Crohn’s disease than with ulcerative colitis, and the identification of a large 
number of susceptibility loci for Crohn’s disease in early genomewide association studies suggested 
that genetic influences play a greater role in Crohn’s disease than in ulcerative colitis [135]. A 
meta-analysis of six such studies recently confirmed the presence of 47 loci associated with 
ulcerative colitis, of which 19 are specific for ulcerative colitis and 28 are shared with Crohn’s 
disease [136]. Several pathways potentially associated with ulcerative colitis were identified in the 
meta-analysis and in individual studies based on validated loci or chromosomal regions [137]. Risk 
loci for ECM1, HNF4A, CDH1, and LAMB1 implicate dysfunction of the epithelial barrier; an 
association with DAP suggests a link to apoptosis and autophagy; and associations with PRDM1, 
IRF5, and NKX2-3 suggest defects in transcriptional regulation. In addition, multiple genes in the 
interleukin-23 signaling pathway overlap in ulcerative colitis and Crohn’s disease (e.g., IL-23R, 
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JAK2, STAT3, IL-12B, and PTPN2). Several risk loci linked to other immune system–mediated 
diseases are associated with ulcerative colitis, particularly HLA-DR and genes involved in helper T-
cell types 1 and 17 (Th1 and Th17) differentiation, such as IL-10, IL-17R, IL-23R, and Interferon 
gamma (IFN-γ). Altogether, genetic studies indicate that both specific and non specific gene 
variants are associated with ulcerative colitis, and the two forms of inflammatory bowel disease 
share disease pathways. Ulcerative colitis appears to be as genetically heterogeneous as Crohn’s 
disease, but given the large number of implicated genes and the small additive effect of each, 
genetic screening is not currently indicated to assess the risk of ulcerative colitis. 
 
Microbiologic Features 
The gut immune system is generally tolerant of this microbial load, and a breakdown in 
tolerance is postulated to be central to the pathogenesis of IBD [138]. Although loss of tolerance to 
gut microbiota is demonstrable in animal models of IBD, there are only limited evidence for this 
finding in patients with Crohn’s disease and none in those with ulcerative colitis. It has also been 
postulated that alterations in the composition of the gut microbiota, defects in mucosal immunity, or 
the two factors combined could lead to ulcerative colitis; however, supportive evidences are sparse. 
A key issue is the characterization of the gut microbiota in the normal intestine and in the intestine 
in patients with IBD. This issue awaits answers from the Human Microbiome Project, which aims 
to define the composition of the intestinal microbiota in conditions of health and disease [139]. 
There is a consensus that the density of microbiota is greater in patients with ulcerative colitis or 
Crohn’s disease than in healthy control subjects, but whether there are reproducible, disease-
specific alterations is unclear [140]. The fact that antibiotic therapy has no clinical effect on 
ulcerative colitis argues against an important role of bacteria in this disease, whereas antibiotics do 
provide some benefit in luminal Crohn’s disease. Although serum antibacterial antibodies are 
present in patients with ulcerative colitis, they are much more common and are found in higher 
titers in patients with Crohn’s disease. Furthermore, the range of antibodies against bacterial 
antigens (anti-I2, anti-OmpC, and anti-CBir1 antibodies) and fungal antigens (anti–Saccharomyces 
cerevisiae antibodies [ASCA]) is broader in Crohn’s disease, whereas the only ulcerative colitis–
associated antibody is perinuclear antineutrophil cytoplasmic antibody (pANCA), which recognizes 
nuclear antigens that may cross-react with bacterial antigens [141]. 
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Mucosal Immune Response 
Intestinal homeostasis requires a controlled innate immune response to the microbiota, which 
is recognized by toll-like receptors and NOD receptors on epithelial and immune cells [142]. This 
recognition process contributes to tolerance, but when the process is dysregulated, inflammation 
ensues. At present, there is no clear evidence of specific, innate immune defects in ulcerative colitis; 
an increased expression of TLR2 and TLR4 by colonocytes [143] is probably secondary to 
inflammation. In contrast, in Crohn’s disease, abnormalities of innate immunity are linked to 
variants of the NOD2, ATG16L1, and IRGM genes, the products of which normally mediate 
microbial recognition [144,145]. The production of proinflammatory cytokines, such as IL-1β, IL-6, 
TNF-α, and tumor necrosis factor–like ligand 1 (TL1A), is universally increased in patients with 
IBD but it does not allow to discriminate between ulcerative colitis and Crohn’s disease. 
Abnormalities in humoral and cellular adaptive immunity occur in ulcerative colitis. Elevated IgM, 
IgA, and IgG levels are common in inflammatory bowel disease, but there is a disproportionate 
increase in IgG1 antibodies in ulcerative colitis [146]. Abnormalities of adaptive immunity that 
differentiate ulcerative colitis from Crohn’s disease are defined by mucosal CD4+ T cells, which 
were initially divided into two lineages: Th1 and type 2 helper T cells (Th2). Crohn’s disease is a 
Th1-like condition, on the basis of evidence of increased production of IFN-γ [147]. In contrast, 
ulcerative colitis represents an atypical Th2 response, as indicated by the presence of non classical 
natural killer T cells in the colon that secrete abundant IL-13, which mediates epithelial- cell 
cytotoxicity, apoptosis, and epithelial barrier dysfunction [148,149]. IL-5–producing Th2-polarized 
T cells are also present in ulcerative colitis. The balance between Th1 and Th2 has been used to 
differentiate between ulcerative colitis and Crohn’s disease. However, additional helper-cell 
lineages have recently been delineated, including Th17 cells that produce the proinflammatory 
cytokine IL-17, the levels of which are increased in the mucosa of patients with IBD [150]. 
 
Epithelial Cells and Autoimmunity 
Because inflammation in ulcerative colitis typically does not extend into the small intestine 
and occurs in proximity to the epithelium, colonocytes are implicated in the pathogenesis of this 
disease. It has been proposed that the epithelium is diffusely abnormal, irrespective of inflammation 
[151]. Other reported abnormalities in ulcerative colitis include an epithelial-barrier defect and 
impaired expression of PPAR-γ, a nuclear receptor that regulates inflammatory genes [152]. In both 
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ulcerative colitis and Crohn’s disease, epithelial cells have a decreased ability to activate suppressor 
CD8+ T cells, but this abnormality is probably secondary to other immune events [153]. Variants of 
the XPB1 gene, the product of which is a component of the stress response of the endoplasmic 
reticulum in epithelial cells, have been linked to IBD, reinforcing the idea that colonocytes are 
involved in its pathogenesis [154]. Autoimmunity may play a role in ulcerative colitis. In addition 
to pANCA, this disease is characterized by circulating IgG1 antibodies against a colonic epithelial 
antigen that is shared with the skin, eye, joints, and biliary epithelium [155]; since these are the sites 
of extraintestinal manifestations in ulcerative colitis, it is possible that crossreacting antibodies 
against the colon cause organspecific damage. Tropomyosin 5, a structural protein, is the putative 
target autoantigen of the IgG1 antibodies [156], but evidence of classical antibody- mediated 
autoimmunity in ulcerative colitis is still lacking. Figure 2.4 summarizes our current understanding 
of the pathogenesis of ulcerative colitis. 
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Fig. 2.4. Current concepts concerning the pathogenesis of ulcerative colitis.Glycolipids from epithelial cells, bacteria, or both induce the up-
regulation of interleukin-13 receptor α2 (IL-13 α2) on mucosal natural killer T cells; autocrine interleukin-13 (IL-13) activates these cells, which 
expand in number and create a positive feedback loop that enhances interleukin-13–mediated natural killer T-cell cytotoxicity, causing epithelial-
barrier dysfunction. This leads to enhanced absorption of bacterial products and the generation of antibacterial antibodies; damage to epithelial cells 
induces the production of anti-tropomyosin antibodies by B cells, while nuclear proteins from neutrophils induce the production of pANCA. In 
addition to type 1 and type 17 helper T cells (Th1 and Th17), an increased number of type 2 helper T cells (Th2) produce interleukin-13, which 
induces epithelial-barrier dysfunction, resulting in increased permeability, and interleukin-5 (IL-5), which may contribute to eosinophil recruitment 
and activation. Increased absorption of bacterial products stimulates dendritic cells and macrophages, resulting in the production of proinflammatory 
cytokines and chemokines. Interleukin-1β–activated epithelial cells secrete epithelial neutrophil-activating peptide 78 (ENA-78) and interleukin-8, 
which recruit neutrophils, as well as monocyte chemoattractant protein 1 (MCP-1), which attracts and activates macrophages, and RANTES 
(regulated upon activation, normal T cell expressed and secreted), which attracts and recruits effector helper T cells. Genetic variants associated with 
ulcerative colitis, reduced expression of PPAR-γ by colonocytes, mucus abnormalities, and abnormalities of regulatory T cells (Treg) may also 
contribute to selective autoimmune and immune-mediated events in the pathogenesis of ulcerative colitis. IL-1 denotes interleukin-1, IL-6 interleukin- 
6, TL1A tumor necrosis factor–like ligand 1, and TNF-α tumor necrosis factor α. Image from: Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 
2011 Nov 3;365(18):1713-25. Doi 10.1056/NEJMra1102942.Review. 
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Pharmacological Therapy 
According to current consensus-based guidelines, the choice of drug treatment for patients 
with ulcerative colitis should take into consideration the level of clinical activity (mild, moderate, or 
severe) combined with the extent of disease (proctitis, left-sided disease, extensive disease, or 
pancolitis), the course of the disease during follow-up, and patient’ s preferences [157,158]. 
 
Drugs for Remission Induction 
Sulfasalazine and 5-aminosalicylates (mesalamine, olsalazine, and balsalazide), given orally, 
rectally (by means of suppository or enema), or both, represent first-line treatment for ulcerative 
colitis, with an expected remission rate of about 50%. Mild-to-moderate proctitis can be treated 
with mesalamine suppositories (1 g per day) or enemas (2 to 4 g per day); clinical remission occurs 
in most patients within 2 weeks, with repeated treatments as needed. If it fails, 5-aminosalicylate 
enemas (2 to 4 g per day) or glucocorticoid enemas (hydrocortisone at a dose of 100 mg per day, or 
new preparations such as budesonide or beclomethasone) are the next step [159]. Patients who do 
not have a response to rectally administered agents may be given oral glucocorticoids (up to 40 mg 
of prednisone or its equivalent). Patients with mild-to-moderate ulcerative colitis that are refractory 
to rectal therapies and to oral 5-aminosalicylate are candidates for oral glucocorticoids or 
immunosuppressive agents (azathioprine or 6-mercaptopurine); to whom do not have a response to 
maximal doses of 5-aminosalicylate or oral glucocorticoids should be given intravenous 
glucocorticoids [157]. 
For patients who continue to require glucocorticoid therapy and for those who do not have a 
response to it, a good therapeutic option appears to be infliximab, a monoclonal antibody against 
TNF-α, administered at a dose of 5 mg per kilogram of body weight at 0, 2, and 6 weeks [160]. 
Infliximab in combination with azathioprine (2.5 mg per kilogram) were reported to be more active 
than infliximab or azathioprine monotherapy for inducing glucocorticoid free remission in patients 
with moderate-to-severe ulcerative colitis. Many specialists suggest that patients with extensive, 
severe disease receive a 5-day to 7-day course of intravenous glucocorticoids [157]; if the disease is 
unresponsive, then intravenous cyclosporine (2 mg per kilogram) or infliximab is usually the next 
step. Although cyclosporine can be effective, it generally delays rather than prevents subsequent 
colectomy [161]; furthermore, infliximab is increasingly used as an alternative treatment for 
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patients with refractory disease, given its effectiveness and better short-term safety profile as 
compared with other therapies [162]. 
 
Drugs for Remission Maintenance  
After remission has been achieved, the goal is to maintain the symptom-free status, which can 
be accomplished with various medications, with the exception of glucocorticoids, which have no 
place in maintenance therapy, given the marked side effects associated with their long-term use. 
Both oral and rectal 5-aminosalicylate have greater efficacy than placebo for maintenance of 
remission in patients with distal disease [163]. Thiopurines (e.g., azathioprine at a dose of 2.5 mg 
per kilogram or 6-mercaptopurine at a dose of 1.5 mg per kilogram) are recommended when 5-
aminosalicylate is ineffective or not tolerated or when the patient is glucocorticoid-dependent, 
although it may take several months before their maximal effectiveness is reached. For patients who 
do not have a response to immunosuppressive therapy or cannot tolerate it, anti–TNF-α agents are 
gradually being adopted; higher rates of remission and improvement on endoscopy, as well as lower 
rates of colectomy, are reported when infliximab trough levels are detectable in the circulation 
[164]. Unlike Crohn’s disease, ulcerative colitis may respond to probiotic therapy. For example, 
Escherichia coli strain Nissle 1917 (200 mg per day) is not less effective than 5-aminosalicylate 
(1.5 g perday) for maintaining remission [165], and the probiotic VSL#3 (3600 billion colony-
forming units per day for 8 weeks) in conjunction with 5-aminosalicylate can help induce remission 
in mild-to moderate ulcerative colitis [166]. There are multiple indications for surgery, including 
the failure of medical therapy, intractable fulminant colitis, toxic megacolon, perforation, 
uncontrollable bleeding, intolerable side effects of medications, strictures that are not amenable to 
endoscopic alleviation unresectable high-grade or multifocal dysplasia, dysplasia-associated lesions 
or masses, cancer, and growth retardation in children[167]. There are also multiple surgical options. 
Traditional proctocolectomy with ileostomy is curative and technically straight forward; however, 
possible complications include small-bowel obstruction, fistulas, persistent pain, sexual and bladder 
dysfunction, and infertility [168]. Total proctocolectomy with ileal pouch–anal anastomosis (IPAA) 
is currently the procedure of choice for most patients who require elective surgery, since it has the 
distinct advantage of preserving anal-sphincter function. This approach is associated with an 
acceptable morbidity rate (19 to 27%), extremely low mortality (0.2 to 0.4%), and good 
postoperative quality of life [169]. Continent ileostomy is an alternative procedure for patients with 
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ulcerative colitis who are ineligible for or have declined IPAA or who have not been helped by it 
[169]. 
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CHAPTER 3: PROBIOTICS, PREBIOTICS AND SYNBIOTICS 
 
Probiotics 
A probiotic is usually defined as a live commensal microorganism that, when consumed in 
adequate quantities, confers a health benefit to the host (FAO/WHO 2001). Criteria for designating 
a commensal strain as a probiotic include nonpathogenic, human origin; acid and bile resistance; 
survival of gastrointestinal transit; production of antimicrobial substances; and immune modulator 
activity [170,171]. The main probiotics on the market are lactobacilli, streptococci and 
bifidobacteria, which are normal constituents of the human gastrointestinal microflora. The first two 
belong to a large group of bacteria designated as lactic acid bacteria (LAB) [172].The genus 
Bifidobacterium is unrelated to LAB phylogenetically, and Bifidobacterium species use a unique 
metabolic pathway for sugar metabolism. However, Bifidobacterium species are often considered to 
be LAB and probiotics because of their documented health promoting effects [173]. Recent studies 
have demonstrated that beneficial effects were achieved not only by live bacteria, but also by heat-
inactivated or gamma-irradiated not viable bacteria, isolated bacterial DNA or even probiotic-
cultured media [174], presuming that probiotics can “talk” to immune cells recognizing directly 
specific receptors or that are otherwise sensitive to probiotic-derived products (e.g., metabolites, 
cell wall components, DNA). The field instead needs to consider specific immunological 
applications, whether prophylactic or therapeutic, and then proceed to address mechanisms by 
which ingested probiotic organisms might be used to prevent or treat several disorders.  
 
Prebiotics 
Prebiotics are indigestible carbohydrates that stimulate the growth and the activity of 
benefical bacteria, particularly lactobacilli and bifidobacteria [175]. Many years ago the prebiotic 
lactulose has been shown to improve symptoms in liver patients increasing the numbers of 
bifidobacteria [176] and today is commonly used in these patients [177]. Oligosaccharides that are 
contained in human milk are considered to be the prototype of prebiotics, since they have been 
shown to facilitate the growth of bifidobacteria and lactobacilli in the colon of breast-fed neonates 
[178,179]. Any food that reaches the colon other than nondigestible carbohydrates, such as 
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peptides, proteins and certain lipids, is a potential prebiotic. Fructooligosaccharides (FOS) consist 
of short- and medium-length chains of β-D- fructans in which fructosyl units are bound by a β 2-1 
linkage, with the degree of polymerization varying between 2 and 60 (inulin) or 2 and 20 
(oligofructose) [180]. Because of the presence of the β-linkages, FOS are indigestible in the upper 
gastrointestinal tract. Consequently, they enter the cecum/large bowel intact, here they are largely 
fermented to short chain fatty acids (mainly acetate, propionate and butyrrate and other metabolites 
e.g. lactate) and cause proliferation of selected anaerobic bacteria, mostly bifidobacteria [180,181]. 
Thus, FOS including inulin, other oligosaccharides, lactulose, resistant starch and dietary fibres 
have been shown to promote a probiotic response [175]. Previously, it was also demonstrated that 
FOS modifying the gene expression of lipogenic enzyme, reduced de novo liver fatty acid synthesis 
[182], contributing to the decrease in TG accumulation in the liver. Studies provide novel insights 
on the possible link between prebiotics and metabolic diseases, such as obesity and IR [183,184]. 
Prebiotic supplementation is able to increase in plasma gut peptide concentrations (glucagon-like 
peptide 1 and peptide YY), which may contribute in part to the changes in satiety and post-prandial 
glycaemic response in healthy subjects [185]. A functional food approach has been utilized to add 
FOS, primarily inulin, to products (cereals, biscuits, infant foods, yogurts breads and drinks) or to 
dietary supplements at concentrations at which a prebiotic effect may occur [186]. Indeed, the 
modification of intestinal microflora (increase in Bifidobacteria and subsequent reduction in 
Enterobacteriaceae), contributes to a reduction in faecal pH, which results in a minor rate of 
ammonia absorption and in a lower amount of total ammonia into the blood stream. Considering all 
this evidence, it is logical to assume that also the prebiotics would be good candidates to protect the 
liver in individuals with fatty liver and other liver problems. 
 
Synbiotic 
The term ‘synbiotic’ is used ‘when a product contains both probiotics and prebiotics’[187]. 
For example, the synbiotic combination of a specific oligofructose-enriched inulin (SYN1) and 
Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 for 12 weeks caused a 16% and 18% 
increase in the numbers of Lactobacillus and Bifidobacterium, respectively, and a 31% decrease in 
the numbers of Clostridium perfringens [188]. Recent in vitro studies have confirmed that synbiotic 
were more effective than prebiotics or probiotics in modulating the gut microflora [189]. 
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3.1 Biological and molecular basis of probiotic action in NAFLD 
 
Clinical and experimental studies suggest that probiotics differ greatly in their effects and 
mechanisms of action. Significant differences exist, not only among the probiotic species, but also 
within the same strains. Understand the various mechanisms of probiotic action is crucial for the 
establishment of definitive selection criteria for certain strains or combination of strains for specific 
clinical conditions. Although the molecular mechanisms of probiotic are not completely elucidated, 
many effects could result beneficial in NAFLD, including the modulation of the intestinal 
microbiota, antibacterial substance production, epithelial barrier function, intestinal inflammation, 
or the immune system (Figure 3.1). 
 
 
 
 
Fig. 3.1. Mechanisms of action of probiotics. Specific mechanisms: involvement of probiotics in cell-mediated and humoral immune responses. 
Aspecific mechanisms: enhancement of epithelial barrier function, competitive exclusion of bacteria along epithelium, modification of local 
microenvironment and reduction of intestinal inflammation. Th, T helper cell; Ig, immunoglobulin; Treg, regulatory T cell; IL, interleukin; TGF, 
transforming growth factor; TNF, tumor necrosis factor; IFN, interferon; M, M cell; DC, dendritic cell; TJ, tight junction; MΦ, macrophage; SCFA, 
short-chain fatty acid; NF-κB, nuclear factor-κB; ROS, reactive oxygen species. Image from: Iacono A, Raso GM, Canani RB, Calignano A, Meli R. 
Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011 
Aug;22(8):699-711. doi: 10.1016/j.jnutbio.2010.10.002. Epub 2011 Feb 2. Review. 
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Modulation of the intestinal microflora composition and 
antibacterial factor production  
Probiotic can limit the role of bacterial pathogens in NAFLD through at least two 
mechanisms: the exclusion or inhibition of invading bacteria and the production of antimicrobial 
factors. Non-specific antimicrobial substances include SCFAs [190], hydrogen peroxide [191], 
bacteriocins, bacteriocin-like inhibitory substances (BLIS), and bacteriophages [192]. SCFA are 
produced during the anaerobic metabolism of carbohydrates especially by strains of lactobacilli and 
have an important role in decreasing pH and inhibiting the growth of a wide range of Gram-
negative pathogenic bacteria. The inhibition of microbial growth by organics may be due to the 
ability of these acids to pass across the cell membranes, to dissociate in the more alkaline cell 
environment and to acidify the cytoplasm [193]. In microbial fermentor systems, pH modification 
could lead to a shift in the composition of the microbiota community [194], limiting the populations 
of certain gut pathogens [195]. Bacteriophages are highly specific and can be active against a single 
strain of bacteria. The 2-component lantibiotics, a class of bacteriocins produced by Gram-positive 
bacteria, such as Lactococcus lactis, are small antimicrobial peptides [196]. These peptides have 
been found to be active at nanomolar concentrations to inhibit multidrug-resistant pathogens by 
targeting the lipid II component of the bacterial cell wall [197]. Other non-lanthionine containing 
bacteriocins are small antimicrobial peptides produced by lactobacilli. These peptides have a 
relatively narrow spectrum of activity and are mostly toxic to Gram-positive bacteria, including 
Lactococcus, Streptococcus, Staphylococcus, Listeria, and Mycobacteria. The main mechanisms of 
bacteriocin action are based on forming pores in the cytoplasmic membrane of sensitive bacteria 
and interfering with essential enzyme activities. In addition, several strains of Bifidobacteria have 
been found to produce bacteriocin-like compounds toxic to both Gram-positive and Gram-negative 
bacteria [198]. Bifidobacteria and Lactobacilli can adhere to intestinal epithelial cells through 
surface-expressed proteins [199]. In particular, Lactobacillus casei binds to extracellular matrix 
components, such as collagen, fibronectin or fibrinogen [200]. Moreover, a part from their 
antimicrobial effects, some secreted probiotic factors are also able to inhibit the binding of 
pathogenic bacteria to the specific receptors expressed on the epithelium surface [201]. Several 
strains of lactobacilli and bifidobacteria are capable to compete with and displace pathogenic 
bacteria, including Bacteroides vulgatus, Clostridium histolyticum, C. difficile, Enterobacter 
aerogenes, Listeria monocytogenes, Staphylococcus aureus, Salmonella enterica, Yersinia 
enterocolitica [202], enterotoxigenic E. coli [203,204], and enteropathogenic E. coli [205], even if 
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the pathogens have attached to intestinal epithelial cells prior to probiotic treatment [202]. In this 
context, recent studies regarding proteinase treatment and carbohydrate competition have confirmed 
that the probiotic binding to intestinal epithelial cells is mediated by lectin-like adhesion and 
proteinaceous cell surface components [206,207], which are the same receptors mediating 
pathogenic bacteria binding to intestinal epithelial cells. For example, Lactobacilli and 
Bifibobacteria establish mannose and Galβ 1-3GalNAc-specific adhesions to attach to intestinal 
epithelial cells and mucus [206], competing with pathogens for lectin binding sites of 
glycoconjugate receptors for intestinal adherence. Therefore, the capability of probiotics to improve 
gut ecology and microbial composition, inhibiting pathogenic bacteria growth and/or competing 
with and displacing pathogenic bacteria can prevent small intestinal bacteria overgrowth.  
 
Modification of intestinal epithelial permeability and function 
Probiotics are able to improve the non-specific intestinal barrier defence mechanism, 
modulating tight junctional proteins and stimulating mucin production. These effects limits small 
intestinal bacterial overgrowth, and bacterial translocation, both events observed in humans and in 
animal models and responsible of the reduced endotoxemia [208]. The mucus layer, covering the 
gastrointestinal mucosa, is considered as the first line of defence against mechanical, chemical, or 
microbiological aggressions arising from the luminal contents. Indeed, the break of the mucus 
barrier in inflamed colon has been shown to allow bacterial adherence to epithelial tissue [209], and 
the removal of the mucus layer favours the penetration of high molecular weight probes in mucosa 
[210]. It has been demonstrated that Lactobacilli upregulate the MUC2 and MUC3 mucins and 
inhibit attachment of enterohemorrhagic E.coli in vitro [211] and that a probiotic mixture of 
lactobacilli and bifidobacteria increased the secretion of mucin, stimulating MUC2 gene expression 
in rat colon in vivo [212]. 
Probiotics stimulate the production of SCFAs [213], which, in turn, are able to modulate 
intestinal permeability as demonstrated several conditions, including antibiotic associated colitis, 
inflammatory bowel disease, colon cancer and hepatic encephalopathy. Probiotic administration 
could potentially reduce bacterial metabolites, that may be toxic to the intestinal epithelium for 
instance hydrogen sulphide and extracellular superoxide [214]. Lactobacillus GG, Bifidobacterium 
infantis, Bifidobacterium lactis and E.coli Nissle 1917 increase tight junction integrity, preventing 
their disruption. The biochemical pathways mediating the probiotic effect on tight junction function 
include protein kinase C and MAP kinase pathways, and involve both redistribution and altered 
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expression of the tight junction proteins occludin, ZO-1 (zonula occludens-1) and ZO-2 and 
claudins 1, 2, 3 and 4 [215,216]. 
 
Modification of endotoxemia 
The clear role for endotoxin levels in alcoholic liver injury, the involvement of endotoxemia 
in NAFLD has also been addressed. In fact, the increase of endotoxemia and the induction of 
hepatic TLR4 and TLR accessory molecules (MD-2 and CD14) were evidenced in mice fed with a 
MCD (methionine choline-deficient) diet, suggesting that TLR4 signalling is, indeed, important for 
the pathogenesis of NASH [217]. Moreover, depletion of Kupffer cells diminished diet-induced 
increases in TLR4 and TNF-α, indicating a crucial role for these cells in mediating TLR4 signalling 
and transcription of cytokines. 
 
Suppression of inflammation 
Intestinal inflammation leads to an increase of mucosal permeability and bacterial 
translocation. It is noteworthy that several cytokines, such as TNF-α, IFN-γ, IL-4 and IL-13 have 
been shown to increase permeability in vitro using intestinal epithelial monolayers [218], altering 
tight junction morphology and distribution [219], and thereby creating a self-perpetuating vicious 
cycle that amplify bacteria translocation and possibly extra-intestinal inflammation and damage. 
Within intestinal epithelial cells, the transcription factor NF-κB, is a master coordinator of immune 
and inflammatory responses to pathogenic bacteria and other stress signals. However, most 
commensal bacteria do not activate NF-κB, while some of them can antagonise it within enterocytes 
by several mechanisms. In particular, the nuclear export of the p65 subunit of NF-κB can occur in a 
PPAR-γ-dependent manner [220]. Soluble components from a mixture of commercially available 
probiotics, VSL#3, and Lactobacillus reuteri inhibit epithelial proteasome function, preventing the 
degradation of IκB [219,221]. This was accompanied by an increased expression of nerve growth 
factor, which has anti-inflammatory properties. This finding implicates a role of the enteric nervous 
system in host-microbial interactions. A variety of probiotic bacteria including the mixture VSL#3, 
L. reuteri, L. salivarius UCC118, and B. infantis 35624 have been shown to suppress IL-8 secretion 
from intestinal epithelial cells in response to several pathogenic bacteria [219,222]. This cytokine 
[223] transcriptionally regulated by NF-κB is a potent neutrophil-recruiting and activating 
chemokine. The anti-inflammatory effects of a number of probiotic bacteria including 
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Bifidobacterium infantis 35624 and L. salivarius UCC118 have been shown also to be mediated, 
only in part, throught NF-κB [222]. Besides NF-κB pathway, other intracellular signal transduction 
pathways have also been associated with the protective effects mediated by probiotics. These 
include MAP Kinase, AP-1, and PPAR-γ pathways [224,225]. A part from intestinal inflammation, 
small intestinal bacterial overgrowth and translocation result in endotoxemia that directly stimulates 
hepatic Kupffer cells to produce TNF-α and oxygen free radicals [226,227]. The role of TNF-α in 
NAFLD has been well documented and was strengthened by the improvement in liver function with 
anti-TNF therapy [45]. A study performed in ob/ob mice, as a model of NAFLD, demonstrated an 
improvement in mice treated with the probiotic mixture VSL#3, also related to a reduction of TNF-
α activity [45]. Similar data were obtained from our group in a model of NAFLD induced by a high 
fat diet; we demonstrated the antioxidative and anti-inflammatory effect elicited by VSL#3 in an 
experimental model of NASH induced in young rats. This probiotic mixture induced a decrease in 
the oxidative stress, evidenced through the reduction of malondialdehyde, and protein 
nitrotyrosilated levels in the liver. Moreover, VSL#3 exhibited an anti-inflammatory activity by a 
reduction of NF-kB activation in the liver and hence COX-2 (Cyclooxygenase-2) and iNOS 
(inducible nitric oxide synthase) expression. This effects was also evidenced by VSL#3 capability 
to reduce hepatic TNF-α level, the key pathogenetic factor responsible of the onset of NASH, and 
restoring PPAR-α expression [70]. Another study measured hepatic natural killer T (NKT)-cell 
depletion in high-fat fed animals. This diet induced the depletion of NKT from the liver, leading 
overproduction of TNF-α and causing inflammation, insulin resistance and steatosis. VSL#3 
significantly improve all these parameters restoring insulin signalling [228]. Considering the anti-
inflammatory properties of more than 550 different lactic acid bacteria strains, a new synbiotic 
composition was obtained, consisting in Lactobacillus plantarum, Lactobacillus paracasei subsp. 
paracasei, Lactococcus raffinolactis and Pediococcus pentosaceus, plus four different fibers known 
for their strong bioactivity: betaglucan, inulin, pectin and resistant starch. This composition, 
Synbiotic 2000, was successfully investigated in surgical operations such as liver transplantation 
reducing the problem of postoperative infections [229]. 
 
Immune system modulation by probiotics 
Commensal bacteria can modulate the immune system both at local and systemic level. 
Signals mediated by these bacteria are essential for optimal mucosal and immune development, and 
to maintain or restore gut integrity [230,231]. In the intestinal tract, immunocytes, such as 
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enterocytes, M cells, and dendritic cells (DCs), are constantly responding to intestinal bacteria. 
These cells express pattern recognition receptors, such as TLRs, that engage bacterial signals 
(lipopolysaccharide, lipotechoic acid, bacterial DNA, and flagellin) and contribute to the activation 
of transcription factors and proinflammatory cascade. Immune engagement and systemic 
immunologic changes are associated with oral consumption of probiotics [232], which share the 
same host-microbial signalling pathways of commensal microbiota. In the intestine, probiotic 
bacteria are internalized by M cells to interact with DCs and follicle associated epithelial cells, 
initiating responses mediated by macrophages and T and B lymphocytes [233]. DCs initiate 
immune responses in vivo by presenting antigens to T cells and influence polarization of T-cell 
responses (Th1, Th2, Th3 or regulatory T cells) through secretion of immunoregulatory cytokines. 
Moreover, DCs contribute to oral tolerance induction by generating regulatory T cells and IgA-
producing B cells through production of cytokines, such as IL-10 and TGF-β (transforming growth 
factor beta) [234]. Regulatory T cells produce high levels of IL-10 and suppress the proliferation of 
effector T cells in an IL-10–dependent manner. Different strains of lactobacilli and other probiotic 
bacteria can modulate DCs function modulating cell maturation and the expression of regulatory 
cytokines, such as IL-10 [235,236]. DCs from different lymphoid compartments exhibit divergent 
cytokine responses to probiotic and pathogenic bacteria [237]. Some strains of probiotic bacteria, 
such as L. casei or L. reuteri, but not L. plantarum, can promote DCs to induce tolerance driving the 
development of regulatory T cells [238]. Similarly, VSL#3 can ameliorate Th1 cell-mediated 
murine colitis, by restoring cytokine balance through the induction of IL-10- and TGF-β-bearing 
regulatory T cells [239]. Probiotics can interact either directly with DCs or indirectly, via the action 
of M cells. Very recently, it has been evaluated the ability of three lactobacilli strains (Plantarum, 
LGG and paracasei B21060) to activate DCs. L. paracasei B21060 was identified as the more 
immunomodulatory among the three strains, and was able to inhibit the inflammatory potential of 
pathogenic Salmonella and protect against experimental colitis [240]. Probiotics, in addition to 
facilitate cell mediated immunity promote humoral response. The administration of probiotic 
bacteria leads to an increase in the levels of pathogen-specific IgA [241], and IgA responses are 
enhanced in formula-fed infants supplemented with probiotics compared with infants receiving 
placebo [242]. Of note, the induction of IgA in the gut is heavily dependent on TGF-β, which is also 
closely involved in the maturation of regulatory T cells [243]. In agreement with these studies, a 
recent randomised, double-blind, placebo-controlled trial demonstrated that the administration of 
two probiotic bacteria, L. gasseri CECT5714 and L. coryniformis, increased the proportion and 
activity of phagocytic and NKT cells, as well as levels of IgA in healthy adults [244]. Particularly 
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desirable strains are those that improve immune function by increasing the number of IgA-
producing plasma cells, improve phagocytosis, and the proportion of Th1 cells and NKT cells 
[245]. Some strains are more likely to have strong clinical effects; among them are strains like L. 
paracasei subsp paracasei, L. plantarum, and Pediococcus pentosaceus. In particular, L. paracasei 
has been shown to induce cellular immunity and stimulate production of suppressive cytokines such 
as TGF-β and IL-10, to suppress Th2 activity and CD4 T-cells [246], suppress splenocytes 
proliferation [247] and decrease antigen-specific IgE and IgG1 [248]. L. paracasei was also shown 
to be the strongest inducer of Th1 and repressor of Th2 cytokines [249]. Moreover, it has been 
shown that co-culturing lactic acid bacteria with human or rodent leukocytes has been shown to 
augment the production of type II interferon (IFN-γ by mitogen-stimulated mononuclear cells), or to 
induce type I interferon (IFN-α production by isolated macrophages) [250]. Both interferons 
promote Th1-type immune responses and reduce IgE production [251]. IL-12 has been shown to be 
an important pro-interferon cytokine involved in the production of lactic acid bacteria-stimulated 
IFN-γ [250]. IL-12 is known to be an effective cytokine during the early differentiation of Th0 cells, 
promoting development of Th1 lymphocytes and augmenting NKT cell function; both of these 
actions increase IFN-γ producing capacity, limiting the overexpression of a Th2 phenotype. 
Moreover, IL-12 has also been demonstrated to regulate IL-4 production, limiting both the 
establishment and maintenance of Th2-type responses [252]. The varying immunological effects of 
bacteria highlight differences that arise when different type, fluid, or tissues are used. 
 
Probiotics efficacy in NAFLD: from animal models to clinical 
evidences 
The major difficulties in our knowledge on probiotics efficacy in NAFLD derived from the 
different experimental models used and bacterial strains tested. Clinical research into mechanisms 
of NAFLD development and progression are limited by ethical considerations, particularly with 
respect to obtaining liver and other tissues, and by inadequate ability to delineate cause and effect 
from complex pathology with several involved mechanisms. It is therefore attractive experimentally 
to use animal models. Research models of NAFLD may be divided into two main typologies, those 
caused by genetic mutation and those with an acquired NAFLD phenotype [253]. The central 
features of the “modern life style” that predisposes to overweight, obesity, insulin resistance and 
fatty liver disease is the constant caloric overconsumption, also known as “over nutrition”. Over 
nutrition has been achieved in animal models in a number of different ways, including forced 
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feeding, administration of high-fat diets, the use of genetically hyperphagic animals, or a 
combination of these approaches. The effects of administering a high fat diet to rodents can be 
highly variable based on treatment duration, animal strain, percentage and nature of fat added to 
diet. The high percentage of fat contained in the diets could range between 40% and 70%. The well 
known study by Lieber and colleagues described the effects of feeding a liquid high-fat diet (HFD) 
to Sprague–Dawley rats [254]. High-fat-fed rats showed quickly extensive mitochondrial 
abnormalities and dysfunction producing reactive oxygen species with an array of responses that 
results in hepatocyte injury and cell death, inflammation, and fibrosis. Conversely, to better study 
the relationship between the visceral adipose tissue and the liver, it is possible to use a high fat and 
calorie solid diet [255] creating in several weeks a model of IR and NAFLD/NASH in non-
genetically modified animals [256]. This model is characterized by visceral obesity, increased 
glucose and insulin levels, decreased PPAR-α expression, and alterations in insulin signalling and 
hepatic steatosis, leading to oxidative stress, necroinflammatory liver injury, cell apoptosis, and 
collagen deposition. On the other hand, different diet manipulations have been shown to induce 
obesity and fatty liver in a number of different strains and species of rodents, suggesting that “over 
nutrition” with either carbohydrates (fructose and sucrose) or fats (fatty acid and cholesterol) or 
both might play a role in the genesis of obesity-related NAFLD. The efficacy of probiotics in 
several experimental models of NAFLD/NASH is reported in table 3.1. As depicted, the most 
characterized probiotic is VSL#3 mixture, active in several murine models of high fat diet-induced 
NAFLD/NASH. Li et al. [45] using ob/ob mice fed with a HFD provided the first evidence that 
manipulation of the intestinal flora in experimental model influences obesity-related fatty liver 
disease. In fact, VSL#3 similarly to anti-TNF-α antibodies improved liver histology, reduced 
hepatic total fatty acid content, and decreased serum alanine aminotransferase (ALT) levels. These 
effects were associated with a reduction of the JNK and NF-kB activity, of fatty acid β-oxidation 
and of mitochondrial uncoupling protein (UCP)-2 expression, all markers and factors characterizing 
IR. Subsequently, Ma et al. [228] showed that oral VSL#3 treatment significantly improved the 
HFD-induced IR and steatosis recovering hepatic NKT cell depletion. Conversely, recent data have 
demonstrated that in another model of NAFLD/NASH, VSL#3 attenuated fibrosis, reducing TGF-β 
and collagen, α-SMA (alpha smooth muscle actin), MMPs expression, but had no effect on liver 
steatosis parameters and inflammation in MCD-fed mice [112]. These data are limited by the type 
of diet used in these animal models. The major disadvantage of the MCD model is that it is 
associated with significant weight loss, low serum leptin level and peripheral insulin sensitivity. 
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Table 3.1. Effect of several probiotics in experimental model of NAFLD.  
Probiotic Experimental 
model 
Duration 
of therapy 
Results Reference 
VSL#3 
 
1.5 x 109 
CFU/mouse/day 
Mice: ob/ob mice 
fed high-fat diet 
(HFD)  
4 wks Improved NAFLD histology and reduction of 
hepatic total fatty acid content, and serum 
ALT levels; amelioration of the hepatic 
insulin resistance 
[45] 
Bacillus 
polyfermenticus 
SCD 
 
3.1 x 106 CFU/day 
Rats: high-fat and 
high-cholesterol 
diet 
6 wks Reduction in plasma LDL, cholesterol, and 
hepatic total cholesterol, and triglycerides, 
[257] 
Lactobacillus 
rhamnosus PL60 
 
1.0 x 107 -1.0 x 109 
CFU/mouse/day 
Mice: high-fat 
diet (HFD) 
8 wks Resolution of hepatic steatosis (at higher dose) 
[258] 
Lactobacillus 
acidophilus and L. 
casei 
Rats: high 
fructose diet  
8 wks Reduced liver oxidative stress, improved 
insulin resistance [259] 
VSL#3 
 
1.5 x 109 
CFU/mouse/day 
Mice: high-fat 
diet (HFD) 
4 wks Improved HFD-induced hepatic NKT cell 
depletion, insulin resistance and hepatic 
steatosis and inflammation 
[228] 
Lactobacillus 
plantarum MA2 
 
1 x 1011 
CFU/rat/day 
Rats: cholesterol-
enriched diet 
5 wks Reduction in liver and serum cholesterol and 
triglycerides 
[260] 
VSL#3 
 
1.3 x 1010 CFU/kg 
Rats: high-fat diet 
(HFD)  
4 wks Amelioration of the hepatic inflammatory, 
steatotic and peroxidative factors and 
reduction in serum aminotransferase levels 
[70] 
VSL#3  
 
in drinking water 
Mice: 
methionine-
choline-deficient 
(MCD) diet 
9 wks No effect on MCD-induced liver steatosis and 
inflammation, but amelioration of liver 
fibrosis 
[112] 
Lactobacillus 
paracasei B21060 
 
2.5 x 108 bacteria/ 
kg/ die 
Rats: high fat diet 6 wks Ameliorated steatosis, improved insulin 
resistance, decreased hepatic inflammatory 
cytokines. [113] 
 
From: Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular 
and biochemical mechanisms. J Nutr Biochem. 2011 Aug;22(8):699-711. doi: 10.1016/j.jnutbio.2010.10.002. Epub 2011 Feb 2. Review. 
 
The severe atrophy of adipose tissue in MCD-fed mice suggests that in this model NASH reflects 
the associated lipodystrophy rather than metabolic syndrome [261]. Among probiotics, several 
strains of lactobacillus have shown to have a protective effect on NAFLD [260]. In particular, an 
eight-week oral treatment with Lactobacillus rhamnosus PL60 showed an anti-obesity effect and 
liver steatosis in DIO (diet inducing obesity) mice. Histopathological analysis of liver steatosis 
evidenced a lowered grading score in DIO mice receiving L. rhamnosus [258]. Moreover, a 
beneficial effect on liver alteration has been shown in L. acidophilus and L. casei treated mice fed 
with a high fructose-diet. This diet, indeed, provides a dietary model of type 2 diabetes associated 
with IR, hyperinsulinemia and hypertriglyceridemia. Concomitantly, this overload of fructose to the 
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liver impairs the glucose metabolism and uptake pathways, leading to an enhanced rate of de novo 
lipogenesis, inducing, other than IR, steatosis. In this study, these two probiotics delayed the onset 
of glucose intolerance, reduced insulinemia and liver glycogen and ameliorated the steatosis, 
reducing MDA (malonyl dialdehyde) and increasing GSH (Glutathione) content [259]. 
Using a cholesterol enriched diet, Wang et al.[260] demonstrated that the administration of L. 
plantarum MA2 in rats, beyond the hypolipidemic effect, reduced both liver cholesterol and 
triglycerides and increased the number of fecal lactobacilli and bifidobacteria. Similar data were 
previously observed when Bacillus polyfermenticus was administered in rat fed with high fat and 
high cholesterol diet [257]. Despite the large number of preclinical studies about the use of 
probiotics in the treatment of fatty liver disease, there are only two pilot studies about their efficacy 
in NAFLD in humans. The first study [262] tested a mixture of probiotics (Lactobacillus 
acidophilus, Bifidus, Rhamnosus, Plantarum, Salivarius, Bulgaricus, Lactis, Casei, Breve) 
associated with prebiotics FOS and vitamins (B6, B2, B12, D3, C and folic acid) in ten patients 
with biopsy-proven NASH. After two months of treatment, the treated patients showed a significant 
improvement of liver damage and function tests, as well as a partial persistence of the effect also 
after the end of treatment. Another pilot study was carried out to evaluate the effects of probiotic 
therapy in patients with chronic liver diseases induced by alcohol or HCV [263]. Independently by 
pathogenesisis of liver disease, VSL#3 administered for three months, significantly improved 
plasma levels of MDA and 4-hydroxynonenal (4-HNE), both markers of lipid peroxidation; 
whereas cytokines (TNF-α, IL-6 and IL-10) were reduced only in alcoholi dependent patients. S-
nitrosothiols (S-NO) plasma levels were improved at the end treatment in all groups. These 
promising preliminary results strongly suggest a great potential for probiotics use in prevention and 
treatment of NAFLD, however as recently stated in a Cochrane meta-analysis, further clinical 
studies are necessary to better define this innovative strategy [264]. The large amount of 
experimental data on probiotics effects that is now available could drive in the next future the 
design of clinical trials.  
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3.2 Biological and molecular basis of probiotic action in IBD 
 
Role of the commensal flora in IBD 
Although many studies have investigated the possibility of a single infectious agent causing 
Crohn’s disease and ulcerative colitis, also called chronic IBD, none has yet been discovered. The 
intestinal bacteria are now believed to be involved in the initiation and perpetuation of IBD. The 
prevailing theory explaining the development of IBD is that the adaptive immune system is hyper-
responsive to the commensal intestinal microflora in genetically susceptible individuals [265]. This 
hypothesis is supported by several observations: most inflammation occurs in areas with the highest 
density of intestinal bacteria, broad spectrum antibiotics improve chronic intestinal inflammation, 
and surgical diversion of the fecal stream can prevent recurrence of Crohn’s disease. Most 
importantly, despite differences in the pathogenesis of chronic intestinal inflammation, a consistent 
feature of many animal models of IBD (such as IL-10 knockout mice and HLA-B27 transgenic rats) 
is the failure to develop chronic intestinal inflammation when these animals are raised in germ-free 
conditions [266,267]. Dysbiosis is also observed in IBD patients. Adherent and intramucosal 
bacteria, particularly Bacteroides spp, Escherichia coli and Enterobacterium spp are more abundant 
in patients with Crohn’s disease than in controls [268,269]. Bacterial overgrowth and dysbiosis are 
also associated with the development of chronic pouchitis, the inflammation of the ileal reservoir 
created after ileo-anal anastamosis following colectomy in ulcerative colitis patients [270]. In 
addition, several selected commensal bacterial species can induce and perpetuate colitis in 
genetically susceptible rodent models of chronic intestinal inflammation [271]. The recognition of 
the compelling association between intestinal microflora and the development of IBD has led to an 
abundance of studies investigating the therapeutic potential of altering luminal bacteria using 
probiotics and/or prebiotics (Figure 3.2). 
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Fig. 3.2. Microbial balance and dysbiosis. The pathogenic immune responses present in IBD are triggered by the presence of luminal bacteria. The 
balance of beneficial vs aggressive intestinal microbes is responsible for either mucosal homeostasis or chronic inflammation. A number of 
environmental and genetic factors influence the balance of beneficial vs aggressive microbes. From: Ewaschuk JB, Dieleman LA. Probiotics and 
prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol. 2006 Oct 7;12(37):5941-50. 
 
Protective mechanisms of probiotics by ameliorating chronic 
intestinal inflammation 
Probiotic bacteria have beneficial effects on the intestinal epithelium both directly and 
indirectly, including enhanced barrier function, modulation of the mucosal immune system, 
production of antimicrobials, and alteration of the intestinal microflora. 
 
Alteration of the mucosal immune system 
The presence of probiotics has been shown to result in several modifications in the mucosal 
immune response, including augmented antibody production [272], increased phagocyte [273] and 
natural killer cell activity [244,274], modulation of NF-κB pathway [171,221], and induction of T 
cell apoptosis [275]. Generally, probiotics increase the production of intestinal anti-inflammatory 
cytokines (such as IL-10 and TGF-β), while reducing the production of pro-inflammatory cytokines 
(e.g., TNF-α, IFN-γ, IL-8) [276,277]. Several probiotic bacteria, including B. breve, Streptococcus 
thermophilus, B. bifidum and Ruminococcus gnavus have been shown to secrete metabolites that 
reduce LPS-induced TNF-α secretion [278]. L. reuteri reduces TNF-α and Salmonella typhimurium 
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induces IL-8 secretion in vitro, by inhibiting nuclear translocation of NF-κB and preventing the 
degradation of ΙκB [219]. Administration of the probiotic cocktail VSL#3 (consisting of L. 
acidophilus, L. bulgaricus, L. casei, L, plantarum, B. breve, B. infantis, B. longum, S. thermophilus) 
to IL-10 deficient mice results in colitis reduction and a concomitant reduction in mucosal secretion 
of TNF-α IFN-γ [279]. E. coli Nissle 1917 is able to down-regulate the expansion of newly 
recruited T-cells into the mucosa and limit chronic intestinal inflammation [280]. In SAMP1/Yit 
mice, Lactobacillus casei strain Shirota inhibits IL-6 production in LPS-stimulated large intestinal 
lamina propria mononuclear cells and down-regulates nuclear translocation of NF-κB [281]. 
Patients with a recent ileo-anal pouch anastomosis who responded to probiotic therapy have 
reduced mRNA levels of IL-1β, IL-8 and IFN-γ, and fewer polymorphonuclear cells, compared 
with patients receiving placebo[282]. Probiotic treatment has also been shown to reduce IFN-γ and 
IL-1α expression and decrease inducible-nitric oxide synthase and gelatinase activities in pouch 
biopsy samples from patients with pouchitis [283]. In mucosal explants of ileal specimens from 
patients with Crohn’s disease, probiotics reduced TNF-α release and the number of CD4 cells [284]. 
In addition to live probiotics, components of probiotic bacteria can also exert effects on the mucosal 
immune system. For example, genomic DNA isolated from VSL#3 inhibits TNF-α-induced IL-8 
secretion, mitogen-activated protein kinase activation and NF-κB activation [171] in HT-29 cells. 
 
Improved barrier function 
Various probiotic bacteria can enhance intestinal epithelial barrier function. For example, oral 
administration of VSL#3 results in normalization of impaired colonic barrier function and 
restoration of intestinal epithelial integrity in IL-10 deficient mice and enhancement of epithelial 
resistance in T-84 cells [279]. Barrier function was enhanced not only by live bacteria, but also by a 
proteinaceous secreted product of VSL#3 [279]. Several strains of lactobacilli are also capable of 
upregulating intestinal MUC3 mRNA expression, thereby improving barrier function by increasing 
the mucus layer [285]. Lactobacillus GG improves barrier function by inhibiting apoptosis of 
intestinal epithelial cells [286]. S. thermophilus and L. acidophilus have been shown to enhance 
phosphorylation of actinin and occludin in the tight junction, thereby preventing the invasion of 
enteroinvasive E. coli into human intestinal epithelial cells [287]. 
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Alteration of the intestinal flora 
Probiotics suppress the growth and invasion of pathogens in several ways. They competitively 
exclude pathogenic bacteria by occupying the limited physical space in the mucus layer and on 
epithelial cells. They also engage pattern-recognition receptors and consume substrate otherwise 
available to other (pathogenic) microbes. In addition, probiotics render their microenvironment 
inauspicious for pathogens by secreting antimicrobial substances such as hydrogen peroxide, 
organic acids, and bacteriocins. For example, both in vitro and in vivo experiments demonstrate that 
B. Infantis suppresses the growth of Bacteroides vulgates [288]. Patients with pouchitis treated with 
VSL#3 have been demonstrated to have increased bacterial diversity in the pouch, and decreased 
fungal diversity [289]. Probiotics may also alter the intestinal microflora by changing the fatty acid 
profile in the colon. VSL#3 probiotic strains are also capable of converting linoleic acid to 
conjugated linoleic acid, a fatty acid with anti-inflammatory and anti-carcinogenic properties [225]. 
 
Therapeutic efficacy of probiotics in IBD treatment 
Results from various animal studies and clinical trials using probiotics to treat intestinal 
inflammation have generated considerable excitement. Data are now emerging which suggest that 
probiotics are capable of preventing relapse of chronic intestinal inflammation. Some probiotics can 
even treat mild to moderately active IBD [170,290]. Although there is a paucity of human studies 
using prebiotics, the few emerging studies showed that there is potential for this treatment modality. 
A multi-center open-label trial reported that oral administration of GBF (germinated barley 
foodstuff) to patients with mild to moderately active UC for 24 wk resulted in a significant decrease 
in clinical activity index, compared to controls [291]. An open-label study of 22 UC patients in 
remission showed that a daily oral intake of 20 g GBF resulted in a significantly improved clinical 
activity index and endoscopic score at 3, 6 and 12 mo, and a reduced relapse rate, compared with 
controls [292]. A recent randomized, double-blinded controlled trial by Furrie et al [293] examined 
the use of synbiotics in 18 patients with active UC, using a combination therapy of B. longum, 
inulin and oligofructose, and found that sigmoidoscopy inflammation scores are reduced in the 
synbiotic-treated population when compared to placebo. Intestinal levels of TNF-α and IL-1β are 
also reduced. Additionally, rectal biopsies have demonstrated reduced inflammation and greater 
epithelial regeneration in the synbiotic-treatment group. 
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Adverse effect of probiotics 
Probiotics are generally regarded as safe. Side effects are rarely reported and generally 
amount to little more than flatulence or change in bowel habit. A review outlining the safety of 
current probiotic compounds has been published [294]. The use of probiotics in 
immunocompromised or in critical ill patients should be carefully evaluated to limit the risk of 
endocariditis or sepsis. However, cases of infection caused by lactobacilli and bifidobacteria are 
extremely rare and are estimated to occur in approximately 0.05% to 0.4% of all cases of infective 
endocarditis and bacteraemia [294]. One important clinical characteristic of lactobacilli is their 
resistance to antibiotic vancomycin, empirically used against Gram negative bacteraemia. 
Lactobacilli are considered as emerging pathogens in high-risk patients with neutropenia induced by 
chemotherapy [295], in neonates submitted to surgery on a count of cardiovascular disorders in 
paediatric patients submitted to gastrojejunostomy [296]. No increase in bacteraemia caused by 
Lactobacillus species was seen in Finland over the period of 1990–2000, despite an increased 
consumption of L. rhamnosus GG. A study of long-term consumption of Bifidobacterium lactis and 
S. thermophilus-supplemented formula in children aged less than 2 years showed the product was 
well tolerated [297]. Complications of treatment with probiotics have been observed in patients who 
are immunocompromised or in the intensive care setting. S. cerevisae fungaemia [298] and 
Lactobacillus bacteraemia [296,299] have been reported in patients with severe underlying 
illnesses. Nevertheless, case reports have identified fungemia in two immunosuppressed patients 
[298] and exacerbation of diarrhoea in two patients with ulcerative colitis who consumed S. 
boulardii [300]. 
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CHAPTER 4: SHORT CHAIN FATTY ACIDS (SCFAs) 
Production 
SCFAs are organic fatty acids with 1 to 6 carbon atoms and are the principal anions which 
arise from bacterial fermentation of polysaccharide, oligosaccharide, protein, peptide, and 
glycoprotein precursors in the colon [301,302]. Fermentation involves a variety of reactions and 
metabolic processes in the anaerobic microbial breakdown of organic matter, yielding 
metabolizable energy for microbial growth and maintenance and other metabolic end products for 
use by the host. The chief end products are SCFAs together with gases (CO2, CH4, and H2) and heat 
[303]. Various population survey data show that fecal SCFA production is in the order of acetate> 
propionate> butyrate in a molar ratio of approximately 60:20:20, respectively [304]. The ratio 
seems to remain fairly constant [22], although alterations in production and absorption may occur 
with dietary changes. 
Carbohydrates are fermented by saccarolytic bacteria primarily in the proximal colon 
producing linear SCFAs, H2, and CO2 [305], and both the presence of carbohydrates in the colon 
and their fermentation can alter the colonic physiology. Fermentation of proteins and amino acids 
by proteolytic bacteria yield branched SCFAs, H2, CO2, CH4, phenols, and amines. The primary 
effects of SCFAs are on colonic function as a result of their uptake and metabolism by colonocytes, 
although SCFAs are also metabolic substrates for other tissues of the host. 
The production of SCFAs are determined by a number of factors, including the numbers and 
types of microflora present in the colon, substrate source [306], and intestinal transit time [306,307]. 
A large microflora population is present in the human colon at 10
10
 to 10
11
 cfu/g wet weight [308], 
and more than 50 genera and over 400 species of bacteria have been identified in human feces 
[181,309]. Bacterial numbers, fermentation, and proliferation are highest in the proximal colon 
where substrate availability is greatest [310]. The principal site of colonic fermentation, therefore, is 
the cecum and proximal colon, whereas the distal colon is carbohydrate and water depleted. The 
total amount of SCFA in the proximal colon is estimated to range from 70 to 140 mM [303,306] 
and fall to 20 to 70 mM in the distal colon [303]. Therefore, the pH is lowest in the proximal colon 
and increases distally. Samples at various sites taken from patients with colonostomies indicate a 
decline in SCFA levels along the colon [303]. Specific species such as Bifidobacterium and 
Lactobacillus have been associated with improved health, resulting in the emergence of the sciences 
of probiotics, or delivery of specific bacteria to the colon and prebiotics, or the administration of 
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dietary components that promote the growth of specific bacteria with defined metabolic functions. 
The production of SCFAs are also determined by the substrate source where dietary intake is the 
most important variable. Nondigestible food components are a source of substrate for fermentation 
by anerobic colonic microflora, because they are resistant to hydrolysis and digestion in the 
stomach and small intestine and eventually enter the colon for fermentation. Carbohydrates 
quantitatively play the most important role in the formation of SCFA [303,305]. On transit through 
the colon, substrates available for fermentation are depleted, as reflected in the decline in SCFA 
production [310] and in a range of other physiologic effects. Furthermore, substrate availability 
during gut transit may also change the bacterial populations and numbers [309]. Neither total SCFA 
nor the individual acids in the distal colon are predictive of those found proximally [311,312]. 
SCFA availability in the distal colon is dynamic as water absorption and loss of digestive material 
alter availability of SCFAs independent of rates of production. A curvilinear relationship exists 
between intestinal transit time and fecal total and individual SCFAs (especially butyrate) so that at 
whole gut transit times >50 hours, butyrate cannot be detected, likely because of colonic uptake 
[303]. Total SCFA and regional differences in SCFA concentration are implicated in diseases of the 
colon, especially in cancer and gastrointestinal disorders, where disease often occurs distally. 
Therefore, increased SCFA production and a greater delivery of SCFA distally, especially butyrate, 
may have a role in preventing these diseases. 
 
Carbohydrate and dietary fiber fermentation 
SCFAs are produced from the fermentation of carbohydrates with the major source coming 
from resistant starches [313,314]. However, dietary fiber, unabsorbed sugars, raffinose, starchyose, 
polydextrose, and modified cellulose also represent significant sources of fermentable substrates in 
the colon [313]. It is estimated that 5% to 20% of dietary starch is not absorbed by the human small 
intestine [315,316]. Insoluble fibers (eg, lignins, cellulose, and some hemicelluloses), which are 
resistant to fermentation by colonic microflora play an important role in fecal bulking and may 
carry with them fermentable carbohydrate substrate, including starches and sugars [317]. Soluble 
fibers (eg, pectins, gums, mucilages, and some hemicelluloses) are more completely fermented by 
colonic microflora and may have little effect in increasing fecal bulk. When transit and laxation are 
unchanged, a greater intake of fermentable carbohydrates will result in higher SCFA production 
because of increased substrate availability [318,319].Concentrations and excretion of SCFA have 
been shown to be greater with feeding of some nonstarch polysaccharides, such as partially 
53 
 
hydrolyzed guar gum but not others such as oat bran [319]. Therefore, there are several factors that 
may affect substrate fermentability that complicate their use in human studies, coupled along with a 
limited ability to measure SCFA directly at specific sites in the colon. Polyfructans are fermented 
by colonic bacteria [320,321] specifically the Bifidobacterium species [320], which have been 
shown to be associated with serum low density lipoprotein- cholesterol (LDL-C) reduction [322]. 
Furthermore, fermentation end products of polyfructans, specifically the SCFA propionate, have 
been shown to decrease the acetate:propionate ratio when compared with lactulose [323] and to 
reduce serum cholesterol levels. Hence, there is a potential use for polyfructans (eg, inulin and 
oligofructose) in combination with viscous fibers (eg, oat bran) to lower serum cholesterol. Such 
combination effects on colonic microflora may be used to achieve a range of therapeutic and 
preventive effects. Various sources of resistant starches [318,319] and acarbose, the glycoside 
hydrolase inhibitor [324,325] also raise fecal SCFAs. The increases in these studies have either 
been reported as higher concentrations, excretion or both, which may reflect changes in production, 
absorption, and intestinal transit time. 
Changes in SCFA may not be observed where significant quantities of lower doses of 
nondigestible oligosaccharides are given, which would be rapidly fermented and immediately 
absorbed in the more proximal colon [303]. Production of individual SCFAs have also been 
measured in various studies. Greater fecal excretion of butyrate and propionate have been observed 
with consumption of wheat bran compared with vegetable fiber [326]. However, feeding of partially 
hydrolyzed guar gum resulted in greater fecal excretion of all 3 major SCFAs, but did not change 
the concentration of propionate and butyrate, or decrease their relative contribution. Studies using 
resistant starch have been consistent in showing raised fecal butyrate [317,319]. Starch fermentation 
primarily yields acetate and butyrate, whereas fermentation of pectin and xylan yields acetate alone 
as the main product. Recent human studies found that acute ingestion of a nondigestible 
monosaccharide, L-rhamnose (25 g), increased serum propionate without increasing acetate [327], 
and this effect did not diminish after 28 days [328]. 
 
Absorption 
Absorption of SCFAs in the cecum and the colon is a very efficient process with only 5% to 
10% being excreted in the feces [329]. Two proposed mechanisms of absorption are (1) diffusion of 
protonated SCFAs and (2) anion exchange [306]. SCFAs are rapidly absorbed in the colon, which is 
associated with enhanced sodium absorption and bicarbonate excretion [306]. Intubation studies 
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have shown that SCFAs are taken up from the perfused human large bowel in a concentration-
dependent manner [330]. At least 60% of that uptake is by simple diffusion of protonated SCFAs 
involving hydration of luminal CO2, whereas the remainder occurs by cellular uptake of ionized 
SCFAs involving transport of Na
+
 and K
+
 [331]. SCFA uptake is associated with transport of water 
that seems to be greater in the distal than in the proximal colon [332]. Human peripheral venous 
blood concentrations of SCFAs are normally low, and only acetate is present in significant amounts 
[303]. However, Wolever et al., [333] measured serum propionate and butyrate, and reported values 
of 4.5 to 6.6 mmol/L and 2.2 to 3.9 mmol/L, respectively. 
The major SCFAs: acetate, propionate, and butyrate are absorbed at comparable rates in 
different regions of the colon [330]. Once absorbed, SCFAs are metabolized at 3 major sites in the 
body: (1) cells of the ceco-colonic epithelium that use butyrate as a major substrate for 
maintenance-energy producing pathways; (2) liver cells that metabolize residual butyrate with 
propionate used for gluconeogenesis and 50% to 70% of acetate also taken up by the liver; (3) 
muscle cells that generate energy from the oxidation of residual acetate. Their oxidation supplies 
some 60% to 70% of the energy needs of isolated colonocytes [334], reduces glucose oxidation 
[335], and spares pyruvate [336] and glutamine [337]. In the presence of competing substrates such 
as glucose and glutamine, butyrate is the preferred intestinal fuel [338] suggesting that a hierarchy 
of oxidation exists with butyrate apparently being oxidized more in the proximal than in the distal 
colon [303]. 
 
Function of SCFAs 
The role of SCFAs has expanded to include their role as nutrients for the colonic epithelium, 
as modulators of colonic and intracellular pH, cell volume, and other functions associated with ion 
transport, and as regulators of proliferation, differentiation, and gene expression [306]. Increases in 
SCFAs result in decreased pH, which indirectly influences the composition of the colonic 
microflora (eg, reduces potentially pathogenic clostridia when pH is more acidic), decreases 
solubility of bile acids, increases absorption of minerals (indirectly), and reduces the ammonia 
absorption by the protonic dissociation of ammonia and other amines (ie, the formation of the less 
diffusible NH4
+
 compared with the diffusible NH3) [339]. In figure 4.1 the structural form of main 
SCFAs are shown. 
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Figure 4.1 : the chemical structure of main SCFAs. 
 
Acetate 
Acetate, the principal SCFA in the colon, is readily absorbed and transported to the liver, and 
therefore is less metabolized in the colon [306]. The presence of acetyl-CoA synthetase in the 
cytosol of adipose and mammary glands allow the use of acetate for lipogenesis once it enters the 
systemic circulation. In human studies, acetate is often used to monitor colonic events because it is 
the main SCFA in the blood. Acetate is the primary substrate for cholesterol synthesis. Subjects 
given rectal infusions of acetate and propionate showed a dose-dependent increase in serum total 
cholesterol and triglyceride levels, providing indirect evidence that SCFA is utilized for lipid 
synthesis [340]. However, the methodology used in this study may have resulted in nonphysiologic 
levels of acetyl CoA from the rapid uptake of acetate. This may have diverted SCFA to lipid 
synthesis rather than oxidation [341]. It is possible that substrate-dependent SCFA produced by 
fermentation inhibits cholesterol synthesis [342]. However, uniform agreement has not been 
reached on the effect of increased colonic fermentation on lipid metabolism, because the possibility 
exists that different substrates may produce different effects [340]. However, results from human 
studies have been inconsistent. One-week intakes of 2.7 g sodium propionate taken as a capsule 
[343] did not affect serum lipids. Only one study showed that 5.4 g of propionate given daily for 2 
weeks lowered LDL-C and total cholesterol in subjects with total cholesterol>5.5 mmol/L [324]. 
Studies using rectal infusions indicated that 180 mmol of propionate did not affect serum lipids or 
triglycerides in healthy young men and women. However, when 60 mmol of propionate was infused 
with 180 mmol of acetate, free fatty acids decreased by an additional 10% and negated the increase 
in total and LDL-C seen when acetate was given alone [344]. Therefore, it still seems possible that 
one of the determinants of the actions of propionate on serum lipids is the ratio of propionate to 
acetate [345,346]. 
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Propionate 
Propionate is produced via 2 main pathways: (1) fixation of CO2 to form succinate, which is 
subsequently decarboxylated (the ‘‘dicarboxylic acid pathway’’); (2) from lactate and acrylate (the 
‘‘acrylate pathway’’) [22]. Propionate is a substrate for hepatic gluconeogenesis and has been 
reported to inhibit cholesterol synthesis in hepatic tissue [343]. However, propionate seems to have 
two competing and opposite effects on gluconeogenesis. It is both a substrate for gluconeogenesis 
and an inhibitor of gluconeogenesis. Propionate enters the Krebs cycle at the level of succinyl CoA. 
The inhibiting effect of propionate on gluconeogenesis may be related to its metabolic 
intermediaries, methymalonyl CoA and succinyl CoA, which are specific inhibitors of pyruvate 
carboxylase. Propionate enhances glycolysis, probably by depleting hepatic citrate, which is an 
important metabolic inhibitor of phosphofructokinase. Propionate may also influence hepatic 
glucose metabolism indirectly by lowering the plasma fatty acid concentration, which, in itself, is 
known to be closely related to the actual rate of gluconeogenesis [347]. 
The majority of our knowledge about the nutritional fate of propionate comes from studies in 
ruminants. Intestinal glucose uptake is minimal in ruminants because of the presence of microbiota 
in their rumen for the digestion and fermentation of carbohydrates. However, propionate 
metabolism in humans is less well understood. In humans, propionate may also have systemic 
effects, specifically a hypolipidemic action. Observations in animals suggest that propionate inhibits 
cholesterol synthesis by inhibiting both 3-hydroxy-3-methylglutaryl- CoA synthase and 3-hydroxy-
3-methylglutaryl-CoA reductase [348]. As previously mentioned, polyfructans are bifidogenic and 
decrease the acetate: propionate ratio, both of which are associated with reductions in serum lipids. 
The use of polyfructans (eg, Neosugar, inulin) in individuals with Type 2 diabetes mellitus (8 g/d) 
[349] and hyperlipidemia (18 g/d) [350] resulted in cholesterol reductions. However, no 
hypolipidemic effect (20 g/d) was observed in healthy subjects [323]. This inconsistency in human 
intervention studies, in contrast to animal experiments, may be related to species differences. A 
number of mechanisms have been suggested to be responsible for the observed lipid lowering 
effect, with increased propionate production being one of the possible mechanisms of action. 
Increased production of propionate, through fermentation, may inhibit hepatic cholesterol synthesis 
[344,345]. This has been supported in studies with hyperlipidemic experimental animals [342] but 
not supported in other animal studies [351]. Currently, there are limited human experimental data 
that have quantified the synthesis of acetate and propionate with use of prebiotics. Propionate is 
better absorbed in the human colon than acetate [352], and studies in ruminant mucosa show that 
propionate is activated to its coenzyme A derivative (a step required for its oxidation) to a greater 
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extent than acetate. The liver extracts 90% of propionate, as opposed to 75% of acetate, during a 
single pass [334] and colon infusions of equal amounts of acetate and propionate suggest that the 
amount of colonic propionate reaching peripheral blood is only 25% of the amount of total colonic 
acetate. 
 
Butyrate 
Butyrate is the preferred fuel of the colonic epithelial cells which also plays a major role in 
regulation of cell proliferation and differentiation [303,353]. It is the most important SCFA in 
colonocyte metabolism, where 70% to 90% of butyrate is metabolized by the colonocyte [306]. 
Butyrate is used preferentially over propionate and acetate in a ratio of 90:30:50 [306], and is 
preferred over glucose or glutamine supplied by blood [354]. Butyrate oxidation has been shown to 
make up more than 70% of the oxygen consumed by human colonic tissue. Sodium butyrate exerts 
an antiproliferative activity on many cell types, and there are evidence from animal and cell line 
studies, that have demonstrated preventive effects of butyrate on colon cancer and adenoma 
development [355]. Acetate and propionate have also been shown to induce apoptosis in colorectal 
tumor cell lines, but to a much lesser extent than butyrate [356]. Butyrate also stimulates 
immunogenicity of cancer cells [357]. Currently, the mechanisms of action of butyrate in relation to 
colon cancer are not clearly defined. Butyrate induces p21WAFI/Cip1 protein and mRNA levels 
[358], which can block the cell cycle at G1, resulting in the inhibition of cell proliferation. This 
blockage of the cell cycle at G1 might allow DNA checkpoint-mediated repair of genomic 
instability or mutations [359]. Through inhibition of histone deacetylase, butyrate has been shown 
to induce apoptosis through hyperacetylation of histones (H3 and H4) [360], resulting in the DNA 
being in a more open form [361]. The open form of the DNA would be ideal if DNA damage had 
occurred and repair enzymes were necessary to approach the damaged DNA. However, the open 
form of the DNA may be more susceptible to mutation in the presence of a carcinogen [362]. The 
ability of butyrate to inhibit histone deacetylase may also have a role in reversing epigenetic events 
[363]. In vitro, butyrate can also induce differentiation of neoplastic colonocytes producing a 
phenotype typically associated with normal mature cells [363]. The drop in colonic pH caused by 
accumulation of SCFAs decrease the solubility of free bile acids, which may decrease the potential 
tumor promoter activity of secondary bile acids [364]. 
Furthermore, increased colonic acidification (pH below 6 to 6.5) may inhibit colonic bacterial 
enzyme 7 α-dehydroxylase, which degrades primary bile acids to secondary bile acids [365]. In 
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addition, decreased colonic pH increases the availability of calcium for binding to free bile acids 
and fatty acids [366]. In vitro and in vivo studies have shown that butyrate is the preferred energy 
substrate and stimulates cell proliferation in normal colonocytes [338,353], yet it suppresses 
proliferation of colon adenocarcinoma cells. This observed inconsistency has been termed the 
‘‘butyrate paradox’’[359,362]. This discrepancy may be explained by differences between in vitro 
and in vivo environments, the timing of butyrate administration in relation to the stage of cancer 
development, the amount of butyrate administered, the source of butyrate (ie, different dietary 
fibers), and interaction with dietary fat [362]. SCFA enemas, especially butyrate, have also been 
used as a possible treatment for bowel inflammation, including diversion and ulcerative colitis. 
Roediger [367] demonstrated that colonocytes of individuals with active and quiescent ulcerative 
colitis have reduced butyrate oxidation compared with controls. Harig et al., [368] administered a 
SCFA enema solution of 60 mM of sodium acetate, 30 mM of sodium propionate, and 40 mM of 
sodium n-butyrate to 5 patients with diversion colitis for a period of 2 to 6 weeks. This study was 
the first to provide evidence that an absence or near absence of SCFAs often lead to rectosigmoid 
colitis, which suggested that a local nutrient deficiency led to an inflammatory state. The resupply 
of nutrients, either by surgical reanastomosis or SCFA irrigation, resulted in marked improvements 
by endoscopic appearance and histologic findings. However, another study using the same SCFA 
enema solution in 13 patients with diversion colitis resulted in no endoscopic or histologic changes 
after 2 weeks [369]. SCFA irrigation for the treatment of distal ulcerative colitis has produced 
inconsistent results [370], some showing it to be an effective treatment [371] and others not [372]. 
Possible explanations for the inconsistencies include type of SCFA used (mixture or butyrate 
alone), SCFA concentrations, frequency of administration, and duration of treatment. Mechanisms 
of action have been proposed to explain the use of SCFA irrigation as a possible treatment of bowel 
inflammation. These include a lack of luminal SCFAs (ie, a nutritional deficiency of colonic 
epithelium) and a block in the uptake or oxidation of SCFA by colonocytes [373,374], possibly 
because of a reduction in coenzyme A which is required for fatty acid oxidation [367]. It has been 
suggested that the latter may result from the production of sulfur-containing compounds by colonic 
microflora [375]. However, this block in uptake and oxidation may be overcome by ‘‘mass action’’; 
in other words, by raising SCFAs to higher than normal concentrations in the colonic lumen [374]. 
The use of SCFA irrigation as a treatment for colitis still remains inconclusive. 
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Fig. 4.2. Production and absorption of SCFAs along colon. 
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4.1 GPR43 and GPR41 as key receptors for short-chain fatty acids 
 
G-protein-coupled receptors (GPCRs) are seven-transmembrane (7TM) receptors that mediate 
cellular responses to the majority of hormones and neurotransmitters, and are therefore attractive 
targets for drug discovery [376]. Free fatty acids (FFAs) have long been considered as key signaling 
molecules in numerous physiological and pathological processes. The recent identification of a 
family of GPCRs that bind FFAs has highlighted new potential mechanisms of action for FFAs in 
health and disease [377]. Among these FFAs receptors, GPR43 is present in a large variety of 
tissues, including adipose tissue, inflammatory cells, and gastrointestinal (GI) tract and it is 
activated by SCFAs [109,378]. The identification of these endogenous ligands of GPR43 has led 
the scientific community to propose a new appellation for GPR43, namely FFA2 or FFAR2 
[377,379]. SCFAs bind GPR43 in the following rank order of potency: propionate > 
acetate=butyrate > valerate > formate [378,379]. Importantly, SCFAs also activate another receptor 
of the same family, GPR41, with propionate and butyrate being the most potent agonists [378,380]. 
Both receptors can couple to Gi/0 resulting in inhibition of the adenylate cyclase pathway, but only 
GPR43 is also able to couple to Gq, thus leading to activation of the phospholipase C (PLC) 
pathway and increased intracellular calcium levels [378,380]. GPR41 and GPR43 bind the same 
family of ligands (SCFAs), exhibit some overlapping expression, and partially share signaling 
pathways (Gi/0). Furthermore, both receptors represent potentially interesting targets for drug 
discovery.  
 
GPR43 and GI tract functions 
Since GPR43 is largely expressed throughout the gut, several authors have suggested that 
some effects of SCFAs could be GPR43-dependent. In 2006, Karaki et al. demonstrated that GPR43 
was expressed in rat distal ileum and colon. Interestingly, peptide YY (PYY)-containing 
enteroendocrine L cells were immunoreactive for GPR43, whereas 5-hydroxytryptamine (5-HT) 
immunoreactive mast cells coexpressed GPR43 [381]. PYY is a satietogenic peptide that inhibits 
upper GI motility and SCFAs have been shown to induce its release in the blood [382]. Therefore, 
SCFAs might stimulate L cells to release PYY via GPR43 activation, thus slowing intestinal transit. 
GPR43 expression in these enteroendocrine L cells was observed likewise in the human colon 
[383]. SCFAs also exert physiological effects on colonic motility and secretion via 5-HT release 
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[384] and Karaki et al. proposed this might be attributable to the activation of GPR43 on 5-HT-
containing mast cells [381]. The presence of GPR43 throughout the rat gut, with the lowest mRNA 
levels observed in the esophagus and stomach and the highest levels detected in the colon, was 
confirmed in another study [385]. 
Glucagon-like peptide 1 (GLP-1) is another gut hormone released by enteroendocrine L cells that is 
involved in the control of intestinal function and glucose metabolism [386]. SCFA infusion was 
shown to induce plasma GLP-1 release in animals and humans [387]. Interestingly, co-localization 
of GPR43 and GLP-1 in enteroendocrine L cells was demonstrated in both rat and human colon and 
terminal ileum [388]. In rodents, supplementation with fermentable carbohydrates increased GLP-1 
production and the density of GPR43/GLP-1-positive enteroendocrine L cells in the proximal colon 
[388,389]. Therefore, a higher colonic production of SCFAs following dietary fiber fermentation 
increase GLP-1 secretion, via GPR43 activation in enteroendocrine L cells. This hypothesis has 
been recently confirmed by Tolhurst et al. [390]. The SCFA-triggered secretion of GLP-1 was 
almost completely abolished in primary colonic cultures from GPR43 KO mice but was also 
reduced, to a lesser extent, in mice lacking GPR41. GPR43-deficient mice had significantly reduced 
colonic GLP-1 protein content. Moreover, basal and glucose-stimulated levels of active GLP-1 were 
reduced in both GPR43 and GPR41 KO mice. These effects were associated with impaired glucose 
tolerance. Even if mice lacking GPR43 also exhibited decreased colonic expression of GPR41, a 
dominant role for GPR43 in SCFA-induced L cell activation was suggested based on the prevailing 
involvement of Gq coupled pathways in this process (Figure 4.3) [390]. These results reveal again 
the difficulty to generate GPR43 KO mice without affecting GPR41, thus introducing uncertainties 
about their interpretation. Studies conducted in germ-free (GF) mice highlighted a potential link 
between gut microbiota and the expression of FFA receptors. The conventionalization (colonization 
by normal mouse microbiota) of GF mice increased adiposity and decreased the expression of 
GPR41 and GPR43 in the distal small intestine [111]. However, another study reported that GF 
mice exhibited decreased intestinal expression of GPR43, GPR41, PYY, and GLP-1 as compared 
with conventional mice. It is worth noting that the expression of GPR43 and GPR41 was 
differentially affected in GF mice, with a 10% and 70% decrease, respectively. This was associated 
with lower levels of circulating PYY [391]. Overall, these results suggest that gut microbiota can 
influence the intestinal expression of SCFA receptors and the secretion of gut peptides, but further 
studies are needed to elucidate the underlying mechanisms. 
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Fig. 4.3. Location and physiological functions of G-protein-coupled receptor 43 (GPR43). Studies in rodents have highlighted that SCFAs bind to 
GPR43 to exert several physiological actions. GPR43 activation on intestinal enteroendocrine cells (in pink) induces the production of PYY and GLP-
1. PYY inhibits intestinal transit and appetite, whereas GLP-1 is anorexigenic and stimulates insulin secretion. In mice, GPR43 expression increases 
during adipogenesis and SCFAs stimulate adipocyte differentiation (fibroblast in orange). Through their binding to GPR43, SCFAs also inhibit 
lipolysis in mature adipocytes (in yellow). Finally, SCFAs induce chemotaxis of neutrophils (in blue) through GPR43 activation. Abbreviations: TG, 
triglycerides; FFAs, free fatty acids. Image from : Bindels LB, Dewulf EM, Delzenne NM. GPR43/FFA2: physiopathological relevance and 
therapeutic prospects. Trends Pharmacol Sci. 2013 Apr;34(4):226-32. doi: 10.1016/j.tips.2013.02.002. Epub 2013 Mar 13. 
 
GPR43 and inflammation 
SCFAs have long been known to modulate the production of pro- and anti-inflammatory 
mediators [392]. For instance, production of prostaglandin E2 is induced by SCFAs. This process 
can be inhibited by pertussis toxin, suggesting the involvement of a G-protein-mediated signalling 
[393]. The formal proof of GPR43 involvement in the management of inflammation was 
simultaneously provided by two research teams. They both established the contribution of GPR43 
to the recruitment of immune cells [6,48], and this observation was further confirmed by others 
[394]. However, these studies showed divergent findings on the potential impact of GPR43 in 
inflammatory diseases. Maslowski et al., [109] demonstrated that stimulation of GPR43 by acetate 
allowed resolution of a colitis-related inflammatory response. GPR43 KO mice showed exacerbated 
or unresolved inflammation in cases of acute and chronic colitis, arthritis, and asthma. This could be 
related to increased immune cell recruitment [109]. By contrast, Sina et al. reported that, in an acute 
colitis model, GPR43 KO mice showed an increased mortality compared with control mice, despite 
reduced immune cell recruitment, decreased colonic inflammation, and attenuated colonic tissue 
damage. The increased mortality was attributed to septic complication. In a chronic colitis model, 
GPR43 deficiency led to reduced colonic inflammation, without any sign of sepsis and any lethality. 
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The authors pointed out the bipotential pathophysiological role of immune cells at the intestinal 
level, being a protective factor against acute bacterial transmigration, but having a detrimental role 
in chronic inflammatory responses [395]. Clearly, GPR43 is involved in the SCFA-induced 
neutrophil chemotaxis in mice (Figure 4.3) [109,394]. However, demonstrating GPR43 
contribution to human neutrophil chemotaxis remains to be accomplished. Interestingly, 
GLPG0974, an orally available small GPR43 inhibitor from Galapagos with undisclosed structure, 
has been claimed to reduce neutrophil migration. GLPG0974 is currently being tested in a second 
Phase I study and results are expected in early 2013 (ClinicalTrials.gov; identifier: NCT01721980). 
The global role of GPR43 in inflammatory conditions needs to be clarified before ruling on the 
therapeutic potential of GPR43 in this context. The dualistic action of SCFAs, being anti-
inflammatory while recruiting neutrophils, might be one of the keys to full understanding of how 
SCFAs and GPR43 manage inflammation. Importantly, a comparison of several studies highlights 
that the biological and molecular responses to SCFAs differ in the several type of immune cell 
[394]. This might be consistent with the various temporal roles of these cells in an inflammatory 
response [393]. Therefore, the different molecular pathways downstream of GPR43 remain to be 
elucidated. Finally, ITF prebiotic feeding can control inflammation in rodent models of colitis, 
obesity, diabetes, and leukemia [396,397]. It is possible to postulate that prebiotics, through their 
fermentation into SCFAs, might exert some of their anti-inflammatory effects in a GPR43-
dependent manner, this hypotetesis need to be confirmed. 
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4.2 Effects of Butyrate at intestinal level 
 
Effects on transepithelial ion transport 
Potentially, SCFAs are absorbed by each intestinal segment, as demonstrated in animal 
models and human volunteers. The colonocytes absorb butyrate and other SCFAs through different 
mechanisms of apical membrane SCFA uptake, including non-ionic diffusion, SCFA/HCO3
-
 
exchange, and active transport by SCFA transporters. The transport proteins involved are 
monocarboxylate transporter isoform 1 (MCT1), which is coupled to a transmembrane H
+
-gradient, 
and SLC5A8, which is Na
+
-coupled co-transporter [398,399]. The absorption of these fatty acids 
has a significant impact on the absorption of NaCl and, generally, on the electrolyte balance [400]. 
In particular, butyrate is able to exert a powerful proabsorptive stimulus on intestinal NaCl transport 
and an anti-secretory effect towards Cl
-
 secretion. The powerful regulatory pro-absorptive/anti-
secretory effects induced by butyrate on the transepithelial ion transport occurs through several 
mechanisms: (1) stimulation of NaCl absorption by the action of two coupled transport systems on 
the intestinal brush border: Cl
-
/HCO3
- 
and Na
+
/H
+
 and Cl
-
/butyrate and Na
+
/H
+
; and (2) inhibition 
of Cl
-
 secretion by blocking the activity of the cotransporter Na
+
-K
+
-2Cl
-
 (NKCC1) on the 
enterocyte basolateral membrane. In vitro studies have shown that butyrate has an inhibitory effect 
on Cl
-
 secretion induced by prostaglandin E2, cholera toxin, and phosphocholine. This effect is due 
to reduced production of intracellular cAMP secondary to the expression and regulation of 
adenylate cyclase [399]. Comparison studies showed that the pro-absorptive and anti-secretory 
effects of butyrate are significantly higher than those of all other SCFAs [400]. Clinical studies in 
children with acute diarrhea caused by V. cholerae showed a reduction in stool volume and a more 
rapid recovery in patients who received oral rehydration therapy in addition to resistant starch, a 
precursor of butyrate, in the diet [401]. These results were confirmed in other forms of infectious 
diarrhea in children and in animal models studies [402]. Moreover, butyrate therapy is beneficial in 
patients affected by Congenital Chloride Diarrhea (CLD) [403]. This rare genetic disease is caused 
by mutations in the gene encoding the solute-linked carrier family 26-member A3 (SLC26A3) 
protein, which acts as a plasma membrane anion exchanger for Cl
-
 and HCO3
-
 [404]. The 
mechanism underlying this therapeutic effect could be related, at least in part, to stimulation of the 
Cl
-
/butyrate exchanger activity [403]. It is also possible that butyrate could reduce mistrafficking or 
misfolding of the SLC26A3 protein, as demonstrated for other molecules involved in transepithelial 
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ion transport [405]. Alternatively, butyrate may enhance gene expression: the SLC26A3 gene 
contains a 290-bp region between residues -398 and -688 that is crucial for high-level 
transcriptional activation induced by butyrate. This may explain the variable response of patients 
affected by CLD to butyrate [406]. In fact, depending on the patient’s genotype, mutations in the 
above-mentioned regulatory regions of the SLC26A3 gene could affect the gene transcription rate. 
It is also conceivable that other channels could be involved in the therapeutic effect of butyrate in 
CLD. 
 
Effects on cell growth and differentiation 
Several epidemiological studies support the role of dietary fiber in the protection against 
colorectal cancer [407,408]. Different mechanisms have been proposed for fiber’s cancer preventive 
properties: reduction in transit time of the feces in the gut, which reduces exposure of the mucosa to 
luminal carcinogens; absorption of bile acids, biogenic amines, bacterial toxins, and production of 
butyrate. Most of the anticarcinogenic effects of butyrate are observed in vitro carcinoma cell lines. 
In these models, addition of butyrate leads to inhibition of proliferation, induction of apoptosis, or 
differentiation of tumor cells [409,410]. Butyrate’s anticarcinogenic effects are in contrast with the 
effects of this compound in normal enterocytes. In fact, it has been shown that butyrate stimulates 
the physiological pattern of proliferation in the basal crypt in the colon, whereas it reduces the 
number and the size of aberrant crypt focus, which are the earliest detectable neoplastic lesions in 
the colon [411]. These contradictory patterns of butyrate represents the so called “butyrate paradox” 
[409]. An important mechanism by which butyrate causes biological effects in colon carcinoma 
cells is the hyperacetylation of histones by inhibiting histone deacetylase (HDAC). This 
compensates for an imbalance of histone acetylation, which can lead to transcriptional 
dysregulation and silencing of genes that are involved in the control of cell cycle progression, 
differentiation, apoptosis and cancer development [412,413]. In particular, in human colon cancer 
cell lines butyrate, acting as HDAC inhibitor, increases the p21 (WAF1) gene expression by 
selectively regulating the degree of acetylation of the gene-associated histones, and induces G1 cell 
cycle arrest [414]. A novel contributory mechanism to the chemopreventive effect of butyrate is the 
downregulation of the key apoptotic and angiogenesis regulator Neuropilin-1 (NRP-1), which has 
been shown to promote tumor cell migration and survival in colon cancer in response to vascular 
endothelial growth factor (VEGF) binding [415]. Several reports have shown that the apoptosis 
triggered by butyrate in vitro is associated with dysregulation of Bcl2 family proteins, especially 
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upregulation of BAK and downregulation of Bcl-xL [416], rather than cellular damage. A study by 
Thangaraju et al suggests a novel mode of action of butyrate in the colon involving GPR109A, a G-
protein–coupled receptor for nicotinate [417], which recognises butyrate with low affinity. This 
receptor is expressed in the normal colon on the lumenfacing apical membrane of colonic epithelial 
cells, but is silenced in colon cancer via DNA methylation. Thangaraju et al., [417] showed that 
inhibition of DNA methylation in colon cancer cells induces GPR109A expression and that 
activation of the receptor causes tumor cell–specific apoptosis. Butyrate is an inhibitor of HDAC, 
but apoptosis induced by activation of GPR109A with its ligands in colon cancer cells does not 
involve inhibition of histone deacetylation. The primary changes in this apoptotic process include 
downregulation of Bcl-2, Bcl-xL, and cyclin D1 and upregulation of death receptor pathway. 
Moreover, a recent study suggested that the protective role of dietary fiber, and its breakdown 
product butyrate, against colorectal cancer could be determined by a modulation of canonical Wnt 
signaling, a pathway constitutively activated in the majority of colorectal cancers [418]. Butyrate is 
recognised for its potential to act on secondary chemoprevention, by slowing growth and activating 
apoptosis in colon cancer cells [359], but it can also act on primary chemoprevention. The 
mechanism proposed is the transcriptional upregulation of detoxifying enzymes, such as 
glutathione-S-transferases (GSTs). This modulation of genes may protect cells from genotoxic 
carcinogens, such as H2O2 and HNE [412]. 
 
Effects on inflammatory and oxidative status 
Butyrate plays a role as an anti-inflammatory agent, primarily via inhibition of NF-κB 
activation in human colonic epithelial cells [419], which may result from the inhibition of HDAC. 
NF-κB regulates many cellular genes involved in early immune inflammatory responses, including 
IL-1, TNF-α, IL-2, IL-6, IL-8, IL-12, iNOS, COX-2, intercellular adhesion molecule-1 (ICAM-1), 
vascular cellular adhesion molecule-1 (VCAM-1), T cell receptor-α (TCR-α), and MHC class Ⅱ 
molecules [420]. The activity of NF-κB is frequently dysregulated in colon cancer [421] and in 
IBDs, such as ulcerative colitis and Crohn’s disease [422]. In CD patients, butyrate decreases pro-
inflammatory cytokine expression via inhibition of NF-κB activation and IκBα degradation [422]. 
The upregulation of PPAR-γ and the inhibition of IFN-γ signaling, are another two of butyrate’s 
anti-inflammatory effects [423]. Butyrate can act on immune cells through GPR41 (or FFA3) and 
GPR43 (or FFA2), which are both expressed on immune cells, including polymorphonuclear cells, 
suggesting that butyrate might be involved in the activation of leucocytes [424]. The possible 
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immune-modulatory functions of SCFAs are highlighted by a recent study on GPR43 -/-mice. 
These mice exhibit aggravated inflammation, related to increased production of inflammatory 
mediators and increased immune cell recruitment [395]. Most clinical studies analyzing the effects 
of butyrate on inflammatory status focused on UC patients. Hallert et al. [425] instructed 22 patients 
with quiescent UC to add 60 g oat bran (corresponding to 20 g dietary fiber) to their daily diet. Four 
weeks of this treatment resulted in a significant increase of fecal butyrate concentration and in a 
significant improvement of abdominal symptoms. In a double blind, placebo-controlled multicenter 
trial, Vernia et al., [426] treated 51 patients with active distal UC with rectal enemas containing 
either 5-aminosalicylic acid (5-ASA) or 5-ASA plus sodium butyrate (80 mmol/L, twice a day). The 
combined treatment with topical 5-ASA plus sodium butyrate significantly improved the disease 
activity score more than 5-ASA alone. These and other intervention studies [427] suggested that the 
luminal administration of butyrate or stimulation of luminal butyrate production by the ingestion of 
dietary fiber results in an amelioration of the inflammation and symptoms in UC patients. 
Numerous studies have reported that butyrate metabolism is impaired in intestinal inflamed mucosa 
of patients with IBD. Recent data show that butyrate deficiency results from the reduction of 
butyrate uptake by the inflamed mucosa through downregulation of MCT1. The concomitant 
induction of the glucose transporter GLUT1 suggests that inflammation could induce a metabolic 
switch from butyrate to glucose oxidation. Butyrate transport deficiency is expected to have clinical 
consequences. Particularly, the reduction of the intracellular availability of butyrate in colonocytes 
may decrease its protective effects toward cancer in IBD patients [428]. Limited evidence from pre-
clinical studies shows that oxidative stress in the colonic mucosa can be modulated by butyrate. 
Oxidative stress is involved in both inflammation [429] and the process of initiation and 
progression of carcinogenesis [430]. During oxidative stress there is an imbalance between the 
generation of reactive oxygen species (ROS) and the antioxidant defense mechanisms, leading to a 
cascade of reactions in which lipids, proteins, and/or DNA may get damaged. In healthy humans, it 
has been demonstrated that locally administered butyrate in physiological concentrations increased 
the antioxidant GSH and possibly decreased ROS production, as indicated by a decreased uric acid 
production [431]. As the human colon is continuously exposed to a variety of toxic stimuli, 
enhanced butyrate production in the colon could result in an enhanced resistance against toxic 
stimuli, thus improving the barrier function. This might be relevant for the treatment of 
gastrointestinal disorders, such as post-infectious irritable bowel syndrome (IBS), microscopic 
colitis, IBDs, and diversion colitis. 
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Butyrate and intestinal epithelial permeability 
Intestinal epithelial permeability has been widely studied as an important parameter of the 
intestinal defence barrier. Under normal conditions, the epithelium provides a highly selective 
barrier that prevents the passage of toxic and proinflammatory molecules from the external milieu 
into the submucosa and systemic circulation. Macromolecules pass the epithelial barrier mainly via 
the paracellular route for which tight junctions are the rate-limiting structures [432]. Increased 
permeability, indicating impaired epithelial barrier function, is thought to be involved in the 
pathophysiology of several gastrointestinal inflammatory diseases, but can either be a cause or a 
consequence of inflammation [433]. Several studies have assessed the effects of butyrate on 
intestinal permeability in vitro as well as ex vivo. At low concentrations, butyrate (up to 2 mM) 
induces a concentration-dependent reversible decrease in permeability in a Caco-2 and HT-29 cell 
lines [434,435]. This decrease in permeability may be related to the butyrate associated increased 
expression of tight junction proteins observed in different cultured cell lines, but this effect was 
shown to be cell type dependent [436]. At higher concentrations (8 mM), however, butyrate 
increased the permeability in a Caco-2 cell line [435]. An ex vivo study, using adult rat distal colon 
mucosa mounted in an Ussing chamber, demonstrated that acute exposure to butyrate at a 
concentration of 10 mM, but not 1 or 5 mM increased paracellular permeability in rat colon [437]. 
This has also been demonstrated in rats fed a diet-containing fermentable FOS. The rapid bacterial 
fermentation of FOS led to accumulation of high concentrations of SCFAs that increased intestinal 
permeability and was associated with increased translocation of Salmonella [438]. However, in 
humans, daily FOS supplementation of 20 g did not increase intestinal permeability [439]. It can be 
concluded that the effect of butyrate on intestinal permeability depends on its concentration and on 
the model system or species used. The effects of butyrate at different concentrations remain to be 
evaluated in the human in vivo situation. 
 
Effects on visceral perception and intestinal motility 
Little is known about the environmental and nutritional regulation of the enteric nervous 
system (ENS), which controls gastrointestinal motility. Butyrate regulates colonic mucosa 
homeostasis and can modulate neuronal excitability. Soret et al., [440] investigated the effects of 
butyrate on the ENS and colonic motility, and showed, in vivo and in vitro, that butyrate 
significantly increased the proportion of choline acetyltransferase (ChAT), but not neuronal nitric 
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oxide synthase (nNOS) immunoreactive myenteric neurons. Butyrate increases the cholinergic-
mediated colonic circular muscle contractile response ex vivo. The authors suggest that butyrate 
might be used, along with nutritional approaches, to treat various gastrointestinal motility disorders 
associated with inhibition of colonic transit. A recent study by Vanhoutvin et al., [441] shows that 
intraluminal administration of a physiologically relevant dose (50 to 100 mmol/L-) of butyrate into 
the distal colon increases compliance and decreases pain, urge, and discomfort measured with a 
rectal barostat procedure in healthy subjects. This study suggests a potential beneficial effect of 
butyrate in disorders that are associated with visceral hypersensitivity, such as IBS and infantile 
colics, and provides a basis for future trials with dietary modulation resulting in intracolonic 
butyrate production in both healthy and IBS subjects. The decrease in visceral perception induced 
by butyrate treatment could be due to an increased 5-HT release, as previously suggested by others 
[442]. Another possible mechanism by which butyrate could affect visceral perception is the 
previous reported inhibition of histone deacetylase. In fact, Chen et al., [443] showed that these 
inhibitors induce microglyal apoptosis and attenuate inflammation-induced neurotoxicity in rats, 
which may affect visceral perception. Butyrate has been reported to induce enhancement of colonic 
motility via the release of 5-HT [444]. In functional studies, butyrate and propionate induced phasic 
and tonic contractions in rat colonic circular muscle. The dose-dependent contractile effect occurred 
only when SCFAs were applied on the mucosal side and disappeared in mucosal free preparations, 
suggesting the presence of sensory mechanisms near the epithelium [384]. 
 
Effects on non-specific intestinal defense mechanisms 
Besides the effects of butyrate on carcinogenesis, inflammation and oxidative stress, butyrate 
has been shown to affect several components of the colonic defence barrier leading to enhanced 
protection against luminal antigens. One important component of this barrier is the mucous layer 
covering the epithelial lining consisting of mainly mucin glycoproteins and trefoil factors (ITF or 
TFF3). Mucin glycoproteins are classified into neutral and acidic subtypes and the latter category 
further includes sulfomucins and sialomucins. Sulphated mucins are generally considered to be 
more resistant to bacterial degradation [445]. Several epithelial mucin (MUC) genes have been 
identified in humans, of which MUC2 is predominantly expressed in the human colon [446]. 
Alterations in goblet cell function, composition and thickness of the intestinal mucous layer have 
been found in several intestinal disorders. For example, a reduced mucous thickness and a 
decreased MUC2 production have been reported in UC patients [447]. In vitro studies, butyrate 
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increased the MUC2 gene expression in specific cell lines [448,449]. In addition, 0.1–1 mM 
butyrate administered to human colonic biopsy specimens ex vivo stimulated mucin synthesis [450]. 
Luminal butyrate administration of 5 mM, but not 100 mM, increased mucous secretion in an 
isolated perfused rat colon [451]. In another rat study, caecal and faecal SCFA concentrations were 
found to correlate with mucous thickness. In humans, effects of butyrate alone on mucous synthesis, 
thickness of the mucous layer and MUC expression in vivo have not been reported. The effects of a 
number of fermentable dietary fibres on the mucous layer have been studied with varying results. 
For example, resistant starch increased the number of acidic mucins, but did not affect the number 
of goblet cells in rats [452]. In contrast, FOS increased the number of goblet cells in piglets [453]. 
In a human intervention study with patients with an ileo-anal pouch, inulin supplementation did not 
alter MUC2 expression or the ratio between sulfomucins and sialomucins [454]. Trefoil factors are 
mucin-associated peptides that contribute to the viscoelastic properties of the mucous layer. TFFs 
are thought to reduce the recruitment of inflammatory cells and to be involved in the maintenance 
and repair of the intestinal mucosa, although the exact mechanism for this effect is not yet known 
[455]. Intestinal trefoil factor is almost exclusively secreted by the intestinal goblet cells [456]. In a 
rat TNBS model of colitis, TFF3 expression was decreased during active disease, and intracolonic 
administration of butyrate increased TFF3 expression [457]. However, butyrate inhibited the 
expression of TFF3 in colon cancer cell lines and in colonic tissue of newborn rats [458]. Other 
components of the colonic defence barrier that are involved in the maintenance of the colonic 
barrier, which may be influenced by butyrate are transglutaminase, antimicrobial peptides and heat 
shock proteins (HSPs). The enzyme transglutaminase is actively involved in intestinal mucosal 
healing and correlates with the severity of inflammation in UC [459]. In a rat model of colitis, 
butyrate restored the colonic transglutaminase levels [460]. Antimicrobial peptides such as 
cathelicidin (LL-37) and defensins, protect the gastrointestinal mucosa against the invasion and 
adherence of bacteria and thereby prevent infection [461,462]. Several in vitro studies have shown 
that butyrate upregulates the expression of LL-37 in different colon epithelial cell lines as well as in 
freshly isolated colorectal epithelial cells [463]. HSPs confer protection against inflammation by 
suppressing the production of inflammatory modulators [464,465]. Butyrate induced the expression 
of HSP70 and HSP25 in Caco-2 cells [465] and in rats [452,464]. However, in a study in rats with 
DSS induced colitis, butyrate inhibited HSP70 expression. This was related to protection against the 
decrease in cell viability, increase in mucosal permeability and neutrophil infiltration in DSS colitis. 
It was concluded that the induction of heat shock response has a protective effect before an injury, 
whereas activation of heat shock response leads to cytotoxic effects after a proinflammatory 
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stimulus [466]. In addition, there is evidence from in vitro studies with human colon cancer cell 
lines that butyrate is involved in repair after mucosal damage through an increase in the rate of cell 
migration. Efficient repair of superficial injuries and mucosal ulcers is important in maintaining and 
re-establishing the epithelial barrier [467]. In conclusion, there are several lines of evidence 
suggesting that butyrate reinforces the colonic defence barrier by affecting several components of 
this barrier, such as the promotion of epithelial migration and the induction of mucins, TFF, 
transglutaminase activity, antimicrobial peptides and HSPs. However, most of these effects still 
have to be confirmed in the human studies. The effects of butyrate at intestinal levels are resumed in 
schematic figure 4.4. 
 
 
Fig. 4.4. Effects of butyrate at intestinal level. 
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4.3 Extraintestinal Effects of Butyrate 
 
Hemoglobinopathies 
Clinical trials in patients with sickle cell disease and β-thalassemia confirmed the ability of 
butyrate to increase fetal hemoglobin (HbF) production [468,469]. Butyrate is an inducer of HbF 
through an epigenetic regulation of fetal globin gene expression via HDAC inhibition, resulting in 
global histone hyperacetylation, including nucleosomes at the γ-globin promoters [470]. Other 
experiments have shown that butyrate can cause a rapid increase in the association of γ-globin 
mRNA with ribosomes [471]. Other authors have demonstrated activation of p38 mitogen activated 
protein kinases and cyclic nucleotide signaling pathways in association with butyrate induction of 
HbF [472]. Taken together, these studies suggest that global histone hyperacetylation induced by 
HDAC inhibition is not the unique mechanism underlying butyrate stimulation of HbF. 
 
Genetic metabolic diseases 
Sodium phenylbutyrate 4 (4-PBA) was approved by the Food and Drug Administration 
(FDA) for use in patients with urea cycle enzyme deficiency, in which it acts as a scavenger of 
ammonia. Indeed, 4-PBA is oxidized to phenylacetate, which binds to glutamine and determines the 
urinary excretion. In patients with ornithine transcarbamylase deficiency, the use of 4-PBA allows 
for better metabolic control and increased intake of natural protein in the diet [473]. The possible 
use of butyrate in the treatment of X-linked Adrenoleukodystrophy (X-ALD), a disorder of 
peroxisomes characterized by altered metabolism and accumulation of very long chain fatty acids, 
has also been studied. Sodium phenylbutyrate 4 induces, in vitro on fibroblasts from patients with 
X-ALD and in vivo in X-ALD knockout mice, an increase in β-oxidation of very long chain fatty 
acids and peroxisome proliferation [474]. 
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Hypercholesterolemia 
Under normal lipidemic conditions, the liver is the most important site of cholesterol 
biosynthesis, followed by the intestine. Biosynthesis in the liver and intestine account for about 
15% and 10%, respectively, of the total amount of cholesterol biosynthesis each day [475]. In 
hypercholesterolemia, when cholesterol biosynthesis is suppressed in most organs by fasting, the 
intestine becomes the major site of cholesterol biosynthesis, and its contribution can increase up to 
50%. Importantly, recent evidence shows that the global effect of butyrate is to downregulate the 
expression of nine key genes involved in intestinal cholesterol biosynthesis, potentially inhibiting 
this pathway [476]. 
 
Obesity and insulin resistance 
Dietary supplementation with butyrate can prevent and treat diet-induced obesity and insulin 
resistance in mouse models. After a 5-wk treatment with butyrate, obese mice lost 10.2% of their 
original body weight. Consistent with the change in body weight, fat content was reduced by 10%. 
Furthermore, fasting glucose was reduced by 30%, insulin resistance was reduced by 50%, and 
intraperitoneal insulin tolerance was improved significantly by butyrate. The mechanism of butyrate 
action is related to promotion of energy expenditure and induction of mitochondrial function. 
Stimulation of peroxisome proliferator-activated receptor (PPAR) coactivator (PGC-1α) activity has 
been suggested as the molecular mechanism of butyrate. Activation of AMPK and inhibition of 
histone deacetylases may contribute to the PGC-1α regulation. These data suggest that butyrate may 
have potential application in the prevention and treatment of metabolic syndrome in humans [477]. 
 
Butyrate and satiety 
It has been hypothesized that SCFAs produced in the large intestine also can influence upper 
gut motility and satiety [478]. Endocrine L-cells present in large concentrations in the colonic 
mucosa secrete peptides such as GLP-1, peptide YY and oxyntomodulin, which are involved in 
appetite regulation and satiety [479]. In several animal studies using fermentable carbohydrates 
such as inulin [479], lactitol [480] and FOS [481], an increased satiety, decreased weight gain and 
increased endogenous production of GLP-1 and ⁄ or PYY were reported. In humans, FOS increased 
satiety [482] and increased plasma GLP-1 concentrations [483]. However, lactitol did not affect 
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plasma concentrations of this gut peptide [480]. The increased satiety is possibly promoted through 
the production of SCFAs. This is supported by a number of studies. Butyrate increased the 
expression of PYY and proglucagon in vitro in rat epithelial cells [484] and increased PYY release, 
but not that of GLP-1, in the isolated colon of rats [485] and rabbits [486]. In addition, colonic 
SCFA infusion in rats stimulated PYY release [487]. However, colonic infusion with SCFAs in 
humans did not increase plasma levels of either PYY or GLP-1 [488]. Activation of the SCFA 
receptor GPR43 expressed in endocrine L-cells may play a role in this effect on satiety [383]. There 
is increasing evidence that the effect of fermentable dietary fibre on satiety is mediated through the 
colonic production of SCFAs. However, most evidence originates from rat studies, while again 
human evidence remains limited. In figure 4.5 the main intestinal SCFA receptors and transporters 
are shown. 
 
 
 
 
 
 
Fig. 4.5. Intestinal SCFA receptors and transporters. SCFAs are taken up by the epithelial cells by diffusion, H+ coupled transport by 
monocarboxylate transporters (MCT) or by Na+ coupled transport by SLC5A8. Other receptors that are activated by SCFA are localized on 
colonocytes, peptide YY expressing enteroendocrine cells, or different immune cells. Receptor FFAR2 is involved in neutrophil chemotaxis toward 
sources of SCFA. Image from: R. Schilderink, C. Verseijden and W. J. de Jonge. Dietary inhibitors of histone deacetylases in intestinal immunity and 
homeostasis. Front. Immunol., 01 August 2013 doi: 10.3389/fimmu.2013.00226. 
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Adverse effects of butyrate 
In contrast to the wide range of positive effects of butyrate on the intestinal mucosa, a small 
number of studies have also shown some adverse effects. Two rat studies revealed that rectal 
administration of butyrate (8–1000 mM), dose dependently increased colonic visceral sensitivity 
[489]. However, these effects have not yet been reported in humans. In faeces of weaning children, 
low butyrate concentrations have been measured [490]. It has been hypothesized that 
overproduction or accumulation of SCFAs may be toxic to the intestinal mucosa of premature 
infants and might play a role in the pathogenesis of neonatal necrotizing enterocolitis. It has been 
demonstrated that the severity of mucosal injury to butyrate, measured in newborn rats, was dose 
dependent and also depended on the maturation of the intestine [458,491]. It remains to be 
established whether luminal butyrate in premature infants can increase towards levels that are toxic 
for the intestinal mucosa [491]. In addition, as mentioned before, increased permeability and 
Salmonella translocation has been found after FOS supplementation in a study with rats, which may 
be the result of SCFA accumulation [438]. However, this was not confirmed in the humans [439]. 
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CHAPTER 5: EFFECTS OF A LACTOBACILLUS PARACASEI 
B21060 BASED SYNBIOTIC ON STEATOSIS, INSULIN 
SIGNALING AND TOLL-LIKE RECEPTOR EXPRESSION IN 
RATS FED A HIGH-FAT DIET 
 
5.1 Introduction 
Non-alcoholic fatty liver disease is an increasingly recognized clinical condition characterized 
by insulin resistance, hepatic steatosis and frequently type 2 diabetes (T2DM). The pathophysiology 
of NAFLD is still not completely defined. Tilg and Moschen have proposed a “parallel hits” 
hypothesis on the evolution of inflammation in NAFLD [29], as opposed to the so called “two hits” 
previously suggested for the development of nonalcoholic steatohepatitis (NASH) [28]. This new 
model suggests that different hits may act in parallel, and that gut- or adipose tissue derived factors 
may have a key role in the onset of liver inflammation. The cytokines tumor necrosis factor α 
(TNF-α) and interleukin (IL)-6 represent a link between IR and liver inflammatory process, 
activating several mechanisms involved in hepatocyte apoptosis and inhibition of insulin signaling 
[93,492]. Evidence suggest the modulation of gut microflora as potential target for the prevention 
and treatment of NAFLD [493,494]. Probiotics are live microbial that have beneficial effects on 
human health and disease modulating intestinal microbiota composition and function, improving 
epithelial barrier function, and reducing inflammation [495]. Immune and epithelial cells can 
discriminate among different microbial species through the activation of TLRs [496]. We have 
recently obtained experimental and clinical evidences that selected probiotics, could be effective 
against NAFLD [70,497]. The effects of probiotics are clearly related to specific strains and dosage 
[498]. It has been reported that some lactic acid bacteria affect the progression of diabetes mellitus 
[259,396]. These studies show that ingestion of determined lactic acid bacteria prevents or delays 
the disease onset in various experimental models of diabetes, induced by a chemical or by diet, or 
genetically modified animals (db/db) [499]. A variety of in vitro experiments and in vivo studies 
provided experimental evidence to support the probiotic roles in lowering serum cholesterol and 
ameliorating lipid profiles [500]. It has been demonstrated that L. paracasei B21026, alone or in 
combination with prebiotics, is effective to limit infectious diseases and to regulate immune system 
[246,501]. A recent study has highlighted the striking difference among species and strains of 
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lactobacilli such as L. plantarum NCIMB8826, L. rhamnosus GG and L. paracasei B21060 in 
modulating immune and inflammatory response [240]. This latter strain of lactobacillus, the most 
active, was isolated from the feces of breast-fed babies and its non-occasional presence in the 
physiological intestinal microflora was established by genetic identification methods [502]. Based 
on these findings, it seemed of great interest to assess the influence of a synbiotic preparation 
containing Lactobacillus paracasei B21060 on liver damage and glucose homeostasis using an 
animal model of NAFLD. This synbiotic is commercially available in Europe as a formulation 
containing prebiotics (arabinogalactan and fructo-oligosaccharide) that are able to improve 
probiotic strain survival [503]. Here, we have demonstrated that this synbiotic could limit 
inflammatory liver damage and insulin signalling impairment by restoring intestinal permeability 
and, thus, preventing the imbalance of TLR pattern in a model of IR and steatosis in young rats. 
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5.2 Materials and methods 
 
Ethics Statement 
This study was carried out in strict accordance with the Institutional Guidelines and complied 
with the Italian D.L. no. 116 of January 27, 1992 of Ministero della Salute and associated guidelines 
in the European Communities Council Directive of November 24, 1986 (86/609/ECC). All animal 
procedures reported herein were approved by the Institutional Committee on the Ethics of Animal 
Experiments (CSV) of the University of Naples “Federico II” and by the Ministero della Salute 
under protocol no. 2008-0099793. Prior to sample collection, animals were euthanized by an 
intraperitoneal injection of a cocktail of ketamine/xylazine, followed by cervical dislocation to 
minimize pain. All efforts were made to minimize animal suffering. 
 
Diets and synbiotic 
High fat diet (HFD) provided in pellet with 58% of energy derived from fats, 18% from 
proteins, and 24% from carbohydrates (5.56 kcal/g) was purchased from Laboratorio Dottori 
Piccioni (Gessate, Milan, Italy). The composition of this diet has been previously described [255]. 
The control standard (STD) pellet diet had 15% of energy from fats, 22% from proteins, and 63% 
from carbohydrates (3.30 kcal/g). The synbiotic formulation containing viable lyophilized L. 
paracasei B21060 mixed with prebiotics fructooligosaccharides and arabinogalactan (Flortec, 
Bracco, Milan, Italy) was available as powder and dispensed in 6 g bag containing about 2.5×10
9
 
CFU of the bacteria. 
 
Animal model and experimental design 
After weaning, young male Sprague–Dawley rats (113.5±1.1 g; Harlan, Corezzano, Italy) 
were randomly allocated in 3 groups (at least n=8) as follows: (1) control group, receiving STD and 
vehicle (tap water); (2) HFD-fed group, receiving vehicle; and (3) HFD-fed group, receiving the 
synbiotic by gavage once daily [HFD+SYN; L. paracasei B21060 2.5×10
7
 bacteria/100 g body 
weight (bw); fructo-oligosaccharides 7 mg/100 g bw, and arabinogalactan 5 mg/100 g bw]. The 
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synbiotic treatment started together with the HFD and continued for 6 weeks. The HFD, 
administered for a long period of time (up to 6 months), creates a nutritional model of IR and 
NASH in non-genetically modified animals [256]. In our experiments, we administered HFD in 
young rats for a shorter period of time (6 weeks) to induce the early events of NAFLD due to fat 
overnutrition in young animals, excluding age and gender influences. Blood samples from animals 
were collected by cardiac puncture and serum obtained. Liver and white adipose tissue were excised 
and immediately frozen. 
 
Histological analysis of liver tissue and transaminase levels 
Liver sections were stained with hematoxylin and eosin or Oil Red O. Steatosis was graded on 
a scale of 0 (absence of steatosis), 1 (mild), 2 (moderate) and 3 (extensive). Alanine amino 
transferase (ALT) and aspartate amino transferase (AST) were measured in serum samples by 
standard automated procedures, according to manufacturer’s protocols (AST Flex reagent cartridge, 
ALT Flex reagent cartridge; Dade Behring, Newark, DE, USA). Blood nonesterified fatty acids 
(NEFA) were determined as previously described [504]. 
 
Oral glucose tolerance test and insulin resistance assessment 
At fifth week of treatment, fasted rats received glucose (2g/kg; per os) and glycaemia was 
measured at 0, 30, 60, 90 and 120 min after glucose administration. The area under the curve 
(AUC) was calculated from time zero, as the integrated and cumulative measure of glycemia up to 
120 min for all animals. Glucose and insulin levels were measured by the glucometer One Touch 
UltraSmart (Lifescan, Milpitas, CA, USA) and by rat insulin radioimmunoassay kit (Millipore 
Corporation, Billerica, MA, USA), respectively. As index of insulin resistance, homeostasis model 
assessment (HOMA) was calculated, using the formula [HOMA=fasting glucose (mmol/L)×fasting 
insulin (μU/ml)/22.5]. 
 
Western blotting 
Liver and visceral white adipose tissues were homogenized and total protein lysates were 
subjected to SDS-PAGE. Blots were probed with anti-suppressor of cytokine signaling 3 (SOCS3, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), or antiperoxisome proliferator-activated 
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receptor α (PPAR-α; Santa Cruz Biotechnology), or anti-TLR4 (Imgenex, San Diego, CA, USA), or 
anti-PPAR-γ (Novus Biologicals, Littleton, CO, USA), or anti-glucose transporter4 (GLUT4, Santa 
Cruz Biotechnology). To evaluate NF-κB activation, IκB-α (Santa Cruz Biotechnology) and NF-κB 
p50 (Santa Cruz Biotechnology) were measured in liver cytosolic or nuclear extracts, respectively. 
Western blot for glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Sigma-Aldrich; Milan 
Italy) or lamin A (Chemicon, Temecula, CA, USA) was performed to ensure equal sample loading. 
 
Immunoprecipitation 
Immunoprecipitation of insulin receptor substrate (IRS)-1 was performed incubating 1.5 mg 
of liver lysate with 2 μg of an antibody against total IRS-1 (Santa Cruz Biotechnology). The 
immunoprecipitates were subjected to SDS-PAGE, and immunoblotted with an antibody against 
total IRS-1 or phospho-IRS-1Ser
307
 (1:1000, Cell Signaling Technology, Danvers, MA, USA). 
 
Real-time semi-quantitative polymerase chain reaction (PCR) 
Total RNA, isolated from liver, colon and visceral adipose tissue, was extracted using TRIzol 
Reagent (Invitrogen Biotechnologies), according to the manufacturer’s instructions. cDNA was 
synthesized using a reverse transcription kit (Maxima First Strand cDNA Synthesized Kit, 
Fermentas, Ontario, Canada) from 2 μg total RNA. PCRs were performed with an ABIPrism 
HT7900 fast Real-time PCR System instrument and software (Applied Biosystem). The primer 
sequences are reported in Table 5.1. The PCR conditions were 10 min at 95°C followed by 40 
cycles of two-step PCR denaturation at 95°C for 15 s and annealing extension at 60°C for 60 s. 
Each sample contained 1–100 ng cDNA in 2X Power SYBRGreen PCR Master Mix (Applied 
Biosystem) and 200 nmol/L of each primer (EUROGENTEC Explera s.r.l, Ancona, Italy) in a final 
volume of 25 μl. The relative amount of each studied mRNA was normalized to GAPDH as 
housekeeping gene, and the data were analyzed according to the 2
-ΔΔCT
 method. 
82 
 
Table 5.1. Real-Time PCR Primer Sequences 
Target gene 
 
Forward primer (5’→3’) 
 
Reverse primer (3’→5’) 
 
Accession 
Number 
Adiponectin 
 
AATCCTGCCCAGTCATGAAG 
 
TCTCCAGGAGTGCCATCTCT 
 
NM_144744 
 
CD14 
 
GTGCTCCTGCCCAGTGAAAGAT 
 
GATCTGTCTGACAACCCTGAGT 
 
AF_087943 
 
FGF21 AGATCAGGGAGGATGGAACA 
 
ATCAAAGTGAGGCGATCCATA NM_130752.1 
GAPDH 
 
GGCACAGTCAAGGCTGAGAATG ATGGTGGTGAAGACGCCAGTA NM_017008 
XM_216453 
 
IL-6 
 
ACAAGTGGGAGGCTTAATTACACAT TTGCCATTGCACAACTCTTTTC NM_012589 
 
MyD88 TGGCCTTGTTAGACCGTGA 
 
AAGTATTTCTGGCAGTCCTCCTC NM_198130.1 
Occludin TTGGGAGCCTTGACATCTTGTTC TCCGCCATACATGTCATTGCTTGGTG NM_031329.2 
 
RPL19 
 
GAAGGTCAAAGGGAATGTGTTCA CCTTGTCTGCCTTCAGCTTGT NM_009078.2 
TLR2 
 
GTACGCAGTGAGTGGTGCAAGT 
 
TGGCCGCGTCATTGTTCTC 
 
NM_198769 
XM_227315 
 
TLR4 
 
CTACCTCGAGTGGGAGGACA 
 
ATGGGTTTTAGGCGCAGAGTT 
 
NM_019178 
 
TLR9 
 
ATGGCCTGGTAGACTGCAACT 
 
TTGGCGATCAAGGAAAGGCT 
 
NM_198131 
 
TNF-α 
 
CATCTTCTCAAAACTCGAGTGACAA TGGGAGTAGATAAGGTACAGCCC NM_012675 
 
ZO-1 
 
CCATCTTTGGACCGATTGCTG TAATGCCCGAGCTCCGATG NM_001106266
.1 
 
 
Measurement of gut permeability in vivo 
In another experiment, after 6 weeks on HFD, rats were fasted for 6 h and then gavaged with 
4,000 kDa FITC-labeled dextran diluted in water (TdB Consultancy AB, Uppsala, Sweden) (500 
mg/kg, 125 mg/ml). After 2 h, blood (500 μl) was collected from intracardiac puncture and 
centrifuged (3000 rpm for 15 min at RT), and FITC-dextran concentration in plasma was 
determined by spectrophotometry (excitation wavelength 485 nm; emission wavelength 535 nm; 
HTS-7000 Plus-plate-reader; Perkin Elmer, Wellesley, MA, USA), as previously described [505]. 
 
Immunofluorescence analysis of occludin and zonula occludens 
(ZO)-1 
Colon segments were immediately removed, washed with phosphate-buffered saline (PBS), 
mounted in embedding medium (Pelco Cryo-Z-T, Ted Pella inc, Redding, California), and stored at 
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−80°C until use. Cryosections (7 μm) were fixed in formaldehyde 2%+PBS at RT for 10 min for 
occludin or in methanol for 10 min at RT for ZO-1. Non-specific background was blocked by 
incubation with normal goat serum in PBS and 0.1% Triton X-100. Sections were incubated for 2h 
with rabbit anti-occludin (1:50 for occludin, Santa Cruz Biotechnology) or rabbit anti-ZO-1 (1:100 
for ZO-1; Invitrogen, Camarillo, CA, USA). Sections were probed with goat anti-rabbit Alexa Fluor 
488 antibodies (1:200, Invitrogen). Slides were mounted in mounting medium (Vectashield; Vector 
Laboratories, Burlingame, CA, USA), and visualized on a fluorescence microscope using a 640 
objective, and images were stored digitally with Leica software. Two negative controls were used: 
slides incubated with or without primary antibody. All the staining were performed in duplicate in 
non-serial distant sections, and analyzed in a double-blind manner by two different investigators. 
 
Semi-quantitative and qualitative assessment of Enterobacteriales 
order and Escherichia coli species by sequence analysis of the microbial 
16S rRNA gene 
Semi-quantitative PCR was performed to investigate modifications in Gram negative bacteria 
relative amount in animals receiving HFD alone or in combination with the synbiotic. For microbial 
content, DNA was extracted from colon tissue by the NucleoSpin Tissue (Macherey-Nagel, Düren, 
Germany). Group-specific primers based on 16S rRNA gene sequences PCR assay were forward 
Enterobacteriales order, CCTTGGTGATTGACGTTACTCGCA; reverse Enterobacteriales order, 
CCACGCTTTCGCACCTGAGC;forward Escherichia coli CATGCAGTCGAACGGTAACAGGA; 
reverse Escherichia coli, CTGGCACGGAGTTAGCCGGTG (Eurofins MWG Operon; Huntsville, 
AL, USA). The PCR conditions were 10 min at 95°C followed by 40 cycles of two-step PCR 
denaturation at 95°C for 15 s and annealing extension at 60°C for 60 s. Each sample contained 50 
ng DNA in 2X Power SYBRGreen PCR Master Mix (Applied Biosystem) and 200 nmol/l of each 
primer) in a final volume of 25 μl. PCR was performed with a Bio-Rad CFX96 Connect Real-time 
PCR System instrument and software (Bio-Rad Laboratories) The relative amount of 16S rRNA 
was normalized to RPL19 rRNA levels as housekeeping gene, and the data were analyzed 
according to the 2
-ΔΔCT
 method. 
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Statistical analysis 
Data are presented as mean±S.E.M. Statistical analysis was performed by analysis of variance 
test for multiple comparisons followed by Bonferroni’s test, using Graph- Pad Prism (Graph-Pad 
software, San Diego, CA, USA). Statistical significance was set at P<0.05. 
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5.3 Results 
 
Effects of the synbiotic on liver steatosis and damage 
Liver sections from HFD-fed rats demonstrated hepatic damage compared to control animals. 
As shown in Fig. 5.1A, foci of inflammatory cell infiltration and hepatocyte necrosis or apoptosis 
appeared throughout the lobule. HFD-fed rats showed microvesicular steatosis of grade 2 (Fig 
5.1B). In the animals treated with synbiotic the severity of steatosis was reduced at grade 1, with a 
microvescicular pattern of lipids accumulation mainly in perivenular and periportal region. 
Scattered inflammation and occasionally apoptotic nuclei were observed, showing that treatment 
prevents the inflammation induced by HFD. Accordingly, the increase in AST, ALT (Fig. 5.1C and 
D) and NEFA (Fig. 5.1E) were reduced by the synbiotic. Weight gain of HFD fed animals did not 
significantly change among groups after 5weeks (STD 209.2±7.2, HFD 225.0±6.6, and 
HFD+synbiotic 213.3±9.3 g), in accordance, at this experimental time, also fat mass did not vary 
among groups (STD 29.05±2.50, HFD 31.78±1.26, and HFD+synbiotic 30.30±2.88 g). Moreover, 
food intake, expressed as grams of food taken daily, did not differ between rats fed the HFD treated 
with vehicle (15.45±0.58 g/day/rat) or treated with synbiotic (15.45±0.82 g/day/rat). 
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Fig. 5.1. The synbiotic effects on liver damage in HFD-fed rats. Paraffin-embedded sections of the liver (n=4 each group) were stained with 
hematoxylin-eosin (A) or oil red O (B). Micrographs in both panels are representative pictures with magnification 400×. Circulating AST (C), ALT 
(D), and NEFA (E) were measured (n=8, each group). (* P<0.05 vs. STD; # P<0.05 vs. HFD). 
 
Effect of the synbiotic on glucose homeostatasis 
The synbiotic administration caused a significant reduction of glycemia 90 min after glucose 
load (Fig. 5.2A). A marked and significant increase of AUC values was shown in HFD group (Fig. 
5.2B), and this effect resulted significantly inhibited by synbiotic. As shown in Fig 5.2C and D, the 
increase in serum glucose and insulin levels induced by HFD was prevented in rats receiving the 
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synbiotic. Accordingly, IR assessed by the HOMA index was reduced (Fig. 5.2E). No significant 
difference in body weight was observed among all groups. 
 
 
 
 
Fig. 5.2. The synbiotic effects on glucose homeostasis. Glucose tolerance test (A) in STD and HFD-fed rats (n=6, each group) was performed and 
AUC evaluated (B). Fasting glucose (C), insulin levels (D), and HOMA-IR (E) were also reported (n=8, each group). (*P<0.05; **P<0.01; 
***P<0.001 vs. STD; # P<0.05; ### P<0.001 vs. HFD). 
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Effects of the synbiotic on TNF-α and IL-6 gene liver expression 
The raise of pro-inflammatory cytokines is one of the early events in many types of liver 
injury. In particular, TNF-α and IL-6 are two prototypic inflammatory cytokines involved in 
metabolic impairment, initiating the pathogenesis of hepatic IR. As shown in Fig. 5.3A and B, 
HFD induced a significant increase in hepatic TNF-α and IL-6 mRNAs, and the synbiotic 
significantly prevented the transcription of both genes. As known, TNF-α and IL-6 are involved in 
IR due to their ability to impair insulin signaling through the phosphorylation of IRS-1 in Ser 
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and up-regulation of SOCS3, respectively. As depicted in Fig. 5.3C, Western blot analysis of P-
IRS-1Ser 
307
 of immune-precipitated IRS-1 from hepatic tissues showed an increase in serine 
phosphorylation in HFD group, partially reverted by the synbiotic. Moreover, the increase in 
SOCS3 in hepatic tissues from HFD rats was significantly inhibited by the synbiotic (Fig. 5.3D). 
 
 
 
Fig. 5.3. The synbiotic effects on TNF-α and IL-6 gene expression in liver and insulin signaling. TNF-α (A) and IL-6 (B) mRNAs expression 
(relative expression to STD) are reported (n=8 each group). Panels C and D show representative western blot analysis of P-IRS-1Ser 307 of IRS-1 
immunoprecipitate from liver tissues and SOCS3 expression, respectively. (*P<0.05; ***P<0.001 vs. STD;# P<0.05; ##P<0.01; P<0.001 vs. HFD). 
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Modulation of hepatic inflammatory transcription factors by the 
synbiotic 
The activation of NF-κB was evaluated through the measurement of cytosolic amount of IκBα 
and nuclear content of p50 NF-κB. In our model, nuclear p50 NF-κB resulted increased in HFD 
group, related to a decrease of the inhibitory protein IκBα, the synbiotic significantly prevented 
both effects (Fig. 5.4A and B). Accordingly, with the metabolic and inflammatory alterations, 
PPAR-α expression resulted significantly reduced by HFD and partially restored by the synbiotic 
(Fig. 5.4C). The evaluation of fibroblast growth factor (FGF)21 transcription, as a downstream 
target gene of PPAR-α, revealed a similar profile of expression of its transcription factor (Fig. 
5.4D). These findings were consistent with carnitine palmitoyltransferase (CPT) 1 expression level, 
whose transcription was up-regulated by synbiotic, suggesting an increase in the oxidation of fatty 
acids (Fig. 5.4E). 
 
 
Fig. 5.4. The synbiotic effect on hepatic activation of NF-κB, PPAR-α and FGF21 expression. Immunoblot of cytosolic inhibitory protein IκB-α 
(A), nuclear p50 NF-κB (B) and PPAR-α (C) protein expression are shown (n=8 each group). FGF21 (D) and CPT1 (E) mRNAs expression (relative 
expression to STD) are also reported. (*P<0.05; **P<0.01; ***P<0.001 vs. STD; # P<0.05; ### P<0.001 vs. HFD). 
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Effect of the synbiotic on hepatic Toll-like receptors pattern 
The activation of TLRs family, especially TLR4, by inflammatory cytokines or increased 
NEFA could modulate insulin sensitivity [115]. As shown in Fig. 5.5A and B, HFD induced an 
increase in liver TLR4 mRNA and protein expression. Interestingly, a similar expression profile 
was also observed for TLR4 co-receptor CD14 (Fig. 5.5C). The synbiotic significantly inhibited 
these effects. Notably, TLR2 and TLR9, which are able to detect lipoproteins and unmetilated CpG-
containing DNA, respectively, were also up-regulated by HFD and both TLRs were reduced by 
synbiotic (Fig. 5.5D and E). 
 
            
 
 
Fig. 5.5. Effect of synbiotic on hepatic Toll-like receptor pattern. Panels A and B are the results from the PCR and Western blot for TLR4 in livers 
from 8 rats on STD or HFD or HFD+SYNBIOTIC. Panel C shows mRNA expression of coreceptor CD14. mRNA expression of TLR2 (D) and TLR9 
(E) are also shown. All mRNA levels are expressed as relative expression to STD. (*P<0.05; **P<0.01; ***P<0.001 vs. STD; # P<0.05; ##P<0.01; 
### P<0.001 vs. HFD). 
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Modulation of PPAR-γ, GLUT4 and adiponectin expression in 
adipose tissue elicited by the synbiotic 
To address whether the change in glucose metabolism was related to a modulation of genes 
expression involved in glucose and fat metabolism in metabolically active tissues, we evaluated the 
expression of PPAR-γ and GLUT4 in visceral white adipose tissue. In animals receiving HFD, a 
significant reduction of PPAR-γ and GLUT4 was observed after 6 weeks. The synbiotic limited 
these effects preventing PPAR-γ decrease (Fig. 5.6A) and partially limiting the effect of HFD on 
GLUT4 expression (Fig. 5.6B). Moreover, the reduction of adiponectin mRNA in mesenteric 
adipose tissue from HFD group was abolished by synbiotic (Fig. 5.6C). 
 
 
 
 
Fig. 5.6. The synbiotic modulation of metabolic and inflammatory proteins in adipose tissue. Representative Western blot of PPAR-γ (A) and 
GLUT4 (B) are shown (n=8 eachgroup). Panel C shows PCR results from adiponectin mRNA expression (relative expression to STD) in adipose 
tissue (n=8 each group). . (*P<0.05; **P<0.01; ***P<0.001 vs. STD; # P<0.05; ### P<0.001 vs. HFD). 
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Effect of the synbiotic on intestinal permeability and tight junction-
associated proteins in gut mucosa 
As a consequence of HFD feeding, epithelial barrier integrity was altered. There was a 
significant increase in gut permeability measured in vivo by appearance in plasma of FITC-labeled 
dextran (Fig. 5.7A), by a mechanism associated with a reduced expression of the epithelial tight 
junction proteins ZO-1 and occludin (Fig. 5.7B-E). These effects were prevented by the synbiotic 
(Fig. 5.7A-E). 
 
 
 
 
Fig. 5.7. Effect of the synbiotic on intestinal permeability and tight junction-associated proteins. Panel A shows the measurement of gut 
permeability by appearance of FITC-labeled dextran in plasma of STD, HFD and HFD+SYNBIOTIC rats (n=8 each group). Immunofluorescent 
images (5×objective) and mRNA expression for ZO-1 (B, D) and occludin (C, E) in the colon tissue are shown (n=4 each group). (*P<0.05; 
***P<0.001 vs. STD; # P<0.05; ## P<0.01 vs. HFD). Immunofluorescence staining are representative of 3 slides for each group. 
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Modulation of Gram-negative bacteria and TLR4 in colonic mucosa 
HFD strongly increased 16S rRNA levels of Enterobacteriales order and related species 
(Escherichia coli spp) at colonic level, while the synbiotic significantly reduced Gram-negative 
bacteria (Fig. 5.8A-B). The modulation of Gram-negative bacteria was associated with a significant 
increase in TLR4 and MyD88 in HFD rat intestinal mucosa. Also this effect was significantly 
blunted by the synbiotic (Fig. 5.8C and D). 
 
 
 
 
Fig. 5.8. Enterobacteriales and Escherichia coli modification and TLR4 and MyD88 transcription in colonic mucosa. Relative amount of 
Enterobacteriales order (A) and semi-quantitative analysis of Escherichia coli species (B) are shown. mRNA abundance of TLR4 (C) and MyD88 (D) 
are also shown. (**P<0.01; ***P<0.001 vs. STD; # P<0.05; ## P<0.01 vs. HFD). 
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5.4 Discussion 
We show that the synbiotic containing L. paracasei B21060 plus arabinogalactan and fructo-
oligosaccharide, is able to prevent liver damage and inflammation, steatosis, IR, and imbalance of 
TLRs pattern in the early stage of NAFLD. The synbiotic not only prevents the increase of hepatic 
markers of steatosis and NEFA, but also preserves glucose tolerance, reduces fasting glucose and 
insulinemia modulating HOMA-IR and adiponectin levels. It is now clear that TNF-α and IL-6 
represent crucial effectors of IR, that link liver inflammatory process to hormonal and metabolic 
alterations [93,506]. In our experimental model, the synbiotic reduces TNF-α levels in parallel with 
a lower Ser
307
-phosphorylation of IRS-1, demonstrating the recovery of insulin signaling 
transduction. IL-6, activating the JAKSTAT pathway, stimulates SOCS1 and SOCS3 transcripts 
that in turn led to ubiquitin-induced degradation of IRS-1 [93]. Here, we show that the synbiotic 
reduces the transcription of both cytokines, TNF-α and IL-6, and inhibits markedly their above 
reported pathways, limiting inflammation and IR. In our experimental conditions, it is plausible to 
argue that the synbiotic, reducing NEFA and cytokines (i.e., TNF-α, IL-6 and IL-1β), modulates the 
activation of NF-κB pathway induced by HFD [507], reducing IκBα degradation and inhibiting p50. 
Moreover, the increased expression of TNF-α by HFD is associated with the reduction of PPAR-α 
expression in liver and adiponectin synthesis in mesenteric adipose tissue. Adiponectin, an insulin-
sensitizing anti-inflammatory adipokine, limits fat accumulation in the liver by a number of 
mechanisms including induction of PPAR-α expression [508], reduces liver TNF-α expression 
[509], and inhibits expression of several cytokines in hepatic stellate cells, with a concomitant 
increase in the release of the regulatory cytokines IL-10 and IL-1RA [510]. The molecular 
mechanisms by which the synbiotic exerts its beneficial effects on NAFLD are linked to the marked 
increase of adiponectin and to the partial recovery of PPAR-α. The level of PPAR-α which 
regulates fatty acid β-oxidation and catabolism, was restored by the synbiotic. We previously 
demonstrated that HFD feeding is associated with the reduction of PPAR-α expression in liver [70] 
and according to our findings, the administration of a PPAR agonist or probiotics restores PPAR-α 
and improves hepatic steatosis [70,71]. Recently, it has been demonstrated that FGF21, a 
cytokine/hormone predominantly produced by the liver, was regulated by PPAR-α [511]. FGF21 
regulates glucose and lipid metabolism through pleiotropic actions in pancreas and adipose tissue 
[512]. In particular, FGF21 is required for the normal activation of hepatic lipid oxidation and 
triglyceride clearance [513]. In our model FGF21 was significantly reduced by HFD and its 
decreased expression was partially prevented by synbiotic. Accordingly, the synbiotic not only 
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increased PPAR-α and FGF21, but also normalized CPT1 transcription, suggesting a role for this 
pathway in synbiotic-induced decrease in fatty acid accumulation in the liver. As known, 
adiponectin up-regulation by PPAR-γ, provides a connection between the two PPAR isotypes [514]. 
PPAR-γ promotes fatty acid uptake and increases insulin sensitivity by up-regulating GLUT4, an 
insulin dependent glucose transporter in adipose tissue and striated muscle [515] and attenuating the 
induction of SOCS3 [516]. Consistently with the modulation of adiponectin synthesis, the synbiotic 
also modulates PPAR-γ and GLUT4 expression in visceral adipose tissue. To address the synbiotic 
mechanisms on HFD-induced hepatic alterations, we evaluated gut permeability. The synbiotic is 
able to significantly inhibit the modification of gut permeability induced by HFD. In fact it 
significantly reduces the amount of FITC-dextran at plasmatic level and restores the HFD-induced 
alteration in tight junction proteins expression and distribution. The synbiotic also prevents the 
increased transcription of TLR4 in the colonic mucosa of HFD animals, suggesting a reduction of 
TLR4 inflammatory pathways. TLRs are involved in bacterial sensing and are crucial for “liver 
tolerance” in the healthy liver [67]. Here, we demonstrate that the synbiotic is able to limit the 
increased transcription and expression of TLRs and co-receptor CD14 or MyD88 at intestinal and 
liver level and restores the imbalance of Gram negative bacteria (Enterobcteriales and in particular 
E. coli) induced by HFD. Recently, it has been demonstrated that during HFD-induced diabetes, 
commensal intestinal bacteria translocate in pathological manner from intestine towards the tissues 
where they trigger a local inflammation. This metabolic bacteremia was reversed by a 
Bifidobacterium animalis strain, which reduced the mucosal adherence and bacterial translocation 
of gram-negative bacteria from the Enterobacteriaceae group [517]. Moreover, an increase in 
Enterobacteriaceae family within Enterobacteriales order has been associated with gut 
inflammation; induction of experimental colitis in rodents was followed by an increase in this 
family, suggesting that it may be a consequence of gut inflammation rather than a cause [518]. In 
our model the increased amount of Enterobacteriales induced by HFD, and probably associated to 
gut inflammation, was restored by this L. paracasei strain, which is well known modulator of the 
inflammatory process [240]. In this study, the increased expression of hepatic TLRs due to HFD 
confirms a greater exposure of the liver to ligands for these receptors (i.e. PAMPs and DAMPs) 
deriving from the intestine. Our data are in agreement with previous studies showing that the 
administration of probiotics (i.e. Lactobacillus and Bifidobacterium) or prebiotics (i.e., inulin and 
oligofructose) can modulate the microbiota and improve gut permeability, thus controlling the 
occurrence of endotoxemia [519,520]. Also NEFA and other non-bacterial substances, may act as 
ligands for TLR2, TLR4, and TLR9 [67,521]. In NAFLD patients, elevated NEFA levels are 
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commonly observed [522]. Very recently, it was demonstrated that free fatty acids could stimulate 
NF-κB activation in hepatocytes in the early stage of HFD-induced NAFLD through the TLR4 
[523]. 
Here, we demonstrate that the synbiotic reduces inflammation and its mediators, not only 
through an effect on NEFA and intestinal permeability, but also inhibiting NF-κB activation 
through the downregulation of TLR pattern. Accordingly, we evidenced the same profile of activity 
of the synbiotic on TLR2 expression. Both TLR2 and TLR4 recognizes NEFAs [524], and share the 
same signaling cascade leading to NF-κB activation. The reduction of TLR2 by the synbiotic may 
contribute to the inhibition of the effects of HFD, impacting on IR and tissue damage. Consistently 
with our data, Ehses et al. [525] have reported that TLR2 deficient mice are protected from IR and β 
cell dysfunction induced by HFD, linking TLR2 to the increased dietary lipid and the alteration of 
glucose homeostasis. Finally, the synbiotic significantly inhibits the HFD-related increase in TLR9 
synthesis. Intracellular TLR9 activates innate immune defenses against viral and bacterial infection 
and plays a role in the pathogenesis of NASH [118]. 
 
5.5 Conclusions 
In conclusion, our results support probiotics as innovative, preventive and therapeutic strategy 
for NAFLD, using synbiotic preparations containing selected strain with clear and demonstrated 
beneficial immunomodulatory effects. Among probiotics, L. paracasei B21060, can be considered a 
potential approach, limiting the main pathogenetic events involved in the onset of IR and steatosis 
induced by HFD. This synbiotic, alone or in combination with other therapies, could be useful in 
the treatment of fatty liver in children who are hardly able to follow a program of hypocaloric diet 
and regular physical activity. The major results of our study are summarized in figure 5.9. 
97 
 
 
 
 
Fig. 5.9. Effects of a Synbiotic based Lactobacillus paracasei B21060 in the liver. The enhancement of epithelial barrier integrity by the synbiotic 
through an increase in tight junction proteins expression (ZO-1 and occludin) , determines a reduction of DAMPs, PAMPs, and FFA afflux to liver. 
This synbiotic effect is related to a reduction in the expression of hepatic TLR4, its accessory molecule CD14, TLR2 and TLR9 and NF-κB-activation 
with a decrease in inflammatory gene transcription. The reduced expression of inflammatory cytokines (TNF- α and IL-6) leads to an improvement of 
insulin signaling (reduction of IRS-1 phosphorylation in Ser 307 and down-regulation of SOC3), accompanied by an increase in insulin sensitivity. 
The synbiotic increases PPAR-α expression in liver, contributing to the reduction of inflammation and the increase in fatty acid catabolism. 
Consistently, in adipose tissue the synbiotic increases PPAR-γ expression and adiponectin transcription, contributing to reduce inflammation. Finally, 
the therapeutic/preventive role of the synbiotic in hepatic steatosis could be related to its ability to limit inflammatory liver damage, insulin signaling 
impairment, and imbalance of TLR patterns induced by high fat diet.  
ALT, alanine transaminase; AST, aspartate aminotransferase; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; TLR, toll-like receptor; IL, 
interleukin; TNF, tumor necrosis factor; TG, triglycerides; PPAR, peroxisome proliferator-activated receptor; FFAs, free fatty acids; DAMPs, damage 
associated molecular patterns; PAMPs, pathogen associated molecular patterns;TJ, tight junction; GLUT4, glucose transporter 4; suppressor of 
cytokine signaling, SOCS; IRS, insulin receptor substrate.  
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CHAPTER 6: EFFECTS OF SODIUM BUTYRATE AND ITS 
SYNTHETIC AMIDE DERIVATIVE ON LIVER INFLAMMATION 
AND GLUCOSE TOLERANCE IN AN ANIMAL MODEL OF 
STEATOSIS INDUCED BY HIGH FAT DIET 
 
6.1 Introduction 
A close association between NAFLD and several findings indicative of IR and metabolic 
disorders has long been reported. The liver produces and is exposed to various types of lipids, such 
as fatty acids, cholesterol and triglycerides via the portal vein from the diet and visceral adipose 
tissues. The liver and adipose tissue jointly participate in maintaining glucose and lipid homeostasis 
through the secretion of several humoral factors and/or neural networks. Perturbation in the inter-
tissue communications may be involved in the development of IR and diabetes. An excessive free 
fatty acids (FFAs) flux into the liver via the portal vein may cause fatty liver disease and hepatic IR. 
However, the initial events triggering the development of IR and its causal relations with 
dysregulation of glucose and fatty acids metabolism remain unclear. It has been suggested that the 
blood glucose- and lipid lowering effects of soluble dietary fibres may be related in part to SCFAs 
generated during anaerobic microbial fermentation [526,527]. Among SCFAs, butyrate constitutes 
one of the major products derived from intestinal fermentation of undigested dietary carbohydrates, 
specifically resistant starches and dietary fibres, but also in a minor part by dietary and endogenous 
proteins. After butyrate uptake by the colon, it is metabolized in part by the colonocytes, and the 
remaining fraction reaches the liver via the portal vein. The colonocytes absorb butyrate through 
different mechanisms of apical membrane uptake, including non-ionic diffusion, SCFA/HCO3
-
 
exchange, and active transport by MCT1 [428]. In particular, butyrate is able to exert a powerful 
pro-absorptive stimulus on intestinal NaCl transport and an anti-secretory effect towards Cl
-
 
secretion [400,403]. The effects exerted by butyrate are multiple and involve several distinct 
mechanisms of action. Its well-known epigenetic mechanism, is the hyperacetylation of histones by 
inhibiting class I and class II histone deacetylases (HDAC), that results in the regulation of gene 
expression and in the control of cell fate [413,528]. HDAC regulates gene transcription through 
modification of chromatin structure by acetylation of proteins, including not only histone proteins, 
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but also transcription factors (i.e. NF-κB, p53 and NFAT) [529]. Butyrate also acts as signal 
molecules, targeting their G protein-coupled receptors Free Fatty Acid Receptor 2 (FFAR2, GPR43) 
and FFAR3 (GPR41) [378]. At intestinal level, butyrate exerts multiple effects, such as the 
prevention and inhibition of colonic carcinogenesis, the improvement of inflammation, oxidative 
status, epithelial defense barrier, and the modulation of visceral sensitivity and intestinal motility. 
At the extraintestinal level, potential fields of application for butyrate seem to be the treatment of 
different pathologies, including metabolic diseases, such as hypercholesterolemia, obesity, IR, and 
ischemic stroke [530]. Recently, it has been demonstrated that dietary supplementation of butyrate 
can prevent or treat diet-induced IR in mice [477]. The mechanism of butyrate action was related to 
promotion of energy expenditure and induction of mitochondrial function through stimulation of 
PGC-1α. Moreover, activation of AMPK and inhibition of HDAC could contribute to PGC-1α 
regulation by butyrate. More recently Li et al., [531] demonstrated that FGF 21, which plays an 
important role in lipid metabolism [532], is induced by butrate and involved in the stimulation of 
fatty acid β-oxidation in liver. Some butyrate-based products are marketed but their spread is still 
very limited and greatly understaffed in view of the wide spectrum of possible indications 
especially in chronic diseases where it is possible to predict a lasting use of these compounds. The 
unpleasant taste and odour make extremely difficult the oral administration of butyrate, these 
difficulties are even more remarkable in children where the administration is complicated. Thus, 
new formulations of butyrate with a better palatability, which can be easily administered orally, are 
needed. The purpose of this study is to investigate the efficacy of sodium butyrate (butyrate) and of 
its more palatable derivative, the N-(1-carbamoyl-2-phenyl-ethyl) butiramide (FBA), in a rat model 
of NAFLD induced by high fat diet. We hypothesized that orally administered butyrate compounds, 
could attenuate steatosis and liver injury, with reduction of inflammatory responses via suppression 
of Toll-like receptors through downregulation of NF-κB activation. 
 
100 
 
6.2 Materials and Methods 
 
Ethics Statement 
This study was carried out in strict accordance with the Institutional Guidelines and complied 
with the Italian D.L. no. 116 of January 27, 1992 of Ministero della Salute and associated guidelines 
in the European Communities Council Directive of November 24, 1986 (86/609/ECC). All animal 
procedures reported herein were approved by the Institutional Committee on the Ethics of Animal 
Experiments (CSV) of the University of Naples “Federico II” and by the Ministero della Salute 
under protocol no. 2008-0099793. Prior to sample collection, animals were euthanized by an 
intraperitoneal injection of a cocktail of ketamine/xylazine, followed by cervical dislocation to 
minimize pain. All efforts were made to minimize animal suffering. 
 
Drugs and reagents 
Standard and high-fat diet (HFD) were purchased from Laboratorio Dottori Piccioni (Gessate, 
Milan, Italy). Standard diet had 15% fat, 22% proteins, and 63% carbohydrates, while HFD had 
58% of energy derived from fat, 18% from protein, and 24% from carbohydrates. The composition 
of high fat diet has been previously described [255]. Standard and high fat diets contained 4.06 
kcal/g and 5.56 kcal/g, respectively. Sodium butyrate was purchased by Sigma-Aldrich (Milan 
Italy) and phenylalanine-butyramide (FBA; Italian patent RM2008A000214; April 21, 2008) was 
provided by Prof. Calignano. Their chemical structure are reported in figure 6.0. FBA is present in 
a solid, poorly hygroscopic, easily weighable form, stable to acids and alkalis and capable of 
releasing butyric acid at small and large bowel level in a constant manner over time. This product 
has demonstrated a toxicological profile comparable to that of butyrate; it shows physicochemical 
characteristics distinctly more suitable for extensive clinical use than those of butyrate. A particular 
aspect of FBA is that it does not present the unpleasant odour of butyrate and is practically tasteless, 
thus making possible to overcome the main limitation to the use of butyrate in the therapeutic field, 
namely its very poor palatability. Moreover, the solubility of FBA in water is satisfactory in that it 
produces clear solutions up to the concentration of 0.1 M and suspensions for higher concentrations. 
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Figure 6.0. Chemical structure of sodium butyrate and its derivative FBA 
 
Synthesis and characterization of butyric acid derivative FBA 
Briefly, 0.01M of phenylalanine carboximide and 0.01M butyroyl chloride were dissolved in 
50 ml of chloroform and the resulting mixture were left to react at room temperature for 24h. The 
mixture, evaporated in vacuo, yields a solid white-coloured residue, that was washed with a 1% 
sodium bicarbonate solution. The aqueous bicarbonate solution was extracted twice with an equal 
volume of ethyl acetate to recover an additional fraction of the mixture of derivatives. To isolate the 
single components, the mixture was treated and processed chromatographically on a silica gel 
column, using dichloromethane as eluent. The compound was re-crystallised with a mixture of 
chloroform/n-hexane 1:1 v: v, obtaining a final yield equal to or greater than 50%. 
 
Animals and treatments 
After weaning, young male Sprague-Dawley rats (average body weight 113.0±2.2 g), 
purchased from Harlan, Italy, were randomly divided into four groups (at least 6 animals for each 
group) as follows: 1) a control group receiving STD and vehicle per os by gavage; 2) HFD-fed 
group receiving vehicle; 3) HFD fed group treated by gavage with sodium butyrate (HFD +butyrate, 
20 mg/kg/die) or 4) with N-(1-carbamoyl-2-phenylethyl) butyramide (HFD+FBA 42.5 mg/Kg/die, 
the equimolecular dose of butyrate). The treatments started together with the HFD and continued 
for 6 weeks. We used a nutritional model of IR in non-genetically modified animals [256] that after 
6 weeks, induced the early events of NAFLD due to fat overnutrition in young animals, excluding 
age and gender influences. Blood sample was collected by cardiac puncture and serum obtained. 
Liver and white adipose tissue were excised and immediately frozen. 
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Blood biochemistry 
Alanine amino transferase (ALT), aspartate amino transferase (AST), total cholesterol, low 
density lipoprotein (LDL) and triglycerides (TGL) were measured by standard automated 
procedures, according to manufacturer’s protocols (Dade Behring Inc., Newark, DE). Fasting 
insulin concentrations were measured by rat insulin radioimmunoassay kit (Millipore Corporation, 
Billerica, MA, USA). Blood glucose concentrations were measured using a glucometer (One Touch 
UltraSmart; Lifescan, Milpitas, CA). Blood NEFA were determined as previously described (Itaya 
and Ui., [504]. 
 
Histological Analysis of Liver Tissue and triglycerides content 
Liver sections were stained with hematoxylin and eosin or Oil Red O. Steatosis was graded on 
a scale of 0 (absence of steatosis), 1 (mild), 2 (moderate) and 3 (extensive). Liver triglycerides were 
determined as previously described [533]. 
 
Oral Glucose Tolerance Test (OGTT) and Insulin Resistance 
Assessment 
Five weeks after the beginning of the experiment, all rats were fasted for 18 h and then 
underwent a glucose tolerance. Glucose was orally administered (2 g/kg body weight). Blood 
samples were collected sequentially from the tail vein before, and 30, 60, 90, and 120 min after the 
glucose load. The area under the glucose concentration versus time curve (AUC) was calculated 
from time zero, as the integrated and cumulative measure of glycemia up to 120 min for all animals. 
To compare the course of the glucose concentration among groups, statistical analysis of AUC 
mean values was performed using the GraphPad Prism software (GraphPad Software, Inc., San 
Diego, CA). As index of insulin resistance, HOMA was also calculated, using the formula [HOMA 
= fasting glucose (mmol/L) × fasting insulin (μU/ml)/22.5]. 
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Western blotting 
Liver and white adipose tissues were homogenized and total protein lysates were subjected to 
SDS-PAGE. Blots were probed with anti-suppressor of cytokine signaling 3 (SOCS3, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), or antiprotein tyrosine phosphatase 1B (PTP1B, Santa 
Cruz Biotechnology), or anti-COX-2 (Cayman Chemical, Ann Arbor, MI), or anti-iNOS (BD 
Trusduction, Franklin Lakes, NJ, USA), or anti-peroxisome proliferator-activated receptor α 
(PPAR-α, Santa Cruz Biotechnology), or anti-PPAR-γ (Novus Biologicals, Littleton, CO, USA), or 
anti-glucose transporter-4 (GLUT-4, Santa Cruz Biotechnology) or anti-glucose transporter-2 
(GLUT-2, Millipore Corporation, Billerica, MA, USA). To evaluate NF-κB activation, IκB-α 
(Santa Cruz Biotechnology) and NF-κB p50 (Santa Cruz Biotechnology) were measured in liver 
cytosolic or nuclear extracts, respectively. Western blot for glyceraldehyde-3- phosphate 
dehydrogenase (GAPDH) or β-actin (in cell lysates, Sigma-Aldrich, Milan, Italy) or lamin A (in 
nuclei lysates, Chemicon. Int, Temecula, CA, USA) was performed to ensure equal sample loading. 
 
Real-time semi-quantitative PCR 
Total RNA, isolated from liver and adipose tissue, was extracted using TRIzol Reagent 
(Invitrogen Biotechnologies), according to the manufacturer’s instructions. cDNA was synthesized 
using a reverse transcription kit (Maxima First Strand cDNA Synthesized Kit, Fermentas, Ontario, 
Canada) from 2 μg total RNA. PCRs were performed with a Bio-Rad CFX96 Connect Real-time 
PCR System instrument and software (Bio-Rad Laboratories). The primer sequences are reported in 
Table 6.2. The PCR conditions were 10 min at 95°C followed by 40 cycles of two-step PCR 
denaturation at 95°C for 15 s and annealing extension at 60°C for 60 s. Each sample contained 1-
100 ng cDNA in 2X Power SYBRGreen PCR Master Mix (Applied Biosystem) and 200 nmol/l of 
each primer (Eurofins MWG Operon, Huntsville, AL) in a final volume of 25μl. The relative 
amount of each studied mRNA was normalized to GAPDH as housekeeping gene, and the data 
were analyzed according to the 2
-ΔΔCT
 method. 
 
Statistical analysis 
All data were presented as mean ± SEM. Statistical analysis was performed by ANOVA test 
followed by Bonferroni’s test for multiple comparisons. Statistical significance was set at P<0.05. 
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Table 6.2. Real-Time PCR Primer Sequences 
Target gene 
 
Forward primer (5’→3’) 
 
Revere primer (3’→5’) 
 
Accession 
Number 
CD14 
 
GTGCTCCTGCCCAGTGAAAGAT 
 
GATCTGTCTGACAACCCTGAGT 
 
AF_087943 
 
F4/80 CCCAGCTTATGCCACCTGCA 
 
TCCAGGCCCTGGAACATTGG NM_001007557.1 
FGF21 
 
AGATCAGGGAGGATGGAACA ATCAAAGTGAGGCGATCCATA NM_130752.1 
GAPDH 
 
GGCACAGTCAAGGCTGAGAATG ATGGTGGTGAAGACGCCAGTA NM_017008 
XM_216453 
 
HMGB-1 
 
TTGTGCAAACTTGCCGGGAGGA ACTTCTCCTTCAGCTTGGC NM_012963.2 
 
IL-1β 
 
TCCTCTGTGACTCGTGGGAT 
 
TCAGACAGCACGAGGCATTT 
 
NM_031512 
 
IL-6 
 
ACAAGTGGGAGGCTTAATTACACAT TTGCCATTGCACAACTCTTTTC NM_012589 
 
MCP-1 
 
CCCACTCACCTGCTGCTACT TCTGGACCCATTCCTTCTTG NM_031530.1 
 
PGC1-α 
 
AACCAGTACAACAATGAGCCTG AATGAGGGCAATCCGTCTTCA NM_031347.1 
Pro-collagen 
type 1 
TCGATTCACCTACAGCACGC GACTGTCTTGCCCCAAGTTCC NM_053304.1 
- SMA 
 
TGCTGGACTCTGGAGATGG GATGGTGATCACCTGCCCATC NM_031004.2 
TGF-β 
 
GAAGCCATCCGTGGCCAGAT 
 
TGACGTCAAAAGACAGCCACT 
 
NM_021578.2 
TLR2 
 
GTACGCAGTGAGTGGTGCAAGT 
 
TGGCCGCGTCATTGTTCTC 
 
NM_198769 
XM_227315 
 
TLR4 
 
CTACCTCGAGTGGGAGGACA 
 
ATGGGTTTTAGGCGCAGAGTT 
 
NM_019178 
 
TLR9 
 
ATGGCCTGGTAGACTGCAACT 
 
TTGGCGATCAAGGAAAGGCT 
 
NM_198131 
 
TNF-α 
 
CATCTTCTCAAAACTCGAGTGACAA TGGGAGTAGATAAGGTACAGCCC NM_012675 
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6.3 Results 
 
Effects of butyrate and FBA on liver steatosis and serum parameters 
Liver sections from rats fed with HFD demonstrated significant hepatic damage in 
comparison with standard diet (STD) fed animals. As depicted in Figure 6.1A, HFD livers showed 
foci of mixed inflammatory cell infiltration, evidenced by arrows, and hepatocyte necrosis or 
apoptosis throughout the lobule. Scattered inflammation and occasionally apoptotic nuclei were 
observed. No alterations were shown in liver of the rats fed with the STD. Furthermore, HFD rats 
showed grade 3 hepatic steatosis with a histological pattern characterized by microvesicular 
steatosis. The hepatocytes showed the cytoplasm filled with small vacuoles which were uniform in 
size and smaller than the centrally located nucleous. Steatosis affected most of the hepatocytes 
(Figure 6.1B). In animals treated with equimolecular doses of butyrate (sodium butyrate or FBA), 
liver inflammatory damage appears reduced and steatosis was graded as grade 1 with a 
microvesicular pattern of lipid accumulation distributed in perivenular and periportal region. This 
effect was also associated with a reduction of triglycerides content which was significantly 
enhanced by HFD (Figure 6.1C). In HFD-fed animals TNF-α, a cytokine involved in the 
development of IR, was significantly increased, butyrate and in particular FBA reduced hepatic 
expression of this cytokine (Figure 6.1D). Similarly the mRNA concentration of chemokine MCP-
1 and a specific marker of mature macrophages F4/80 were increased in HFD rats and normalized 
by butyrate treatments (Figure 6.1E and F). Moreover, HFD induced the expression TGF-β1, an 
early marker of the fibrotic process (Figure 6.1G), which was significantly down-regulated in the 
butyrate-treated group (P < 0.01) and more significantly by FBA (P < 0.001). We also evaluated α-
SMA and pro-collagen type 1 transcript by real time-PCR but it did not show a significant 
modification after 6 weeks of HFD. Biochemical serum parameters are reported in table 6.1. 
Circulating levels of AST, ALT and cholesterol resulted increased at 6 weeks of HFD, while LDL 
and triglycerides showed a trend of increase. All these parameters were reduced by butyrate and 
FBA. Compared with animals fed with STD diet, HFD rats showed a marked increase in fasting 
glucose without change in insulin levels. Both butyrate and FBA prevented glucose alteration. 
Homeostasis model assessment for insulin resistance (HOMA-IR) was 25% and 30% lower in 
butyrate and FBA groups, respectively. No difference in body weight was shown among all groups, 
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weight gain of HFD fed animals did not change after 6 weeks neither modified by butyrate and 
FBA treatments (data not shown). 
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Figure 6.1. Effects of butyrate and FBA on liver steatosis. Paraffin-embedded sections of the liver (n=4 each group) were stained with 
hematoxylin-eosin (A) or oil red O (B). Micrographs in both panels are representative pictures with original magnification 400X. Foci of 
inflammatory cells are shown (arrows). (C) Triglycerides were measured in liver and normalized on 500 mg of frozen tissue (n=6 each group). The 
mRNA levels of pro-inflammatory cytokines TNF-α (D), MCP-1 (E), F4/80 (F), and TGF-β (G) were analyzed by real-time PCR in liver extracts 
(n=6, each group). (*P<0.05, ***P<0.001 vs. STD; # P<0.05, # # P<0.01, # # # P<0.001 vs. HFD). 
 
 
Table 6.1. Changes in serum parameters of rats fed with control standard diet (STD), high fat diet (HFD) or high 
fat diet and treated with Butyrate or FBA for 6 weeks. 
 
 
 
STD HFD  HFD+Butyrate HFD+FBA 
ALT (U/l) 26.17±3.40 38.83±3.69 *
 
22.00±1.59 
##
 18.83±1.56 
###
 
AST (U/l) 157.33±12.23 226.16±24.15 ** 152.0±3.65 
##
 146.60±12.79 
##
 
Colesterol (mg/dl)  71.50±1.72 86.14±6.37 * 74.50±1.52 
#
 74.67±3.03 
#
 
LDL (mg/dl)  
24.55±0.74 27.23±2.39 20.40±0.86 
#
 23.46±0.82 
TGL (mg/dl) 38.50±3.52 43.86±3.70 35.17±0.40 39.67±1.62 
Fasting glucose 
(mg/dl) 
110.3±3.22 149.0±16.27* 115.2±6.71
#
 118.4±5.48
# 
Fasting insulin (µg/l) 0.20±0.06 0.27± 0.02 0.21±0.01 0.20±0.01 
HOMA index 0.97±0.03 1.56±0.16** 1.17±0.11
#
 1.13±0.06
#
 
 
Values are means ± S.E of six animals. (* P<0.05, **P<0.01 vs. STD. #P<0.05; ##P<0.01; ###P<0.001 vs. HFD). 
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Modulation of hepatic inflammatory parameters and NF-κB 
activation by butyrate and FBA 
Hepatic and extra-hepatic IL-1 sources contribute to liver inflammation related to metabolic 
alterations. In fact, IL-1β is strongly up-regulated by activated macrophages or other liver cell types 
(including Kupffer cells and hepatic stellate cells), participating in liver injury. Beyond TNF-α, also 
IL-6 is involved in metabolic impairment, initiating the pathogenesis of hepatic IR. As shown in 
Figure 6.2A and B, HFD induced a significant increase in hepatic IL-1β and IL-6 mRNAs, and 
both treatments significantly prevented the transcription of these genes. Moreover, the high-fat diet 
determined an increase in liver proinflammatory enzymes, COX-2 and iNOS (Figure 6.2C and D) 
and butyrate and FBA reduced the expression of these proteins. In agreement both treatments 
significantly prevented the increase of nuclear content of p50 NF-κB related to a reduction of the 
inhibitory cytosolic protein IκBα, showing the inhibition of NF-κB activation (Figure 6.2E and F). 
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Figure 6.2. Modulation of hepatic inflammatory parameters and NF-κB activation by butyrate and FBA. IL-1β (A) and IL-6 (B) mRNA 
expression (relative fold change to STD) are reported (n=6, each group). Panels C and D show representative Western blot analysis of pro-
inflammatory enzymes COX-2 and iNOS, respectively, in the liver extracts. Nuclear p50 NF-κB (E), and cytosolic inhibitory protein IκB-α (F) 
expression is reported (n=6 each group). (*P<0.05, **P<0.01, ***P<0.001 vs. STD; # P<0.05, # # P<0.01 vs. HFD). 
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Effect of butyrate and FBA on hepatic Toll-like receptors pattern 
The activation of TLRs family, especially TLR4, by inflammatory cytokines or increased 
NEFA could modulate insulin sensitivity [115]. Recently, it has been hypothesized that FFA-related 
high–mobility group box 1 (HMGB1) release mediates the activation of TLR4 signaling in 
hepatocytes and plays an essential part in the early stage of NAFLD induced by HFD [523]. Here, 
HMGB-1 mRNA levels were strongly up-regulated by HFD feeding while both butyrate, and in 
particular FBA, determined a significant reduction of these levels (Figure 6.3A). As shown in 
Figure 6.3B and C, HFD induced the mRNA increase of TLR4 and its co-receptor CD14 in liver. 
FBA and, to a lesser extent, butyrate inhibited these effects. Notably, TLR2 and TLR9, which are 
able to detect lipoproteins and unmetilated CpG-containing DNA, respectively, were also 
upregulated by HFD and reduced by two treatments, with a great effectiveness of the FBA (Figure 
6.3D and E). 
 
 
Figure 6.3. Effect of butyrate and FBA on hepatic Toll-like receptors pattern. Panels A and B are the results of real-time PCR for HMGB-1 and 
TLR4, respectively, in liver extracts from 6 rats on STD, HFD, HFD+butyrate, and HFD+FBA. Panel C shows mRNA expression of coreceptor 
CD14. TLR2 (D) and TLR9 (E) mRNA levels are shown and expressed as relative fold change to STD. *(P<0.05, **P<0.01 and ***P<0.001 vs. 
STD; # P<0.05, # # P<0.01, # # # P<0.001 vs. HFD). 
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Effect of butyrate and FBA on glucose homeostasis and insulin 
resistance 
To confirm the effects of butyrate and its derivative on insulin resistance in HFD-fed rats, 
glucose tolerance and insulin signaling were analyzed. In oral glucose tolerance test, blood samples 
were collected sequentially before, and 30, 60, 90, and 120 min after the glucose load, HFD induced 
an altered response to glucose at all time points paralleled with STD (Figure 6.4A and B): in fact, a 
marked and significant increase of AUC values was shown in HFD group (P<0.001), which was 
significantly reduced by FBA (Figure 6.4A and B). Butyrate and FBA groups exhibited improved 
response to glucose at all time points, in particular FBA raised a significant reduction of glycemia 
90 min after glucose load (Figure 6.4A). The insulin receptor is acted on an unique group of 
regulatory proteins, including PTP1B, which is considered as a major negative regulator of insulin 
receptor signaling. As depicted in Figure 6.4C the HFD feeding determined an over-expression of 
this enzyme while both treatments showed a significant reduction of this protein in hepatic tissue. 
Moreover, we showed an increase in SOCS3 protein expression in hepatic tissues from HFD rats, 
that was significantly inhibited by butyrate and FBA (P<0.05, Figure 6.4D) confirming the 
restoration of insulin signaling. According with the inflammatory alterations, other modifications 
demonstrated metabolic impairment and insulin tissue resistance in HFD fed rats. The basal level of 
PPAR-α, which regulates fatty acid β-oxidation and catabolism, was detected in liver homogenates 
from STD fed animals. PPAR-α decreased in liver from HFD rats (P<0.01) and restored by butyrate 
or FBA (P<0.01 and P<0.05, respectively, Figure 6.5A). Very recently, it has been demonstrated 
that FGF21, a cytokine/hormone that plays an important role in the regulation of lipid and 
carbohydrate metabolism, was induced by butyrate [531]. In liver extracts, FGF21 was significantly 
reduced by HFD and its decreased expression was slightly prevented by butyrate and significantly 
by FBA (Figure 6.5B). Moreover, GLUT2, a glucose-sensitive gene in liver cells [534], was 
markedly reduced by HFD and this effect was significantly prevented by butyrate and FBA (and 
Figure 6.5C). It is well known that adipose tissue, behind its reserve and secretory role, represents 
an important insulin-sensitive target tissue contributing to glucose homeostasis. Here, the 
expression of PPAR-γ, a ligand-dependent transcription factor, was lower in HFD compared with 
STD group, whereas both treatments significantly increased it (Figure 6.6A). Consistently, PGC-
1α, was significantly reduced in HFD group, while both treatments prevented this effect (Figure 
6.6B). It is well known that this coactivator controls energy metabolism interacting with 
severaltranscription factors, including PPAR-α, and its reduction is associated with mitochondrial 
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dysfunction, reduction in fatty acid oxidation and insulin resistance [535]. Moreover, in adipose 
tissue butyrate and FBA were also able to restore GLUT-4 protein expression, that was deeply 
reduced by HFD (P<0.05, respectively, Figure 6.6C). 
 
 
 
 
Figure 6.4. Effect of butyrate and FBA on glucose homeostasis and insulin resistance. Glucose tolerance test (A) in STD and HFD-fed rats (n=6, 
each group) was performed and AUC evaluated (B). Panels C and D show representative Western blot analysis of PTP1B and SOCS3 expression 
from liver tissue, respectively (n=6 each group). (**P<0.01, ***P<0.001 vs. STD; # P<0.05, # # P<0.01 vs. HFD). 
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Figure 6.5. Effect of butyrate and FBA on metabolic impairment and insulin resistance in liver from HFD fed rats. Panel A shows a Western 
blot analysis of PPAR-α expression (n=6 each group). FGF21 mRNA abundance (B) and GLUT-2 protein expression level (C) in the liver extracts 
were quantified by real-time PCR and Western blot analysis, respectively (n=6 each group). (**P<0.01, ***P<0.001 vs. STD; # P<0.05, # # P<0.01, # 
# # P<0.001 vs. HFD). 
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Figure 6.6. Butyrate and FBA are able to modulate metabolic proteins in adipose tissue. Representative Western blot of PPAR-γ (A) is shown 
(n=5 each group). Panel B shows real-time PCR results from PGC-1α mRNA levels (relative expression toSTD) in adipose tissue (n=6 each group). 
(C) Western blot analysis of GLUT-4 protein expression in adipose tissue extracts is shown (n=5 each group). (**P<0.01 and ***P<0.001 vs. STD; # 
P<0.05, # # P<0.01 vs. HFD). 
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6.4 Discussion 
Metabolic and anti-inflammatory effects of butyrate and its derivative, phenylalanine-
butyramide (FBA), were examined in this study in a HFD-induced rat model of hepatic steatosis 
and insulin resistance. Sodium butyrate shows considerable drawbacks: it has fairly strong 
hygroscopicity and butirric nauseating smell, associated to a poor compliance related to extremely 
unpleasant taste and epigastric discomfort after oral assumption. On the other hand, the conjugate of 
butyrate to phenylalanine, FBA, has allowed to obtain a molecule with chemical-physical 
characteristics suitable for an easier oral administration compared to butyrate. The most important 
observation is that both treatments prevented the impairment of glucose homeostasis and the 
development of insulin resistance. In our model there are two major hallmarks of insulin resistance: 
hepatic inflammatory process and alteration of glucose tolerance related to an impairment of insulin 
signaling. The improvement in insulin sensitivity may be, at least in part, a consequence of anti-
inflammatory effects of these compounds in this nutritional model. Insulin controls whole body 
glucose homeostasis with several mechanisms, such as the promotion of glucose disposal in 
sensitive target tissues, such as liver and fat. Our study shows that both treatments are able to 
prevent liver inflammation and damage, steatosis, the onset of IR, and imbalance of TLRs pattern in 
the early stage of NAFLD. In particular, we showed a reduction in hepatic lipid accumulation 
mainly significant in FBA treated rats, together with a reduction of the inflammatory infiltrates. The 
evaluation of the fibrotic process revealed no appreciable modification in HFD fed rats, and 
consequently no modification by both butyric treatments (data not shown), even if TGF-β, an early 
pro-fibrogenic marker, was up-regulated in liver from rats on HFD, and markedly reduced by both 
treatments. TGF-β is considered the most powerful mediator of hepatic stellate cell activation and 
kupffer cells are a main source of TGF-β in the liver, promoting, collectively to inflammatory 
cytokines and oxidative stress, later fibrosis [536]. 
Moreover, both treatments normalize the hepatic markers of steatosis, and preserve glucose 
tolerance, reducing fasting glucose and modulating HOMA-IR. It is now clear that TNF-α and IL-6 
represent crucial effectors of IR, that link liver inflammatory process to hormonal and metabolic 
alterations [93,506]. In our experimental model, both compounds reduce the above reported 
cytokines in parallel with a lower expression of PTP1B and SOCS3 inhibitory proteins, suggesting 
two molecular mechanisms of insulin sensitization. In accordance, recently it has been highlighted 
how the prototypic phoshotyrosine-specific phoshatase PTP1B dephosphorylates the insulin 
receptor and downstream IRS-1/2 proteins. Its inhibition enhances insulin signaling and attenuates 
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insulin resistance both in conventional and non conventional insulin responsive tissues [537], 
indicating PTP1B as a target for the development of novel therapeutics for diabetes and obesity. On 
the other hand, SOCS family, including SOCS3, associates with the insulin receptor and inhibits its 
signaling through ubiquitin-induced degradation of IRS-1. In particular, the induction of SOCS3 in 
liver may be an important mechanism of IL-6-mediated insulin resistance [93]. Moreover, both 
treatments reduce the activation of NF-κB pathway induced by HFD, reducing IκBα degradation 
and inhibiting p50, with a subsequent reduction not only in cytokine transcription (TNF-α, IL-6 and 
IL-1β), but also in inflammatory enzymes (COX-2 and iNOS). Furthermore, we found that HFD 
increases macrophage infiltration markers, MCP-1 and F4/80, and both butyrate treatments are able 
to reduce these parameters, in particular reducing F4/80-positive macrophage, indicative of 
M1state, associated with inflammation and tissue injury [538]. 
Here, we demonstrate that both treatments reduce inflammation and its mediators inhibiting 
NF-κB activation arguably through the down-regulation of TLR pattern in the liver, which are 
involved in bacterial sensing and are crucial for “liver tolerance”. We demonstrate that FBA and, to 
a lesser extent, butyrate are able to limit the increased transcription and expression of TLRs induced 
by HFD. The increased expression of hepatic TLRs confirms a greater exposure of the liver to 
ligands for these receptors deriving from the intestine (i.e. pathogen-associated molecular patterns 
or PAMPs and endogenous damage-associated molecular patters or DAMPs), including the widely 
expressed nucleus protein HMGB1. Recently, it has been hypothesized that FFA-related HMGB1 
release mediates the activation of TLR4 signaling in hepatocytes and plays an essential part in the 
early stage of NAFLD induced by HFD [523]. Here, hepatic HMGB1 transcription was strongly up-
regulated by HFD feeding while both butyrate, and in particular, FBA determined a significant 
reduction of its levels. In parallel, they also normalized the expression of TLR4 and its co-receptor 
CD14 in liver. Accordingly, we evidenced the same profile of activity of butyric treatments on 
TLR2 mRNA. Consistently with our data, Ehses et al., [525] have reported that TLR2 deficient 
mice are protected from IR and β cell dysfunction induced by HFD, linking TLR2 to the increased 
dietary lipid and the alteration of glucose homeostasis. Finally, FBA significantly inhibits the HFD-
related increase in TLR9 synthesis. Intracellular TLR9 activates innate immune defenses against 
viral and bacterial infection and plays a role in the pathogenesis of NASH [118]. We previously 
demonstrated that HFD feeding is associated with the reduction of PPAR-α expression in liver [70] 
and the administration of a PPAR-α agonist or probiotics restores PPAR-α and improves hepatic 
steatosis [70,71]. Here, we evidence that butyrate and FBA are also able to do this. Our data 
confirm recent in vitro and in vivo findings that identify butyrate as a new inducer of FGF21 [531]. 
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In that study, butyrate injection increased FGF21 serum concentration and protein levels in the liver 
of obese mice through activation of PPAR-α which was dependent on HDAC3 inhibition by 
butyrate. Despite the differences in the two experimental models (6 weeks vs. 20 weeks of diet, an 
sub-chronic treatment vs an acute one), in our experiments, butyrate and its derivative are still able 
to restore hormone levels in the early stage of NAFLD, in liver of non obese rats assuming the 
involvement of HDAC3 inhibition. FGF21 is a metabolic hormone predominantly produced by the 
liver, but also expressed in adipocytes and pancreas, where it regulates glucose and lipid 
metabolism through pleiotropic actions [512]. We studied PPAR-α and PPAR-γ expression in 
tissues where they are more abundant, liver and adipose tissue, respectively [539]. PPAR-γ 
promotes fatty acid uptake and increases insulin sensitivity by upregulating GLUT-4, an insulin 
dependent glucose transporter in adipose tissue and striated muscle [515] and attenuating the 
induction of SOCS3 [516]. In the current report, we provide evidence that butyrate and FBA not 
only prevent, in adipose tissue, the HFD-induced reduction of PPAR-γ but also positively modulate 
PPAR-γ-coactivator PGC-1α [540]. This transcription coactivator controls energy metabolism, 
interacting with several transcription factors, including PPAR-α and PPAR-δ, that regulate gene 
transcription for mitochondrial biogenesis and respiration [541]. In fact, the reduction in PGC-1α 
function is associated with mitochondrial dysfunction, reduction in fatty acid oxidation, and risk for 
IR or type 2 diabetes [542]. Dietary intervention of PGC-1α activity holds promise in the prevention 
and treatment of metabolic syndrome [477,543]. Our data support the concept that the stimulation 
of PGC-1α activity may be a molecular mechanism of butyrate activity, in agreement with previous 
data demonstrating that the inhibition of histone deacetylases and activation of AMPK may 
contribute to the PGC-1α regulation [477]. Consistently, butyrate and FBA are able to normalize the 
facilitative hexose transporter, GLUT-2 and insulin-stimulated glucose transport GLUT-4 
expression in liver and adipose tissue, respectively, supporting systemic effects of both compounds. 
Our data are in agreement with previous findings demonstrating that butyrate up-regulates GLUT-2 
mRNA abundance in other cell types, such as Caco2-BBe monolayers, by activating specific 
regions within the human GLUT2 promoter [544]. GLUT-2 is located in the plasma membrane of 
hepatocytes and pancreatic beta cells, in contrast with GLUT-1 and GLUT-3, has a low affinity for 
glucose. Their high Km (15-20 mM) allows for glucose sensing; rate of glucose entry is 
proportional to blood glucose levels. GLUT-4 transporters are insulin sensitive, and are found 
mainly in muscle and adipose tissue. As muscle is a principle storage site for glucose and adipose 
tissue for triglyceride (into which glucose can be converted for storage), GLUT-4 is important in 
post-prandial uptake of excess glucose from the bloodstream or in other conditions of over-nutrition 
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(i.e. HFD). Moreover, recent findings have reported an improvement of liver glycogen storage by 
acute butyrate supply that was explained by the competition between butyrate and glucose 
oxidation, and by a likely reduced glycogenolysis from the newly synthesized glycogen [545]. 
 
6.5 Conclusions 
To our knowledge, our work is the first to propose concomitant biochemical mechanisms in 
the liver and adipose tissue to better understand how butyrate and its derivative may regulate 
glucose metabolism and improve insulin sensitivity. Our results show a protective effect of butyrate 
to limit early molecular events underlying IR linked to steatosis, suggesting a potential clinical 
utility as innovative, preventive and therapeutic strategy for NAFLD. In fact, these treatments 
prevent the transition from steatosis toward steatohepatitis, dampening the onset of several hits 
responsible for the shift and the progression of the disease. Since FBA does not have the 
characteristic odor of rancid butyrate, this derivative may represent a viable therapeutic alternative 
to butyrate, favoring a better compliance and a greater effectiveness. 
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CHAPTER 7: EFFECTS OF A SYNBIOTIC-BASED 
LACTOBACILLUS PARACASEI B21060 ON EPITHELIAL 
BARRIER FUNCTION AND TISSUE REPAIR IN DEXTRAN 
SODIUM SULFATE-INDUCED COLITIS IN MICE. 
 
7.1 Introduction 
IBDs are thought to result from inappropriate and ongoing activation of the mucosal immune 
system driven by penetration of normal luminal flora through defective tight-junction proteins (TJ). 
The altered TJ structure in ulcerative colitis results in impaired barrier function, which may lead to 
increased uptake of luminal antigens and/or adjuvants that overwhelm the net suppressive tone of 
the mucosal immune system [546]. Commensal bacteria regulate key epithelial cell functions that 
contribute and maintain intestinal epithelial barrier integrity against injury [547]. However, the 
precise innate immune mechanisms of beneficial host-microbial interactions are not yet fully 
understood [548]. The intestinal epithelium is the interface for the interaction between gut 
microbiota and host tissues [549]. This barrier is enhanced by the presence of a mucus layer and 
immune factors that are produced by the host [550]. Antimicrobial peptides for innate immunity are 
produced by Paneth cells (e.g., α-defensins, lysozyme C, phospholipases, and C-type lectin, 
primarily regenerating islet derived 3-gamma, RegIIIγ) or enterocytes (RegIIIγ) [551,552]. 
Adaptive immune system effectors that are secreted into the intestinal lumen, such as IgA, may also 
restrict bacterial penetration into the host mucus and mucosal tissue [553]. These immune factors 
allow the host to control its interactions with gut microbiota and shape its microbial communities 
[552]. The development of immune-modulating probiotic therapeutic approaches for IBD is related 
to observations that several invasive pathogenic bacteria including E. coli and C. Difficile are pro-
inflammatory and associated with disease development in patients [554,555]. In contrast, 
bifidobacteria are reported to be deficient in rectal biopsies from patients with IBD [556] and 
studies of faecal flora in patients with Crohn’s disease suggest a deficiency in both lactobacilli and 
bifidobacteria [557]. Therefore, in IBD patients there are respectively reduced and increased levels 
of commensal bacteria and pathogenic bacteria. The most widely used probiotics are 
Bifidobacterium and Lactobacillus species, both of which have been tested in clinical trials of 
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irritable bowel syndrome [558]. Overall, human IBD trials to date suggest that probiotics display no 
overt side effects, but conflicting reports on probiotic efficacy highlight the importance of selecting 
well-characterised probiotic strains and in delivering intact pharmaceutical formulations at an 
appropriate dose level to the inflamed regions of the intestine [559]. Testing of probiotics in mouse 
models of IBD has yielded encouraging data that have prompted human trials. The distal intestine 
of humans contains tens of trillions of microbes: this community (microbiota) is dominated by 
members of the domain Bacteria but also includes members of Archaea and Eukarya, and their 
viruses. The vast repertoire of microbial genes (microbiome) present in the distal gut microbiota 
performs myriad functions that benefit the host [560]. The mucosal immune system co-evolves with 
the microbiota beginning at birth, acquiring the capacity to tolerate components of the microbial 
community while maintaining the capacity to respond to invading pathogens. The gut epithelium 
and its overlying mucus provide a physical barrier. Epithelial cell lineages, notably the Paneth cell, 
sense bacterial products through receptors for microbe-associated molecular patterns (MAMPs), 
resulting in regulated production of bactericidal molecules [561]. Mononuclear phagocytes 
continuously survey luminal contents and participate in maintenance of tissue integrity, and the 
initiation of immune responses [562,563]. Several families of innate receptors expressed by 
hematopoietic and non-hematopoietic cells are involved in recognition of MAMPs, such as Toll-
like receptors, nucleotide binding oligomerization-domain protein-like receptors (NLRs), and C-
type lectin receptors [564,565]. Recently, the NLRP sub-family of the NLR family of proteins, 
distinguished from the other NLRs by an N-terminal pyrin domain, has been implicated in the 
pathogenesis of chronic inflammatory conditions [566,567]. Inflammasomes are cytoplasmic multi-
protein complexes composed of one of several NLR proteins, including NLRP1, NLRP3, and 
NLRC4, that function as sensors of endogenous or exogenous stress or damage-associated 
molecular patterns [568]. Upon sensing the relevant signal, they assemble, typically together with 
the adaptor protein, apoptosis-associated speck-like protein (ASC), into a multi-protein complex 
that governs caspase-1 activation and subsequent cleavage of effector pro-inflammatory cytokines 
including pro-IL-1β and pro-IL-18 [565,569]. Several other members of the NLR family, including 
NLRP6 and NLRP12, possess the structural motifs of molecular sensors, and are recruited to the 
“specks” formed in the cytosol by ASC oligomerization, leading to pro-caspase-1 activation [570]. 
Given these considerations, a specific aim of this study was to investigate whether in a mouse 
models of ulcerative colitis, the synbiotic formulation Flortec based on Lactobacillus paracasei 
B21060 could prevent or repair the damage inuced by sodium dextran sulphate. Drugs that can 
decrease epithelial permeability through closing epithelial tight junctions are currently the focus of 
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intense research efforts [571]. Thus, a key question posed in the current study was whether this 
probiotic strain could preserve innate immune barrier equilibrium through TJ regulation, which 
balances mucosal homeostasis against inflammatory stress-induced damage in mice. Besides, in 
order to investigate how this synbiotic regulate the epithelial repair process, we sought to explore 
the mechanism that requires an inflammasome, involving NLRP6, NLRP3 and caspase-1, and leads 
to the cleavage of pro-IL-18 in our model of colitis. Our data showed significant curative effects of 
this synbiotic formulation in DSS model of colitis and suggests not only a potential therapeutic role 
for this agent in this pathology, but also the possibility that a supplement of these lactobacilli might 
prevent the relapse of UC. 
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7.2 Materials and Methods 
 
DSS-induced colitis and animal treatments 
Experimental colitis was induced in ten weeks old BALB/c male mice (25±2 g) (Harlan-
Corezzano, Italy) by 2.5% DSS (wt/vol) (MP Biomedicals, Irvine, CA) in sterile drinking water ad 
libitum for five days, followed by drinking water without DSS for twelve days. Mice were 
randomly divided into four groups (n=10 each group) as following: 1. a control animals (CON), 2. 
DSS treated mice (DSS), 3. DSS mice treated with Flortec as preventive therapy (FLO PREV) and 
4. DSS mice treated with Flortec as curative therapy (FLO CUR). Flortec (Bracco, Milan, Italy) is a 
synbiotic formulation containing viable lyophilized Lactobacillus paracasei B21060 mixed with 
prebiotics fructo-oligosaccharides and arabinogalactan. This formulation was available as powder 
and dispensed in 6 g bag containing about 2.5 × 10
9
 CFU of the bacteria. Daily synbiotic treatment 
(L. paracasei B21060 2.5x10
7
 bacteria/10g bw; fructo-oligosaccarides 7mg/10g bw, and 
arabinogalactan 5mg/10g bw by gavage) started seven days before (PREV) or two days after (CUR) 
DSS challenge. DSS group without synbiotic formulation, received H2O by gavage as drug’s 
vehicle. Colitis was assessed by the daily monitoring of body weight, stool consistency and fecal 
blood. All procedures involving animals were carried out in accordance with the Institutional 
Guidelines and complied with the Italian D.L. no.116 of January 27, 1992 of Ministero della Salute 
and associated guidelines of the European Communities Council Directive of November 24, 1986 
(86/609/ECC). Prior to sample collection, animals, kept overnight fasted, were euthanized by an 
isoflurane anesthesia, followed by cervical dislocation to minimize pain. All efforts were made to 
minimize animal suffering. Blood samples from animals were collected by cardiac puncture and 
serum obtained. At 19
th days mice were killed and full intestine and colons measured. Colon tissue 
was excised and immediately frozen. Segments of colon were assessed histologically by 
hematoxylin and eosin staining. In figure 7.0 the scheme of experimental protocol and animal 
treatments are summarized. 
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Figure 7.0. Experimental protocol used for this study 
 
Evaluation of experimental colitis 
In all animals, weight, presence of blood and stool consistency were determined daily as 
previously described [572]. Disease activity index (DAI) was determined by combining scores of a) 
weight loss b) stool consistency and c) bleeding (divided by 3). Each score was determined as 
follows, change in weight (0:<1%, 1: 1–5%, 2: 5–10%, 4:>15%), stool blood (0: negative, 2: 
positive) or gross bleeding (4), and stool consistency (0: normal, 2: loose stools, 4: diarrhea) as 
previously described [573]. Body weight loss was calculated as the percent difference between the 
original body weight and the actual body weight on any particular day. Typically in DSS colitis 
animals will lose 10–15% body weight over the course of 10 days. The appearance of diarrhea is 
defined as mucus/fecal material adherent to anal fur. The presence or absence of diarrhea was 
scored as either 1 or 0, respectively, and the cumulative score for diarrhea was calculated by adding 
the score for each day and dividing by the number of days of exposure. Rectal bleeding was defined 
as diarrhea containing visible blood/mucus or gross rectal bleeding and scored as described for 
diarrhea. 
 
Western Blotting 
Segments of colon tissue were homogenized on ice in lysis buffer (Tris-HCl, 20 mM pH 7.5, 
10 mM NaF, 150 mM NaCl, 1% Nonidet P-40, 1 mM phenylmethylsulphonyl fluoride, 1 mM 
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Na3VO4, 10 g/ml leupeptin and trypsin inhibitor). After 1 h, tissue lysates were obtained by 
centrifugation at 21000xg for 15 min at 4°C. The protein concentration of the samples was 
determined by Bio-Rad protein assay (Bio-Rad Laboratories, Segrate, Milan, Italy), using bovine 
serum albumin as the standard. For Western blot analysis, tissue lysate was dissolved in Laemmli’s 
sample buffer, boiled for 5 min, and subjected to SDS-PAGE. The blot was performed by 
transferring proteins from a slab gel to nitrocellulose membrane at 264 mA for 45 min at room 
temperature. The filter was then blocked with 1x PBS, 5% non fat dried milk for 40 min at room 
temperature and probed with rabbit polyclonal antibody anti-3-nitrotyrosine (1:8000; Millipore, 
Billerica, MA USA) dissolved in 1x PBS, 5% non fat dried milk, 0.1% Tween 20 at 4°C, overnight. 
The secondary antibody was incubated for 1 h at room temperature. Subsequently, the blot was 
extensively washed with PBS, developed using enhanced chemiluminescence detection reagents 
(Amersham Pharmacia Biotech, Piscataway, NJ, Piscataway, NJ, USA). The optical density of the 
bands was determined by a GS-800 imaging densitometer (Bio-Rad). Western blot for GAPDH 
(Sigma-Aldrich; Milan Italy) was performed to ensure equal sample loading. 
 
MDA measurement 
MDA levels in colon were determined as an indicator of lipid peroxidation [574]. Tissues 
were homogenized in 1.15% KCl solution. An aliquot (200 μl) of the homogenate was added to a 
reaction mixture containing 200 ml of 8.1% SDS, 1.5 ml of 20% acetic acid (pH 3.5), 1.5 ml of 
0.8% thiobarbituric acid, and 600 ml of distilled water. Samples were then boiled for 1 h at 95°C 
and centrifuged at 3000xg for 10 min. The supernatant absorbance was measured at 550 nm by 
spectrophotometry and the concentration of MDA was expressed as µmol MDA/mg protein of 
tissue homogenate. A standard curve was prepared using MDA bisdimethylacetal as the source of 
MDA. All solutions were freshly prepared on the day of assaying. 
 
Measurement of MPO activity 
Proximal colonic tissues were homogenized twice for 30s at 4°C in 0.5% 
hexadecyltrimethylammonium bromide (HTAB) in 50 mM sodium phosphate, pH 6.0, according to 
Bradley et al., [575]. The homogenates were clarified by centrifugation at 13000xg for 15 min, at 
4°C, and were assessed for MPO (Myeloperoxidase) activity in 3 ml 50 mM sodium phosphate, pH 
6.0, containing 16 mM aqueous guaiacol and 5.9 mM H2O2, as previously described [576]. The 
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increase in absorbance was measured for 2 min at 470 nm using The iMark microplate absorbance 
reader (Bio-Rad). Protein concentrations were determined using the Bio-Rad protein assay. MPO 
activities were expressed in U.MPO/mg protein with 1 U hydrolyzing 1 μmol H2O2/min. 
 
Real-time semi-quantitative PCR 
Total RNA isolated from colon was extracted using TRIzol Reagent (Invitrogen 
Biotechnologies), according to the manufacturer’s instructions. cDNA was synthesized using a 
reverse transcription kit (Maxima First Strand cDNA Synthesized Kit, Fermentas, Ontario, Canada) 
from 2 μg total RNA. PCRs were performed with Bio-Rad CFX96 Connect Real-time PCR System 
instrument and software (Bio-Rad Laboratories). The primer sequences are reported in Table 7.1. 
The PCR conditions were 10 min at 95°C followed by 40 cycles of two-step PCR denaturation at 
95°C for 15 s and annealing extension at 60°C for 60 s. Each sample contained 1-100 ng cDNA in 
2X Power SYBRGreen PCR Master Mix (Applied Biosystem) and 200 nmol/l of each primer 
(Eurofins MWG Operon; Huntsville, AL, USA). in a final volume of 25 μl. The relative amount of 
each studied mRNA was normalized to GAPDH as housekeeping gene, and the data were analyzed 
according to the 2
-ΔΔCT
 method. 
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Table 7.1. Real-Time PCR Primer Sequence 
Target 
gene 
 
Forward primer (5’→3’) 
 
Reverse primer (3’→5’) 
 
Accession 
Number 
Casp1 
 
TGGTGTTGAAGAGCAGAAAGC 
 
GCCCAGAGCACAAGACTTCTGAC 
 
NM_009807.2 
 
CCL5 
 
AGATCTCTGCAGCTGCCCTCA 
 
GGAGCACTTGCTGCTGGTGTAG 
 
NM_013653.3 
 
COX-2 
 
TGTGACTGTACCCGGACTGG 
 
GGGTGAACCCAGGTCCTCGCTT 
 
NM_011198.3 
 
Defb-1 
 
GGTGTTGGCATTCTCACAAG ACAAGCCATCGCTCGTCCTTTATG  NM_007843.3 
GAPDH 
 
 
GGCACAGTCAAGGCTGAGAATG ATGGTGGTGAAGACGCCAGTA NM_017008 
XM_216453 
 
IL-10 
 
GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT NM_010548.2 
 
IL-18 
 
CAGGCCTGACATCTTCTGCAAC  
 
CTGACATGGCAGCCATTGT 
 
NM_008360.1 
 
MUC-1 
 
TCGTCTATTTCCTTGCCCTG ATTACCTGCCGAAACCTCCT NM_013605.2 
 
NE 
(Elane) 
 
CCTTCTCTGTGCAGCGGATCTTC ACATGGAGTTCTGTCACCCAC NM_015779.2 
 
NLRP3 
 
TGCTCTTCACTGCTATCAAGCCCT ACAAGCCTTTGCTCCAGACCCTAT NM_145827.3 
 
NLRP6 
 
CTGAGACTGGTGAGCTGTGGA ATTGCCTCACAGAGTGGACG NM_133946.2 
Occludin 
 
ATGTCCGGCCGATGCTCTCTC CTTTGGCTGCTCTTGGGTCTGTAT NM_008756.2 
 
TNF- 
 
CATCTTCTCAAAACTCGAGTGACAA TGGGAGTAGATAAGGTACAGCCC NM_012675.3 
ZO-1 
 
ACCCGAAACTGATGCTGTGGATAGA AAATGGCCGGGCAGAACTTGTGTA NM_001163574.1 
 
 
Immunofluorescence analysis of occludin and zonula occludens 
(ZO)-1 
Colon segments were immediately removed, washed with PBS, mounted in embedding 
medium (Pelco Cryo-Z-T, Ted Pella inc, Redding, California), and stored at -80 °C until use. 
Cryosections (7 μm) were fixed in formaldehyde 2%+PBS at RT for 10 min for occludin or in 
methanol for 10 min at RT for ZO-1. Non-specific background was blocked by incubation with 
normal goat serum in PBS and 0.1% Triton X-100. Sections were incubated for 2 h with rabbit anti-
occludin (1:50 for occludin, Santa Cruz Biotechnology, Inc.) or rabbit anti-ZO-1 (1:100 for ZO-1, 
Invitrogen corporation, Camarillo, California, USA). Sections were probed with secondary 
antibodies goat anti-rabbit Alexa Fluor
® 
488 for ZO-1 and goat anti-rabbit Alexa Fluor
®
 594 for 
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occludin (1:200, Invitrogen corporation). Slides were mounted in mounting medium (Vectashield; 
Vector Laboratories, Burlingame, California, USA), and visualized on a fluorescence microscope 
using a 640 objective, and images were stored digitally with Leica software. Two negative controls 
were used: slides incubated with or without primary antibody. All the staining were performed in 
duplicate in non-serial distant sections, and analyzed in a double-blind manner by two different 
investigators. 
 
Serum Adiponectin detection 
Whole blood taken through cardiac puncture was centrifuaged after 24h at 1500xg at 4°C for 15 
min. So serum obtained was stored at -80°C and then used for adiponectin levels detection by 
Enzyme Linked Immuno Sorbent Assay (ELISA) (Quantikine
®
 Immunoassay, RD & SISTEMS, 
Minneapolis, MN) following manufacturer’s instructions. 
 
Statistical analysis 
Data are presented as mean ± SEM. Statistical analysis was performed by ANOVA test for 
multiple comparisons followed by Bonferroni’s test, using Graph-Pad Prism (Graph-Pad software 
Inc., San Diego, CA). Statistical significance was set at P<0.05. 
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7.3 Results 
 
Flortec reduces mice susceptibility to DSS-induced colitis 
During all experimental time body weight was monitored every day. As depicted in weight 
change graph (Fig. 7.1A), DSS-challenged mice treated with vehicle showed a reduction of weight, 
which becames significant from 15
th
 day until end of experimental period (18
th
 day) (P<0.05 vs. 
CON). Both preventive and curative treatment with Flortec preserved from this body weight loss, 
showing so a beneficial effect on animal’s gain and health. This protective action of synbiotic was 
more evident by area under curve (AUC) analysis (Fig. 7.1A). Assessment of disease activity index 
(DAI) after 7 days from DSS end, reveals in DSS-challenged mice plus vheicle, a strong increase of 
colitis gravity (**P<0.01 vs. CON). Instead both therapeutic schemes with synbiotic (PREV and 
CUR) significantly prevented the development of ulcerative colitis manifestations (Fig. 7.1B) (## 
P<0.01 vs. DSS). 
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Fig. 7.1 Effects of synbiotic on induction and recovery from DSS induced colitis. Mice were treated with 2.5% DSS in the drinking water for 5 
days and then returned to normal drinking water for an additional 7 days. (A) Changes in body weight and (B) DAI values on day 12. Data are mean ± 
SD from eight mice/group. 
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Flortec improves tissue histopatholgy and prevents colon damage 
Administration of Flortec
 
significantly ameliorated all clinical signs of DSS-induced colonic 
inflammation (weight loss, rectal bleeding, and mortality), whereas DSS-control mice showed 
marked colitis-associated signs. Histological examination of the distal part of DSS-alone colons 
revealed hemorrhagic walls with multiple ulcerations, mucosal edema, and large hyperplasia of the 
mucosa-associated lymphoid tissue (MALT). DSS mice treated with Flortec had intact colonic 
epithelium, no erosions, and rarely inflammatory infiltrates in the lamina propria (Fig. 7.2A and C). 
Both therapeutic schemes (PREV and CUR), significantly restored DSS induced colon shortening 
(Fig. 7.2B) (***P<0.001 vs. CON; ## P<0.01 vs. DSS). 
 
 
 
             
 
Fig. 7.2 Effects of Flortec on acute DSS-induced colitis. (A) Representative H&E-stained section of colons from synbiotic or DSS+vehicle-treated 
mice ( Scale bar = 200 µm, magnification 100X). (B) Colon length measurement and (C) representative colon images of control mice and DSS- 
challenged mice treated or untreated with synbiotic. Data are mean ± SEM from 7 to 8 mice/group. H&E images are representative of 5 slides for 
each group. 
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Flortec reduces DSS-induced CCL5 production and inflammatory 
immune cell recruitment in colon tissue 
Analysis of chemokine mRNA levels by Real-Time PCR, showed a significant up-regulation 
of Chemokine (C-C motif) ligand 5 (also CCL5) (Fig. 7.3A) and Neutrophil Elastase (NE) (Fig. 
7.3B) in colon tissue from DSS mice (*P<0.05; **P<0.01 vs. CON). The immune cell recruitment 
was also evidenced by high levels of MPO (Fig. 7.3C), nitrosylated proteins (Fig. 7.3D) and MDA 
amount (Fig. 7.3E) revealed in these animals. The synbiotic treatment was able to significantly 
reduce all these parameters (#P<0.05; P<0.01; P<0.001 vs. DSS), exhibiting so an effect not only on 
immune cells trafficking but also on inflammatory status in colonic mucosa (Fig. 7.3A-E). 
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Fig. 7.3. DSS induces leukocytes infiltration and ROS damage in colon tissue. (A) mRNA levels of chemokine (C-C motif) ligand 5 (CCL5) and 
(B) Neutrophil elastase. (C) MPO activity measurement in proximal colon section. (D) Nitrosylated proteins levels and MDA production assessment 
in colon from DSS-challenged mice treated or untreated with synbiotic as preventive or curative protocol. Data are mean ± SEM from 7 to 8 
mice/group. 
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Effects of Flortec on pro- and anti-inflammatory parameters and 
adipokines after DSS damage 
After 5 days exposure to DSS followed by 7 days of recovery, there was a significant 
(P<0.001 vs. CON) increase in TNF-α and COX-2 mRNA levels in the colons of DSS-challenged 
mice relative to control group (Fig. 7.4A-B). Additionally, downregulation in colon levels of 
mRNA IL-10 (Fig. 7.4C) and in serum levels of adiponectin (Fig. 7.4D), following exposure to 
DSS, were also evidenced in these animals. Treatment of mice for 19 days (PREV) or 12 days 
(CUR) with synbiotic, reduced pro-inflammatory cytokines and enzymes (TNF- and COX-2 
respectively), and restored regulatory cytokines (IL-10) or adipokine (adiponectin) levels in colon 
tissue and serum respectively (#P<0.05; #P<0.01; P<0.001 vs. DSS). 
 
 
Fig. 7.4. Pro- and anti-inflammatory mediators production in colonic mucosa and serum. DSS can increase the production significantly of pro-
inflammatory mediators TNF-and COX-2 (B) in colon tissue, and reduce transcriptional levels of anti-inflammatory mediators in colon (C) and 
serum (D). Data are mean ±SEM from 7 to 8 mice/group. 
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Therapy with Flortec ameliorates colitis restoring TJ barrier 
function 
To evaluate barrier integrity morphologically, we investigated mRNA levels of TJ occludin 
and zonula occludens 1 (ZO-1), and their distribution in distal colon. As shown in figure 7.5, 
intensity of staining for occludin (A) and ZO-1 (C) was significantly diminished in colonic mucosa 
of DSS mice. This reduction was confirmed by analysis of mRNA levels for these proteins (Fig 
7.5B-D) (*P<0.05; ***P<0.001 vs. CON). In contrast, synbiotic treatment led to substantial 
preservation of TJ architecture of epithelial cells in DSS colitis, comparable to that observed in 
control mice. Occludin and ZO-1 remained localized through enterocytes with a continuous staining 
pattern and also mRNA transcripts were recovered (#p<0.05; p<0.001 vs. DSS). 
 
 
 
 
Fig. 7.5. TJ impairment in colon tissue from DSS mice. Representative immunofluorescent images of Occludin (A) and ZO-1 (C) reveals TJ loss in 
distal colon sections of DSS- challenged mice. Synbiotic treatment recovered distribution and mRNA amount of both Occludin (B) and ZO-1 (D). 
PCR data are mean ± SEM from 7 to 8 mice/group. Immunofluorecence images are representative of 5 slides for each group (Magnification 100X). 
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Flortec prevents the inhibition of inflammosome complex pathway 
in DSS-challenged mice 
Among members of the NLRP sub-family, NLRP3 and NLRP6 are the better characterized. 
They has been shown to trigger IL-1β and IL-18 processing and release in response to a variety of 
pathogen and endogenous danger signals including monosodium urate crystals (MSU), adenosine 
triphospate (ATP), silica and asbestos [577,578]. As depicted in figure 7.6 a downregulation of 
NLRP3 (A) and NLRP6 (B) mRNA were observed in colon tissue of DSS mice. In the same way 
also mRNA levels of Caspase 1 and IL-18 were reduced in these animals (Fig. 7.6C and D 
respectively). So DSS treatment led to a significant reduction of several components of 
inflammosome complex in colonocytes (**P<0.01; ***P<0.001 vs. CON). Both therapeutic 
schemes with synbiotic (PREV and CUR) were able to prevent the downregulation of these 
components and to preserve the colonocyte’s capability to contrast the tissue damage induced by 
DSS (#P<0.05; P<0.01 vs. DSS). 
The role of inflammasome–caspase 1–IL‑18–IL‑18R–MYD88 axis in mediating tissue repair 
in the intestine is summarized in figure 7.7 
 
 
 
Figure 7.7. The inflammasome–caspase 1–IL‑18–IL‑18R–MYD88 axis mediates tissue repair in the intestine. (a) Following tissue damage with 
the intestinal epithelial cell (IEC) cytotoxic agent dextran sulphate sodium (DSS), the NLRP3 (NOD-, LRR- and pyrin domain-containing 3) 
inflammasome, which contains NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC) and caspase 1, assembles in IECs. This 
leads to the production of interleukin-18 (IL-18), which is then released at the mucosal sites. IL-18 binds the IL-18 receptor (IL-18R), which is 
expressed by myeloid cells in the lamina propria (and possibly by other cell types) and signals through the adaptor molecule myeloid differentiation 
primary response protein 88 (MYD88). IL-18 signalling induces compensatory proliferation of IECs and tissue repair. (b) If this innate immune 
signalling pathway is impaired (as observed in mice that are deficient in caspase 1, ASC, NLRP3, IL-18, IL-18R or MYD88), persistent tissue 
damage leads to the translocation of commensal microorganisms to the submucosa, where they stimulate resident immune cells through Toll-like 
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receptors (TLRs) and other pattern recognition receptors (not shown). Secretion of cytokines by activated immune cells results in tumour necrosis 
factor (TNF)-induced IEC apoptosis and chronic intestinal inflammation. TNFR1, TNF receptor 1. Picture from: Saleh M, Trinchieri G. Innate 
immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol. 2011 Jan;11(1):9-20. doi: 10.1038/nri2891. Epub 2010 
Dec 10. Review. 
 
 
 
Fig. 7.6. Flortec restores inflammasome components in intestinal epithelium of DSS-challenged mice. (A) mRNA amount of NLRP3 and (B) of 
NLRP6. (C) and (D) transcriptional levels of caspase 1 and IL-18 respectively. Data are mean ± SD from eight mice/group. 
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DSS alteres colonic β-defensin expression and decreases mucin 
production: effect of synbiotic treatment 
Given the colonic nature of the injury observed in our model, we sought to assess the 
expression of select colonic β-defensins in DSS-challenged mice. Significant changes in β-defensin 
1 (Defb1) transcript expression were observed in DSS-alone animals (Fig.7.8A). Alterations in 
defensin expression were associated with a reduction in the antimicrobial capability of these mice. 
In the same way also mucus production was impaired in DSS-challenged mice, in fact, mRNA 
levels of MUC-1 were significantly reduced compared to control (Fig. 7.8B) (***P<0.001 vs. 
CON). In spite of this effects, the curative and in particular the preventive treatments with Flortec, 
contrasted the downregulation of Defb-1 and MUC-1 induced by DSS in colon tissue exhibiting a 
protective role on intestinal epithelium (#P<0.05; P<0.01 vs. DSS). 
Several immune mechanisms work in concert to limit contact between the dense luminal 
microbial community and the intestinal epithelial cell surface and to maintain homeostasis. Some of 
them, including defensins and mucin are reported in figure 7.9. 
 
 
 
 
Fig. 7.8. DSS impairs antimicrobial capacity and mucus production in colon tissue. mRNA relative expression of Defb-1 (A) and MUC-1 (B) 
were recovered by synbiotic treatment. Data are mean ± SD from eight mice/group. 
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Figure 7.9. Immune adaptations that maintain homeostasis with the intestinal microbiota. Several immune mechanisms work in concert to limit 
contact between the dense luminal microbial community and the intestinal epithelial cell surface. Goblet cells secrete mucin glycoproteins that 
assemble into a thick, stratified mucus layer. Bacteria are abundant in the outer mucus layer, whereas the inner layer is resistant to bacterial 
penetration. Epithelial cells (such as enterocytes, Paneth cells and goblet cells) secrete antimicrobial proteins that further help to eliminate bacteria 
that penetrate the mucus layer. Plasma cells secrete IgA that is transcytosed across the epithelial cell layer and secreted from the apical surface of 
epithelial cells, limiting numbers of mucosa-associated bacteria and preventing bacterial penetration of host tissues. Image from: Lora V. Hooper & 
Andrew J. Macpherson. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nature Reviews Immunology 10, 159-169 
(March 2010) doi:10.1038/nri2710. 
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7.4 Discussion 
At birth, the gastrointestinal tract is a sterile environment. Initial exposure of the gut to 
microbes occurs during the birthing process from the maternal fecal and vaginal flora. Within a few 
months after birth, a relatively stable microbial population is established [3]. This abundant, diverse 
and dynamic intestinal microflora normally lives in a complex, symbiotic relationship with the 
eukaryotic cells of the mucosa. About 100 trillion bacterial cells benefit from the constant nutrient 
flow, stable temperature and niches for various metabolic requirements provided by the intestinal 
environment. Likewise, the host benefits from the ability of the intestinal microflora to synthesize 
vitamin K, exert trophic effects on intestinal epithelial cells, salvage energy from unabsorbed food 
by producing short chain fatty acids, inhibit the growth of pathogens, sustain intestinal barrier 
integrity and maintain mucosal immune homeostasis. Studies from germ-free animals reveal that 
the absence of resident intestinal microflora results in significant alterations in intestinal structure 
and function, including slender villi, shallow crypts, low leukocyte count [579], a decrease in the 
number and density of Peyer’s patches [580] and decreased stimulation of migrating motor 
complexes [581]. In their co-evolution with bacteria, vertebrates develop pattern-recognition 
receptors, which are activated by specific molecular patterns unique to bacteria, fungi and viruses 
that are absent in eukaryotes (lipopolysaccharides, peptidoglycan, ssRNA, muramyl dipeptide, 
flagellins, etc). These include the Toll-like receptors and nucleotide oligomerization domains 
(NODs). TLRs and NODs are critical for the initiation of innate immune defense responses. 
Activation of their signaling cascades usually results in the production of pro-inflammatory 
cytokines. TLR signaling also provides a link between innate and adaptive immunity, as TLR 
signaling results in the maturation of dendritic cells, which activate adaptive immune responses 
[114]. Although stimulation of these receptors in most parts of the immune system results in 
production of inflammatory cytokines, these ligands are not only tolerated by the gut mucosal 
immune system, but also essential for adaptation to intestinal bacteria and maintenance of 
homeostasis [582]. The tolerance to the intestinal microflora is not completely understood, but 
several aspects of commensal physiology have been defined which contribute to their inability to 
activate the immune system. Some commensal bacteria can modify TLR ligands, resulting in a 
hypoactive immune response. For example, the endotoxic portion of LPS is pentacylated in many 
Bacteroides species, and has minimal toxicity [583]. An important feature of commensal bacteria is 
their inability to penetrate the intestinal epithelial barrier. If some of these organisms do penetrate, 
they are usually rapidly swallow up by the innate mucosal immune system. Indeed, in healthy host, 
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the systemic immune system seems to overlook intestinal microflora [584]. Maintaining tolerance 
to these intestinal bacteria is a remarkable accomplishment achieved by the mucosal immune 
system, and disturbances in this bacterial-epithelial homeostasis result in considerable deleterious 
effects on the host. More than 20 animal models of IBD are available [585] and have been widely 
used to study the efficacy and mechanisms of probiotics in ameliorating inflammation in order to 
provide support for human clinical trials. In IL-10 knockout mice, L. plantarum 299v [586], L. 
Reuteri [587], L. salivarius subspecies salivarius UCC118 [588] and VSL#3 [279] have all been 
shown to successfully attenuate intestinal inflammation. L. GG prevents recurrent colitis in HLA-
B27 transgenic rats after antibiotic treatment, whereas L. Plantarum has no effect [589]. Dextran 
sulphate sodium (DSS)-induced colitis in mice is ameliorated by soluble bacterial antigens extracted 
from E. coli (strain Laves) or by Bifidobacterium strains Breve, Catenulatum, and Longum [590]. 
Daily administration of live but not heat-killed auto-aggregating L. Crispatus reduces the severity of 
DSS-colitis in mice [591]. Interestingly, DNA from VSL#3 has been reported to reduce colonic 
inflammation, thus improving intestinal barrier function in IL-10 KO mice and DSS-induced colitis 
[171,592]. It is important to note that probiotics should be divided into immunostimulatory and 
immunomodulatory according to their ability to interact with immune and non-immune cells, and 
their clinical use should be tailored accordingly. For instance, LGG, which is immunostimulatory 
has been shown to be more appropriate in the prevention of nosocomial rotavirus-dependent 
diarrhea in infants [593] or in decreasing the incidence of atopic dermatitis [594], than as an 
additive therapy in children with Crohn’s disease (CD) [595] or in CD patients after surgery [596]. 
In contrast L. paracasei, which is immunomodulatory, may be used to dampen inflammatory 
responses and may be recommended to maintain the remission phase in IBD. In fact, L. paracasei 
was a poor inducer of cytokines (both inflammatory and non-inflammatory) and impacted on the 
ability of DCs to produce inflammatory cytokines in response to pathogens, suggesting that this 
could represent a new class of immunomodulatory probiotics. On the basis of these instances the 
aim our work was to evaluate the preventive and curative effects of Flortec on a murine model of 
colitis induced by DSS. Flortec
 
is a synbiotic formulation containing a probiotic component as 
Lactobacillus paracasei strain B21060 with a prebiotic component represented by fructo-
oligosaccharides and arabinogalactane. DSS at 2.5% (wt/vol) in drinking water was administered ad 
libitum to the animals for 5 days followed by 7 days of washout. After these 12 days the animlas 
were sacrified. This model is able to reproduce the complexity and the event’s cascade which 
characterize the development of moderately active ulcerative colitis [597]. In our experiment, DSS 
mice showed a reduction of body weight only after DSS challenge, while both therapeutic schemes 
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(PREV and CUR) prevented this loss in DSS-challenged mice. Our result appear in contadiction to 
data in letterature because we didn’t observe weight loss immediately after DSS administration. 
Anyway many factors can contribute to this event: primary the percentage of DSS, secondary the 
time of exposure to ulcerative agent. Some papers show a strong reduction of weight when mice are 
exposed to DSS assumption for five or more days and when DSS is used at higher percentage then 
our one [598]. 
Feighery et al., [599] showed the effects of Lactobacillus salivarius 433118 on intestinal 
inflammation, immunity status and in vitro colon function. The authors used DSS 2.5% (wt/vol) for 
5 days and then returned to normal drinking water for an additional 7 days. Even in their conditions 
DSS-challenged mice exhibit weight reduction after DSS treatment but this strain was not able to 
prevent this reduction. Our results on mice weight change were observed also in others DSS 
induced colitis protocols [231,600]. The protective effect of Flortec was evident also on colon 
health. Both treatments reduced colon shortening and ameliorated necrosis and bleeding induced by 
DSS. About histological analysis, H&E staining of distal colon sections revealed crypt distruction 
and loss of tissue architecture in DSS mice. Flortec treatment was able not only to preserve mucosa 
structure and crypt organization, but also to reduce the growth of MALT shown in DSS sections. 
This effects of synbiotic display its ability both to protect tissue integrity and to modulate immune 
response in colonic mucosa remarking immunomodulatory skills of this Lactobacillus strain. Our 
model displays that DSS administration led to a strong exacerbation of disease activity at the end of 
experimental time while both therapeutic schemes with synbiotic protected DSS-challenged mice 
from colitis symptoms. On the basis of immunomodulatory skills of Lactobacillus paracasei 
B21060, we searched for immune cells involvement in this model of ulcerative colitis. Our results 
show that the DSS promotes local epithelial induction of CCL5 transcription leading to an 
exaggerated autoinflammatory response. CCL5 is chemotactic for T cells, neutrophils, eosinophils, 
and basophils, and plays an active role in recruiting leukocytes into inflammatory sites. This 
chemokine is potently induced by bacterial and viral infections, and in turn it induces massive 
recruitment of a variety of innate and adaptive immune cells carrying CCR1, CCR3, CCR4 and 
CCR5 [601]. Interestingly, both PREV and CUR have been shown to reduce CCL5 transcription in 
colon tissue. Since neutrophil infiltration and crypt abscess are histological features common to 
both ulcerative colitis and the murine DSS-induced colitis model, neutrophils may play a critical 
role in the pathogenesis of both damages. NE is a major secretory product from neutrophils and is 
capable of hydrolyzing most connective tissue components, leading to tissue injury at inflammatory 
sites. In this regard we performed Real-Time PCR analysis of NE transcript in colonic mucosa to 
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confirm CCL5 data about neutrophil recruitment. Inflammed colon sections from DSS mice 
exhibited significant levels of neutrophil elastase mRNA, confirming so the strength link between 
this marker of neutrophils and ulcerative colitis. Two important classes of products that are released 
by activated neutrophils are reactive oxygen intermediates (ROI) and neutrophil-derived proteases 
[602,603]. MPO assay represent another indicator of immune cells recruitment in inflammed tissue. 
In accordance with NE data, high levels of U.MPO/mg protein were discovered in colon of mice 
treated with DSS. Similarly, nitrosylated-proteins levels derived from ROI production, resulted up-
regulated in these animals. These data confirme in our experimental protocol of DSS-induced 
colitis, an evident correlation between immune cells infiltration, particulary neutrophils, and 
inflammation leading tissue damage. As consequence of oxidative stress and tissue damage, also 
malondialdehyde (MDA) levels resulted increased in colon tissue of DSS mice. In fact MDA is an 
endogenous genotoxic product of enzymatic and oxygen radical-induced lipid peroxidation and can 
be considered as indicator of tissue oxidative stress and damage [604]. In support of a role for 
probiotics in modulating immunity, rectal administration of Lactobacillus species prevented the 
development of spontaneous colitis in IL-10 gene deficient (IL-10-/-) mice [268]. Similarly, a 
reduction in mucosal inflammation was detected in IL-10-/- mice in response to long-term oral 
administration of Lactobacillus salivarius ssp. salivarius UCC118 (UCC118) in milk, which was 
also associated with a reduced rate of progression to dysplasia and colonic cancer [269]. 
Attenuation of inflammation by bifidobacteria and Lactobacillus in IL-10-/- mice may be in part 
related to induction of a reduced mucosal and systemic T helper (Th)1-type cytokine response 
[270]. In another example, while pretreatment with L. casei subsp. Shirota could not prevent the 
induction of DSS-induced colitis in mice, it did appear to improve the condition when administered 
at the time of colitis induction [605]. Our data demonstrated that Flortec was able to down-regulate 
all markers of immune cells infiltration and so to reduce inflammation and tissue injury. This 
antinflammatory effect of synbiotic was evident also from analysis of TNF-α, COX-2 and IL-10 
transcriptional levels in colonic mucosa. In fact, Flortec reduced significantly pro-inflammatory 
mediators and restored IL-10 mRNA levels in colon tissue. IL-10 can inhibit the expression of IL-
1α, IL-1β, IL-6, IL-12, IL-18, granulocyte-macrophage colony-stimulating factor (GM-CSF), G-
CSF, M-CSF, TNF, leukemia inhibitory factor and platelet activating factor produced by activated 
monocytes or macrophages. It exerts strong immune inhibitory function [266] and plays a major 
role in the immune tolerance of intestinal mucosa [606,607]. Lack of this cytokine, in fact, in knock 
out mice is responsible of spontaneous colitis in these animals [608]. Another protective cytokine is 
adiponectin. This is an adipokine (secreted from adipose tissue), which plays important role not 
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only in lipid and carbohydrate metabolism but also in anti-inflammatory process [609]. In our 
model, serum adiponectin levels were dow-regulated by DSS administration while Flortec 
prevented this action confirming anti-inflammatory property of this synbiotic formulation when 
used as preventive or curative treatment. Our data display an inflamed condition of colon tissue and 
a pro-resolving effect of the synbiotic, but this anti-inflammatory ability is a consequence rather 
than a mechanism of action of Lactobacillus paracasei. Beyond its immunomodulatory properties 
which respresent a specific mechanism of probiotics, these can act with aspecific mechanisms as 
enhancement of epithelial barrier function, competitive exclusion of bacteria along epithelium and 
modification of local microenvironment. In another study of our group we demonstrated that Flortec 
was able to ameliorate intestinal barrier function altered by high fat diet feeding fo 6 weeks in rats 
[113]. In this experiment, in fact, Lactobacillus paracaresi B21060 improved gut permeability 
restoring mRNA levels and tissue distribution of tight junctions proteins ZO-1 and occludin among 
colon epithelium. Furthermore, the loss of ZO-1 and increased permeability preceded the 
development of significant intestinal inflammation suggesting that in DSS colitis, alterations in the 
TJ complex occur before the intestinal inflammation and not as a consequence of it. These changes 
in the TJ complex may facilitate the development of the inflammatory infiltrate seen in colitis [433]. 
Since alterations in TJ expression and distribution could be considered the onset of colon 
inflammation and ulcerative colitis, we analyzed transcriptional levels of ZO-1 and occludin and 
their localization among epithelium. Our findings show that DSS determinated an impairment of 
epithelial barrier integrity reducing mRNA levels of these TJ proteins. This data was confirmed by 
immunofluorecence analysis which showed a strong reduction in intensity staining for both 
proteins. In contrast the synbiotic preserved colonic mucosa from DSS action improving tight 
junctions expression and distribution among colonic epithelium. 
Recent studies assessing the role of the inflammasome in models of experimental intestinal 
inflammation have revealed that mice deficient in NLRP3 (NOD-, LRR- and pyrin domain-
containing), NLRP6, apoptosis-associated speck-like protein containing a CARD (ASC) or caspase-
1 exhibit enhanced susceptibility to DSS and 2,4,6-trinitrobenzenesulfonic acid (TNBS) [610,611]. 
Zaki et al., [612] reported that NLRP3−/− mice exhibited severe transmural inflammation following 
oral DSS treatment, a phenotype that was dependent on NLRP3- deficiency in non-bone-marrow-
derived tissues. Dupaul-Chicoine et al., [613] also found that loss of NLRP3 resulted in more severe 
DSS colitis and again it appeared that this was dependent on non-bone marrow derived tissues. 
They also found that the increase in colitis severity was due to the impaired IL-18 processing and 
that the phenotype could be partially reversed with exogenous IL-18 [613]. Allen et al., [614] also 
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found that loss of NLRP3 resulted in increased DSS-induced intestinal injury and inflammation but 
their chimeric studies found that the increased disease severity was dependent on the loss of NLRP3 
in bone-marrow-derived cells. Similarly, in mice deficient in NLRP6, caspase-1, or IL-18, gut 
microbial ecology is altered, with prominent changes in the representation of members of several 
bacterial phyla. Strikingly, this altered microbiota is associated with a colitogenic phenotype that is 
transmissible to cohoused wild-type mice, both early in postnatal life and during adulthood [611]. 
Futhermore, in these animals aberrant microbiota promotes local epithelial induction of CCL5 
transcription as a downstream mechanism, ultimately leading to an exaggerated autoinflammatory 
response [611]. Normally, following tissue damage with the intestinal epithelial cell (IECs) 
cytotoxic agent dextran sulphate sodium, the NLRP inflammasome, which contains NLRP3 or 6, 
ASC and caspase 1, assembles in IECs. This leads to the production of interleukin-18 (IL-18), 
which is then released at the mucosal sites. IL-18 binds the IL 18 receptor (IL-18R), which is 
expressed by myeloid cells in the lamina propria (and possibly by other cell types) and signals 
through the adaptor molecule MYD88. IL-18 signalling induces compensatory proliferation of IECs 
and tissue repair. If this innate immune signalling pathway is impaired (as observed in mice that are 
deficient in caspase 1, ASC, NLRP, IL-18, IL-18R or MYD88), persistent tissue damage leads to 
the translocation of commensal microorganisms to the submucosa, where they stimulate resident 
immune cells through TLRs and other pattern recognition receptors. Secretion of cytokines by 
activated immune cells results in TNF-induced IEC apoptosis and chronic intestinal inflammation 
[615]. Therefore, a physiological level of inflammasome activation, triggered by the commensal 
microbiota in the presence of mucosal injury, is necessary for epithelial cell regeneration and is 
protective from colitis and colitis-associated colorectal cancer. Here, we showed that synbiotic was 
able to recover this physiological level of inflammasome activation components impaired by DSS 
treatment. So beyond the improvement of intestinal permeability, Flortec preserved intestinal 
epithelial repair functionality in response to injury signals. The mucus layer overlying the 
epithelium secreted by the goblet cells promotes the elimination of gut contents and provides the 
first line of defense against physical and chemical injury caused by ingested food, microbes and the 
microbial products. The major component of the mucus is secreted mucins, large glycoproteins with 
highly polymeric protein backbone structure, linked to numerous hygroscopic and hydrophilic 
oligosaccharide side-chains that contribute to the formation of gel-like structure [616]. Commensal 
bacteria are trapped in the mucus layer, failing to reach the epithelial cell surface, and are 
eliminated by peristaltic movement [617]. The microbes and microbial products are recognized by 
the sensor system of the intestinal epithelial cells and the immune cells, activating the host innate 
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defense system. Balanced and dynamic interactions among mucus layers, intestinal epithelial cells, 
microbiota, and host immune defense is essential for the maintenance of the intestinal mucosal 
homeostasis. The disruption in the intestinal homeostasis results in the defective mucus barrier with 
increased permeability that results in inflammation and injury of the intestinal mucosal cells [618]. 
Besides, it has been demonstrated that lactobacilli up-regulate the MUC2 and MUC3 mucins and 
inhibit attachment of enterohemorrhagic Escherichia coli in vitro [211], and that a probiotic mixture 
of lactobacilli and bifidobacteria increase the secretion of mucin, stimulating MUC2 gene 
expression in the rat colon in vivo [212]. Furthermore, Mack et colleagues showed that some 
Lactobacillus strain stimulated extracellular MUC 3 secretion following adherence to epithelial cell 
[285]. Besides, NLR signaling has been linked to the regulation of Paneth cell function and the 
release of antimicrobial compounds terms defensins [619]. On the basis of these observations, given 
the colonic nature of the injury observed in our model, we sought to assess the expression of colonic 
β-defensin 1 and mucin 1 (MUC-1). In our results, marked changes in β-defensin 1 and MUC-1 
transcript expression were observed in DSS-treated animals. Conversely, Flortec protected colonic 
mucosa from this significant reduction. So another possible mechanism of action for this synbiotic 
formulation is the maintenance of the intestinal mucosal homeostasis regulating mucus and 
antimicrobial peptides secretion by colonic mucosa. 
 
7.5 Conclusions 
In this work we show that this synbiotic formulation is able to enhance intestinal barrier 
function and epithelial repair capability in response to DSS induced colitis in mice. These effects 
are able to reduce bacterial traslocation with consequent impairment of immune cells recruitment 
and reduction of colon inflammation. Besides, probiotics lead to competitive exclusion of negative 
bacteria along epithelium by stimulating paneth cells to produce antimicrobial compounds and 
goblet cell to secret mucus, restoring beneficial local microenvironment. On this basis, our data 
display relevant curative effects of this synbiotic formulation in DSS model of colitis and suggests 
not only a potential therapeutic role for this agent in this pathology, but also the possibility that a 
supplement of these lactobacilli might prevent the relapse of ulcerative colitis. 
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CHAPTER 8: N-(1-CARBAMOYL-2-PHENYL-ETHYL) 
BUTYRAMIDE, A NEW SYNTHETIC BUTYRATE DERIVATIVE, 
REDUCES INTESTINAL INFLAMMATION IN DEXTRAN 
SODIUM SULPHATE-INDUCED COLITIS. 
 
8.1 Introduction 
The rate and amount of SCFAs production depends on the species and amounts of microflora 
present in the colon, the substrate source and gut transit time. SCFAs are readily absorbed after their 
producion and represent a clear example of the importance of the intestinal ecosystem. SCFAs are 
organic acids produced by intestinal microbial fermentation of mainly undigested dietary 
carbohydrates, specifically resistant starches and dietary fiber, but also in a minor part by dietary 
and endogenous proteins. SCFAs are 2-carbon to 5-carbon weak acids, including acetate (C2), 
propionate (C3), butyrate (C4), and valerate (C5). SCFAs are essentially produced in the colon. The 
ratio of SCFA concentrations in the colonic lumen is about 60% acetate, 25% propionate, and 15% 
butyrate. As a result of increasing concentrations of acidic fermentation products, the luminal pH in 
the proximal colon is lower. This pH seems to boost the formation of butyrate, as mildly acidic pH 
values allow butyrate-producing bacteria to compete against Gram-negative carbohydrate-utilizing 
bacteria, such as Bacteroides spp. [402]. The ability to produce butyrate is widely distributed among 
the Gram-positive anaerobic bacteria hat inhabit the human colon. Butyrate-producing bacteria 
represent a functional group, rather than a coherent phylogenetic group. Numerically, two of the 
most important groups of butyrate producers appear to be Faecalibacterium prausnitzii, which 
belongs to the Clostridium leptum (or Clostridial cluster Ⅳ) cluster, and Eubacterium 
rectale/Roseburia spp., which belongs to the Clostridium coccoides (or clostridial cluster XIVa) 
cluster of Firmicute bacteria [403]. Butyrate is the major energy source for colonocytes and is 
involved in the maintenance of colonic mucosal health [406]. Recently several intestinal and 
extraintestinal effects of butyrate have been demonstrated [530,620]. Butyrate has been studied for 
its role in nourishing the colonic mucosa and in the prevention of cancer of the colon, by promoting 
cell differentiation, cell-cycle arrest and apoptosis of transformed colonocytes; inhibiting the 
enzyme histone deacetylase and decreasing the transformation of primary to secondary bile acids as 
a result of colonic acidification. Therefore, a greater increase in SCFA production and potentially a 
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greater delivery of SCFA, specifically butyrate, to the distal colon may result in a protective effect. 
At intestinal level butyrate exhibits several effects, for example, on transepithelial ion transport, on 
cell growth and differentiation, on inflammatory and oxidative status, on non-specific intestinal 
defense mechanisms and finally on visceral perception and intestinal motility [530]. About the 
mechanism/s of its effects, numerous studies have reported that butyrate metabolism is impaired in 
intestinal inflamed mucosa of patients with IBD [621]. Recent data show that butyrate deficiency 
results from the reduction of butyrate uptake by the inflamed mucosa through downregulation of 
MCT1. 
The concomitant induction of the glucose transporter GLUT1 suggests that inflammation 
could induce a metabolic switch from butyrate to glucose oxidation. Butyrate transport deficiency is 
expected to have clinical consequences. Particularly, the reduction of the intracellular availability of 
butyrate in colonocytes may decrease its protective effects against cancer in IBD patients [428]. In 
spite of these several preclinical and clinical studies analyzing the efficacy of SCFAs mixture or 
butyrate alone in various models of ulcerose colitis, often the results are contradictory. The 
equivocal results in clinical studies using enemas may partly be explained by differences in 
treatment duration, butyrate enemas vs. SCFA mixture enemas, differences in concentrations and 
volumes of these SCFAs and the small number of patients included. Some butyrate-based products 
are marketed even if their spread is still very limited and greatly understaffed in view of the wide 
spectrum of possible indications, especially in chronic diseases where it is possible to predict their 
lasting use. The unpleasant taste and odour make extremely difficult the oral administration of 
butyrate reducing the compliance. Thus, new formulations of butyrate with a better palatability, 
which can be easily administered orally, are needed. The purpose of this study is to investigate the 
efficacy of sodium butyrate (Butyrate) and of its more palatable derivative, the N-(1-carbamoyl-2-
phenyl-ethyl) butiramide (FBA), in dextran sulfate sodium (DSS)-induced colitis. We hypothesized 
that orally administered butyrate compounds, could attenuate colitis and colon injury, with 
reduction of inflammatory responses via gut permeability improvement, suppression of immune 
cells recruitment, inhibition of HDAC9 activity and restoration of PPAR-γ levels in colon tissue. 
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8.2 Materials and Methods 
 
DSS-induced colitis and animal treatments 
Experimental colitis was induced in ten weeks old BALB/c male mice (25±2 g) (Harlan-
Corezzano, Italy) by 2.5% DSS (wt/vol) (MP Biomedicals, Irvine, CA) in sterile drinking water ad 
libitum for five days, followed by drinking water without DSS for twelve days. Mice were 
randomly divided into six groups (n=10 each group) as following: 1. a control animals (CON), 2. 
DSS treated mice (DSS), 3. DSS mice treated with sodium butyrate as preventive therapy (PREV 
Butyrate), 4. DSS mice treated with N-(1-carbamoyl-2-phenylethyl) butyramide (FBA) as 
preventive therapy (PREV FBA) 5. DSS mice treated with sodium butyrate as curative therapy 
(CUR Butyrate). 6. DSS mice treated with FBA as curative therapy (CUR FBA). We have recently 
obtained a high palatable synthetic butyrate derivative, N-(1-carbamoyl-2-phenylethyl) butyramide 
(FBA; Italian patent RM2008A000214; April 21, 2008). FBA is present in a solid, poorly 
hygroscopic, easily weighable form, stable to acids and alkalis and capable of releasing butyric acid 
at small and large bowel level in a constant manner over time. This product has demonstrated a 
toxicological profile comparable to that of butyrate; it shows physicochemical characteristics 
distinctly more suitable for extensive clinical use than those of butyrate. A particular aspect of FBA 
is that it does not present the unpleasant odour of butyrate and is practically tasteless, thus making 
possible to overcome the main limitation to the use of butyrate in the therapeutic field, namely its 
very poor palatability. Moreover, the solubility of FBA in water is satisfactory in that it produces 
clear solutions up to the concentration of 0.1 M and suspensions for higher concentrations. The oral 
treatment with Butyrate (20 mg/kg/die) or FBA (42.5 mg/kg/die), started 7 days before DSS 
challenge (PREV) or two days after (CUR) DSS challenge and continued for all experimental 
period (20 days). DSS group without pharmacological treatments received H2O+Tween20 0.01% as 
both drug’s vehicle. Colitis was assessed by the daily monitoring of body weight, stool consistency 
and fecal blood. All procedures involving animals were carried out in accordance with the 
Institutional Guidelines and complied with the Italian D.L. no.116 of January 27, 1992 of Ministero 
della Salute and associated guidelines of the European Communities Council Directive of 
November 24, 1986 (86/609/ECC). Prior to sample collection, animals, kept overnight fasted, were 
euthanized by an isoflurane anesthesia, followed by cervical dislocation to minimize pain. All 
efforts were made to minimize animal suffering. Blood samples from animals were collected by 
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cardiac puncture and serum obtained. At 20
th days mice were killed and full intestine and colons 
measured. Colon tissue was excised and immediately frozen. Segments of colon were assessed 
histologically by hematoxylin and eosin staining. In figure 8.0 the scheme of experimental protocol 
and animal treatments are summarized. 
 
 
 
Figure 8.0. Experimental protocol used in this study 
 
Evaluation of experimental colitis 
In all animals, weight, presence of blood and stool consistency were determined daily as 
previously described [572]. Disease activity index (DAI) was determined by combining scores of a) 
weight loss b) stool consistency and c) bleeding (divided by 3). Each score was determined as 
follows, change in weight (0:<1%, 1: 1–5%, 2: 5–10%, 4:>15%), stool blood (0: negative, 2: 
positive) or gross bleeding (4), and stool consistency (0: normal, 2: loose stools, 4: diarrhea) as 
previously described [573]. Body weight loss was calculated as the percent difference between the 
original body weight and the actual body weight on any particular day. Typically in DSS colitis 
animals will lose 10–15% body weight over the course of 10 days. The appearance of diarrhea is 
defined as mucus/fecal material adherent to anal fur. The presence or absence of diarrhea was 
scored as either 1 or 0, respectively, and the cumulative score for diarrhea was calculated by adding 
the score for each day and dividing by the number of days of exposure. Rectal bleeding was defined 
as diarrhea containing visible blood/mucus or gross rectal bleeding and scored as described for 
diarrhea. 
150 
 
Measurement of MPO activity 
Proximal colonic tissues were homogenized twice for 30s at 4°C in 0.5% 
hexadecyltrimethylammonium bromide (HTAB) in 50 mM sodium phosphate, pH 6.0, according to 
Bradley et al., [575]. The homogenates were clarified by centrifugation at 13000xg for 15 min, at 
4°C, and were assessed for MPO activity in 3 ml 50 mM sodium phosphate, pH 6.0, containing 16 
mM aqueous guaiacol and 5.9 mM H2O2, as previously described [576]. The increase in absorbance 
was measured for 2 min at 470 nm using The iMark microplate absorbance reader (Bio-Rad). 
Protein concentrations were determined using the Bio-Rad protein assay. MPO activities were 
expressed in U.MPO/mg protein with 1 U hydrolyzing 1 μmol H2O2/min. 
 
Real-time semi-quantitative PCR 
Total RNA isolated from colon was extracted using TRIzol Reagent (Invitrogen 
Biotechnologies), according to the manufacturer’s instructions. cDNA was synthesized using a 
reverse transcription kit (Maxima First Strand cDNA Synthesized Kit, Fermentas, Ontario, Canada) 
from 2 μg total RNA. PCRs were performed with Bio-Rad CFX96 Connect Real-time PCR System 
instrument and software (Bio-Rad Laboratories). The primer sequences for GPR43, IL-10, IL-6, 
TNF- Occludin and ZO-1 were purchased by Eurofins MWG Operon (Huntsville, AL, USA) and 
are reported in Table 8.1. For Annexin A1 (AnxA1), Ccl2, CD14, CD68, Fpr1, Fpr2, GAPDH, Ly-
6G and NOS2 we used QuantiTect
®
 Primer Assays for SYBR Green by Qiagen. The PCR 
conditions were 15 min at 95°C followed by 40 cycles of three-step PCR denaturation at 94°C for 
15 s, annealing at 55 or 60°C for 30 s and extension at 72°C for 30 s. Each sample contained 40-100 
ng cDNA in 2X Power SYBRGreen PCR Master Mix (Applied Biosystem) and 200 nmol/l of each 
primer in a final volume of 25 μl. The relative amount of each studied mRNA was normalized to 
GAPDH as housekeeping gene, and the data were analyzed according to the 2
-ΔΔCT
 method. 
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Table 8.1. Real-Time PCR Primer Sequence 
Target 
gene 
 
Forward primer (5’→3’) 
 
Reverse primer (3’→5’) 
 
Accession 
Number 
GPR43 
 
TTCTTACTGGGCTCCCTGCC TACCAGCGGAAGTTGGATGC NM_146187 
 
HDAC9 
 
GCGGTCCAGGTTAAAACAGAA GCCACCTCAAACACTCGCTT NM_001271386.1 
 
IL-10 
 
GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT NM_010548.2 
 
IL-6 
 
ACAAGTGGGAGGCTTAATTACACAT  
 
TTGCCATTGCACAACTCTTTTC  
 
NM_031168.1 
 
MCT-1 
 
GAGCGCGCGAAGCTGCATTTGCT TGCTCCCAGGCCCGCTTTACA NM_009196.3  
 
PPAR- 
 
CTGCTCAAGTATGGTGTCCATGA ATGAGGACTCCATCTTTATTCA 
 
NM_001127330.1 
  
Occludin 
 
ATGTCCGGCCGATGCTCTCTC CTTTGGCTGCTCTTGGGTCTGTAT NM_008756.2 
 
TNF- 
 
CATCTTCTCAAAACTCGAGTGACAA TGGGAGTAGATAAGGTACAGCCC NM_012675.3 
ZO-1 
 
ACCCGAAACTGATGCTGTGGATAGA AAATGGCCGGGCAGAACTTGTGTA NM_001163574.1 
 
Immunofluorescence analysis of Ly-6G, Annexin A1 and GPR43 
Colonic and liver tissue samples for immunofluorescence were embedded in O.C.T. (Pelco 
Cryo-Z-T, Ted Pella inc, Redding, California), and cryosectioned (10 µm thick). Tissue sections 
were then fixed in 4% paraformaldehyde for 10 min at room temperature (RT) and washed in TBS 
with 0.05% TX-100. For immunofluorescence detection of Ly-6G, sections were blocked with 10% 
FCS in TBS for 30 minutes at RT and then incubated with a monoclonal antibody anti Ly-6G-FITC 
(BD Biosciences) overnight at 4°C. To examine co-localization of AnxA1 and GPR43 with Ly-6G, 
rabbit monoclonal anti-AnxA1 antibody [622] and goat polyclonal anti-GPR43 antibody (Santa 
Cruz Biotechnology, Inc.) were incubated alongside anti Ly-6G-FITC antibody overnight at 4°C. 
Sections were washed in 1% FCS plus 0.025% TX-100 and incubated with Alexa-Fluor
®
 546 goat 
anti-rabbit IgG (for AnxA1) and with Alexa-Fluor
®
 594 donkey anti-goat IgG (for GPR43) 1 h at 
RT. After incubation with secondary antibody, sections were washed in TBS, and then incubated 
with DAPI to visualize nuclei. Slides were mounted in mounting medium (Vectashield; Vector 
Laboratories, Burlingame, California, USA). Fluorescence was visualized on a Olympus BX51 
fluorescence microscope (Olympus) equipped with a DS-QiMc monochromatic camera (Nikon) and 
X-Cite
®
 Series 120Q Xenon lamp. NIS-Elements BR3.1 software (Nikon) was used for all analyses. 
Merge images were performed with ImageJ
®
 software. Two negative controls were used: slides 
incubated with or without primary antibody. Images were recorded at identical gain settings, 
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performed in duplicate in non-serial distant sections, and analyzed in a double-blind manner by two 
different investigators. Four image fields were taken of each section. 
 
Serum Adiponectin detection 
Whole blood taken through cardiac puncture was centrifuaged after 24h at 1500xg at 4°C for 
15 min. So serum obtained was stored at -80°C and then used for adiponectin levels detection by 
Enzyme Linked Immuno Sorbent Assay (ELISA) (Quantikine
®
 Immunoassay, RD & SISTEMS, 
Minneapolis, MN) following manufacturer’s instructions. 
 
Statistical analysis 
 
Data are presented as mean ± SEM. Statistical analysis was performed by ANOVA test for 
multiple comparisons followed by Bonferroni’s test, using Graph-Pad Prism (Graph-Pad software 
Inc., San Diego, CA). Statistical significance was set at P<0.05. 
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8.3 Results 
 
Effect of Sodium butyrate and FBA on weight change and disease 
activity index in DSS mice 
As shown in Fig. 8.1A both pharmacological treatments (preventive and curative protocol) 
were able to preserve weight loss induced by dextran sulphate sodium challenge (*P<0.05; 
**P<0.01 vs. CON). As reported in AUC graph, among these therapeutical schemes both curative 
administrations appeared more effective than preventive ones. Assessment of disease activity index 
(DAI) after 7 days from DSS end, revealed in DSS-challenged mice, a strong increase of colitis 
gravity (***P<0.001 vs. CON). Instead, Butyrate and FBA (PREV and CUR) significantly 
prevented the development of ulcerative colitis manifestations (Fig. 8.1B) (### P<0.001 Vs. DSS). 
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Fig. 8.1 Effects of Butyrate and FBA on induction and recovery from DSS induced colitis.WT mice received 2.5% DSS for 5 days followed by 
treatment and then returned to normal drinking water for an additional 7. Mice were sacrificed on day 12. (A) Evolution of body weight and (B) DAI 
values on day 12. Data are mean ± SD from eight mice/group. 
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Butyrate and FBA improve tissue histopatholgy and prevent colon 
shortening in DSS- induced colitis 
Control mouse colon sections (Fig. 8.2A) showed the intact epithelium, well defined crypt 
length, no edema, no neutrophil infiltration in mucosa and submucosa, and no ulcers or erosions. In 
contrast, colon tissue from DSS treated mice showed clear and severe inflammatory lesions 
extensively throughout the mucosa. Ulcers, shortening and loss of crypts were seen focally at the 
beginning progressing to more extensive areas of mucosal involvement and finally the whole colon. 
Infiltration of immune cells including neutrophils and lymphocytes were seen in the lamina propria 
in DSS treated mice. In spite of DSS treatment, Butyrate and FBA were able to protect colonic 
mucosa structure and to reduce immune cellular recruitment. Besides both preventive and curative 
treatments ameliorated mucosa integrity and crypt structure improving epithelial surface. Beneficial 
effects of all therapeutics schemes were shown macroscopically after colon excission. In fact, as 
depicted in Fig. 8.2B, Butyrate and FBA preserved colon from inflammation and bleeding induced 
by DSS. Futhermore, both therapeutic protocols, in particular curative ones, with Butyrate and FBA 
reduced colon shortening shown in DSS-challenged mice (Fig. 8.2C) (*P<0.05 vs. CON; #P<0.05 
and ##P<0.01 vs. DSS). 
156 
 
 
           
Fig. 8.2. Therapy with Butyrate and FBA ameliorates DSS colitis. (A) Representative histology of the distal DSS colon (H&E staining; original 
magnification 200X, bar 0.2 mm). Black arrows indicates infiltrated cells in the submucosa. (B) Colon images and (C) assessment of total colon 
length after DSS treatment. Data are mean ± SD from eight mice/group. Histological images are representative of 5 slides for each group. 
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Annexin A1 and its receptors are increased in colonic mucosal 
tissue following DSS treatment:Effect of butyrate formulations 
In DSS-challenged mice transcriptional levels of Annexin A1 (AnxA1) and its receptors Fpr1 
(Formyl peptide receptor 1) and Fpr2 (Formyl peptide receptor 2), were significantly up-regulated. 
(Fig. 8.3A-C) (*P<0.05; **P<0.01 vs. CON). Butyrate and FBA when used as preventive or 
curative therapy, contrasted with dextran sodium sulphate challenge reducing pro-resolving factor 
and receptor mRNA levels in colon tissue (#P<0.05; ##P<0.01 vs. DSS). 
 
 
 
Fig.8.3. Increased expression of AnxA1 and its receptors in colonic mucosal tissues following DSS treatment. Total RNA was extracted from 
mucosal tissues from control and DSS mice treated or untreated with Butyrate and FBA. Real-Time PCR reveales increased AnxA1 mRNA levels 
(A). A further diminishment of Fpr1 (B) and Fpr2 (C) mRNA was observed in DSS-challenged animals following treatment with Butyrate and FBA 
(PREV and CUR). Data are presented as means ± standard error of 5 animals for each group. 
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Effects of Butyrate and FBA on DSS-induced neutrophil infiltration 
in colonic mucosa 
Given the important role of PMNs in the inflammatory response, we next assessed the 
infiltration of these cells into the colonic mucosa. PMN infiltration was significantly elevated in 
colon tissue from mice treated with DSS, as assessed by Ly-6G (a neutrophil granule protease) 
mRNA levels and MPO activity (Fig. 8.4A-B) (**P<0.01; ***P<0.001 vs. CON). Furthermore, we 
used fluorescence microscopy to determine the expression and localization of Ly-6G in colonic 
mucosal tissue. In control group, a basal low level of this marker expression was observed (Fig. 
8.4C-D). In contrast, there was a significant increase in Ly-6G staining in colon from DSS-
challenged mice. Double-staining experiments revealed high AnxA1 staining in neutrophils, 
confirmed by a marked co-localization with Ly-6G in colon of mice with active disease (Fig. 8.4D). 
Both therapeutical schemes with Butyrate and FBA were able to reduce neutrophil infiltration. This 
effect was also evident by impairment of number of PMNs in colonic mucosa (Fig. 8.4E) 
(##P<0.01; ###P<0.001 vs. DSS). 
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Fig. 8.4 . Butyrate and FBA reduce PMN infiltration in colonic mucosa. (A) Ly-6G transcriptional levels and (B) MPO activity were increased in 
DSS-challenged mice untreated with Butyrate or FBA. (C-D) Immunofluorescence detection of Ly-6G (green) and AnxA1 (red) demonstrates that 
PMN infiltrate was increased in DSS-alone group compared to control, Butyrate and FBA groups. Furthermore AnxA1 (red) staining could be 
localized to infiltrating PMNs (Ly-6G+AnxA1 yellow staining) (C). Real-Time data are presented as means ± standard error of 5 animals for each 
group. Immunofluorescence staining are representative of 3 slides for each group. Magnification 200X. (E) PMN infiltration score was obtained by 
counting PMN cellularity in four random mucosal and submucosal views of three different sections from the descendent colon and was expressed as 
number of cells/ area mm2. 
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Butyrate and FBA increase GPR43 expression and distribution 
along intestinal epithelium in colonic mucosa 
As depicted in Fig. 8.5A Butyrate and FBA, in particular curative protocol, were able to 
increase GPR43 trascriptional levels compared to control and DSS-untreated mice (**P<0.01 vs. 
CON and #P<0.05 vs. DSS). This effect was also evident by immunofluorecence staining for 
GPR43 (Fig. 8.5B). Furthermore, as shown in Fig. 8.5C, this receptor was particularly expressed 
along intestinal epithelium, and only in DSS-alone group was co-localized with PMNs positive 
cells. These data suggested involvement of GPR43 in neutrophil recruitment under inflammatory 
condition and confirmed that Butyrate and FBA reduced PMN infiltrate. Furthermore, to confirm 
the authenticity and accuracy of GPR43 staining in colon tissue, we performed an 
immunofluorescence analysis for this receptor also in liver tissue from control mice. We chose liver 
because in normal conditions it doesn’t exprime GPR43. In fact, as depicted in Fig. 8.5D we didn’t 
observe differences between liver sections stained with GPR43 and its isotype negative control. So, 
we confirmed that differences in staining intensity observed among colon sections from our 
experimental groups, were due to various levels of GPR43 expression and not to background 
staining. 
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Fig. 8.5 . Effect of Butyrate and FBA on GPR43 expression and localization in colonic mucosa. (A) Real-Time PCR of GPR43 in colon tissue. 
(B) Immunofluorescence staining of GPR43 (red) and DAPI (blue) on distal colon sections. (C) Double staining of GPR43 (red) and Ly-6G (green) 
(Ly-6G+GPR43 yellow staining). (D) Immunofluorescence analysis of liver GPR43 content using primary associated with secondary antibody (up) or 
secondary antibody alone (down). Real-Time data are presented as means ± standard error of 5 animals for each group. Immunofluorescence staining 
are representative of 3 slides for each group. Magnification 200X. 
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Effects of butyrate-based compounds on mucosal infiltration by 
monocytes / macrophages 
Butyrate and FBA reduced monocytes infiltration in colonic mucosa by impairment of 
chemokine expression and lowering macrophages markers. In particular, either pharmacological 
treatments, both preventive and curative protocol, preserved NOS2, CD14 CD68, Ccl2 
enhancement induced by DSS challenge (Fig. 8.6A-D) (*P<0.05; **P<0.01 vs. CON; #P<0.05; 
##P<0.01 vs. DSS). 
 
 
 
Fig. 8.6. DSS treatment induces up-regulation of monocytes / macrophages markers in colon tissue. Relative amount of (A) NOS2, (B) CD14, 
(C) CD68 and (D) Ccl2 mRNA was significantly increased in DSS-challenged mice treated with vehicle alone. Both Butyrate and FBA were able to 
prevent infiltration of immune cells reducing chemoattractant release in colonic mucosa. Data are presented as means ± standard error of 5 animals for 
each group. 
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Effect of Butyrate and FBA on inflammatory mediators in colon and 
serum 
Inflammatory state in colonic mucosa was estabilished by TNF-α and IL-6 transcriptional 
levels evaluation (Fig. 8.7A-B). Both these cytokines were significantly up-regulated in DSS-
challenged mice, conversely mRNA levels of IL-10, an anti-inflammatory mediator, were reduced 
(*P<0.05; **P<0.01 vs. CON). Protective effect of Butyrate and FBA (PREV and CUR) was shown 
not only in reducing pro-inflammatory cytokines TNF-α and IL-6 but also in recovered IL-10 and 
adiponectin, (another anti-inflammatory adipokine), levels in colon tissue and serum respectively 
(Fig. 8.7C-D) (#P<0.05; ##P<0.01; ###P<0.001 vs. DSS). 
 
 
 
Fig.8.7. Butyrate and FBA inhibit secretion of pro-inflammatory mediators and restore anti-inflammatory cytokines. mRNA trascriptional 
levels of (A) TNF-(B) IL-6 and (C) IL-10 in colon tissue. (D) Serum levels of adiponectin. Data are presented as means ± standard error of 5 
animals for each group. 
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DSS-challenge impairs butyrate uptake and modulates pro-
inflammatory response in colonocytes 
As depicted in Figure 8.8A-B, DSS-challenged mice showed lower mRNA levels of MCT1 
and PPAR-γ compared to control group. Furthermore, dextran sodium sulphate was able to induce 
significantly mRNA transcript of HDAC9 (Fig. 8.8C) (*p<0.05; ***P<0.001 vs. CON). Instead, 
Butyrate and FBA, in particularly when used as curative treatments, recovered mRNA expression of 
MCT1 and PPAR-γ, and at the same time down-regulated HDAC9 mRNA levels (#P<0.05; 
##P<0.001 vs. DSS). 
 
 
 
Fig. 8.8. Mechanisms of anti-inflammatory actions adopted by Butyrate and FBA in colonic mucosa. Impaired mRNA expression of (A) MCT-1 
and (B) PPAR-γ. Butyrate and FBA act as a histone deacetylase inhibitor reducing HDAC9 trascriptional levels (C). Data are presented as means ± 
standard error of 5 animals for each group. 
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8.4 Discussion 
In this study we demonstrated that Butyrate and its derived amide FBA are able to protect 
from colitis injury induced by DSS administration in mice. In particular, they play their effects 
restoring epithelial barrier integrity and reducing colon inflammation. Effects of butyrate in 
intestinal disease and its role on colonic functions were evidenced in many studies [530,620]. Since 
the major limit of butyrate use in clinical practise is its unpleasant taste and odour despite the wide 
spectrum of possible indications, we obtained a more palatable derivative, the N-(1-carbamoyl-2-
phenyl-ethyl) butiramide (FBA), and comparatively evaluated the efficacy of these two compounds 
in an animal model of colitis induced by DSS. For this purpose, DDS at 2.5% (wt/vol) in drinking 
water was administered ad libitum to the animals for 5 days followed by 7 days of washout. After 
these 12 days the animals were sacrificed. This model is able to reproduce the complexity and the 
cascade of events that characterizes the development of moderately active ulcerative colitis [597]. 
In our experiment, DSS mice showed a reduction of body weight only after five day of DSS 
administration, while both butyrate-based drugs (PREV and CUR) prevented this loss in DSS-
challenged mice. Some papers show a strong reduction of weight when mice are exposed to DSS 
assumption for five or more days and when they use high percentage of DSS [598]. Anyway many 
factors can contribute to this discrepancy: primary the percentage of DSS, secondary the time of 
exposure to ulcerative agent. Our results on mice weight change were comparable to these ones 
shown in others DSS induced colitis models [231,600]. The clinical and histological changes were 
determined by phenotypic and pathologic changes such as diarrhea, rectal bleeding, body weight 
loss and colon shortening, which were the common phenomenon seen in DSS-induced experimental 
colitis. Diarrhea is due to the increased permeability of intestinal cells or hyper-osmolarity in lumen 
led by DSS [597]. Weight loss and the shortening of the colon, as indicators for the severity of 
intestinal inflammation, correlate with the pathologic and histological changes and are consistent 
markers for colitis. After 5 days of DSS challenge followed by 7 days of washout, Butyrate and 
FBA, when used as preventive or curative protocol, protected mice from exacerbation of colitis 
symptoms. IBDs are thought to result from inappropriate and ongoing activation of the mucosal 
immune system driven by penetration of normal luminal flora due to tight-junction defects of the 
intestinal epithelial barrier. Our results showed a protective effect of Butyrate and FBA in restoring 
transcriptional levels of two major tight junction as occludin and ZO-1 (data not shown). These data 
demonstrate that butyrate has a noticeable effects on colonic epithelial integrity and physiology. 
The altered TJ structure in ulcerative colitis results in impaired barrier function, which may lead to 
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increased uptake of luminal antigens and/or adjuvants that overwhelm the net suppressive tone of 
the mucosal immune system [546]. SCFAs modulate key epithelial cell functions that help to 
maintain intestinal epithelial barrier integrity against injury [547]; however, the precise innate 
immune mechanisms of beneficial host-microbial interactions are not yet fully understood. Peng L 
et al., [623] demonstrated that butyrate enhances the intestinal barrier by facilitating tight junction 
assembly via activation of AMPK in Caco-2 cell monolayer. So, our results showed a protective 
effect of Butyrate and FBA in restoring transcriptional levels of two major tight junction as 
occludin and ZO-1. These data demonstrate that butyrate has a noticeable effects on colonic 
epithelial integrity and physiology. Furthermore, butyrate ability to improve gut permeability was 
shown in a model of cow’s milk allergy (CMA) induced by BLG (β-lactoglobulin) sensitization 
(Berni Canani et al, submitted)*. Here, in fact, mice were treated by daily gavage with 20 
mg/kg/day of sodium butyrate, beginning at two weeks prior to sensitization and continuing 
throughout the sensitization protocol. In this work the authors display that oral administration of 
sodium butyrate reduced plasma levels of FITC-Dextran and ameliorated gut barrier integrity in 
mice with CMA. The most important effect of gut permeability integrity is the reduction of bacterial 
translocation and maintenance of mucosal immunity homeostasis. In fact DAMPs and PAMs 
penetration determine a strong recruitment of immune cells in infection site and subsequent 
inflammation establishment. While recent studies have focused mainly on lymphocytes or antigen-
presenting cells such as dendritic cells, little is known about the pathogenic role of neutrophils in 
ulcerative colitis. Indeed, dense neutrophil infiltration and crypt abscess formation are characteristic 
pathological findings in the inflamed mucosa of these patients [624]. Moreover, in Japan, 
granulocyte adsorption apheresis therapy has been reported to show a remarkable therapeutic effect 
in active colitic patients [625]. Taken together these data support the idea that neutrophils can play 
an important role in the pathogenesis of this pathology. In fact, trans-epithelial migration of PMNs 
from the microcirculation to the mucosa results in impaired barrier function and destruction of 
tissue [626]. Consistent with literature data, we observed strong PMN infiltration in colonic tissue 
obtained from DSS-challenged mice. In fact, in these mice MPO activity (the neutrophil’s most 
abundant enzyme stored in the azurophilic granules), and Ly-6G mRNA levels were significantly 
up-regulated compared with control group. In our studies, we have used the marker Ly-6G to 
uniquely identify neutrophils in colonic mucosa. Henderson et al., [627] described that markers 
such as NIMP-R14 and GR-1, widely used to define the neutrophil lineage, not only detect 
neutrophils but also subsets of macrophages and even lymphocytes. Our study shows that Ly-6G, 
reacting only with neutrophils, is a very useful marker to detect specifically cells of the neutrophil 
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lineage [628], which was also recently described in a study by Tsou et al., [629]. Our results not 
only show a strong infiltration of neutrophils but also a co-localization between Ly-6G and Annexin 
A1 positive cells. Annexin A1 is a 37 kDa protein (also known as lipocortin 1; encoded by ANXA1) 
and is a member of a superfamily of annexin proteins that bind acidic phospholipids with high 
affinity in the presence of Ca
2+
 [630]. It can be considered one downstream mediator of 
glucocorticoids action. In fact, administration of glucocorticoids to healthy human volunteers leads 
to an increase in the levels of Annexin A1 expression by circulating monocytes and neutrophils 
[631]. In resting conditions, human and mouse neutrophils, monocytes and macrophages 
constitutively contain high levels of Annexin A1 in their cytoplasm [632,633]. Following cell 
activation (for example, by neutrophil adhesion to endothelial-cell monolayers), Annexin A1 is 
promptly mobilized to the cell surface and secreted [634]. The molecular mechanisms that are 
responsible for this rapid secretion are cell specific. Increased expression and secretion of AnxA1 
has been reported to occur in inflamed mucosal tissues in rodent models of colitis as well as in 
human ulcerative colitis [635,636]. Given the homeostatic and anti-inflammatory properties of 
AnxA1, it is likely that this increased expression might serve to counteract pro-inflammatory and 
injurious responses in the mucosa. However, experiments demonstrating the functional significance 
of such increased AnxA1 expression in the injured intestine are lacking. We therefore sought to 
examine the expression and role of AnxA1 in the DSS-induced acute colitis model. We first 
examined the transcriptional levels of AnxA1 in colonic mucosa in DSS-treated and untreated 
BALB/c animals. As shown in Fig. 8.3A, real-time PCR analysis of colonic mRNA revealed 
increased expression of AnxA1 in DSS-treated animals compared with untreated controls. The 
effects of AnxA1 are mediated via Gi-protein-coupled receptors, Fpr1 and Fpr2 [622]. In similar 
way, transcriptional levels of both these receptors were increased in DSS-alone mice. It is of 
interest to note that increased susceptibility, mucosal injury, and clinical morbidity were observed 
in AnxA1-deficient mice administered DSS. This dys-regulated inflammatory response is 
compounded by an ablated recovery following withdrawal of DSS administration, thereby 
providing strong proof-of-concept to the pro-resolving nature of AnxA1 in gut inflammation [598]. 
Furthermore, Babbin et al., [598] showed an increase of Annexin A1 in both crypt and surface 
intestinal epithelial cells following 7% DSS treatment for 7 days. In our condition, we found high 
levels of AnxA1 in colonic mucosa of DSS-challenged mice but this proresolving factor was 
located principally in neutrophils rather than in epithelial cells. Probably this condition is due to 
differences in the experimental protocols applied. In fact, 7% DSS administration for 7 days elicits 
a stronger injury rather than 2.5% administered over 5 days. So, considering AnxA1 involvement in 
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epithelial repair [637], it could be plausible that upon presence of a severe injury, this pro-resolving 
factor may be secreted by intestinal epithelial cells. At lower degrees of damage, the mediator is 
mostly if not exclusively associated with infiltrated neutrophils. In relation to the effects of butyrate 
on neutrophil chemotaxis, investigations have produced discordant results [109,394,395]. In these 
cases, butyrate could influence chemotaxis of immune cells but the ultimate effect depended on the 
type of immune cells and concentration of butyrate applied, as well as on the species [424]. In our 
study we showed that Butyrate and FBA up-regulated GPR43 mRNA levels in colonic mucosa. At 
same time we confirmed the involvement of this receptor in neutrophil recruitment. Thus, as shown 
in Fig. 8.5C, GPR43 was co-localized with neutrophil cells only in DSS-challenged mice. So these 
data suggest that in inflammatory conditions GPR43 can regulate neutrophil chemotaxis while 
Butyrate and FBA, improving intestinal barrier integrity and reducing immune cells recruitment, are 
able to increase GPR43 expression only on intestinal enteroendocrine L cells [638]. Taken together 
these actions, both butyrate-based compounds displayed anti-inflammatory properties.  
This protocol for DSS-induced colitis model reproduced the typical events of active and 
transition phases of self-resolving acute inflammatory process. In this phase, in fact, after 
penetration of DAMPs and PAMPs due to altered barrier integrity or impaired antimicrobial peptide 
secretion by Paneth cell and mucus production by Goblet cells, these bacterial products are 
recognized by resident cells (tissue macrophage, dendritic cell and epithelial cell). 
Polymorphonuclear leukocytes (mainly neutrophils) are the first cells that extravasate into inflamed 
tissues followed by mononuclear cells. With progression of the inflammatory response, there is 
intense leukocyte influx into inflamed tissue. Butyrate and FBA reduced transcriptional levels of 
Ccl2 gene, which encodes for MCP-1, in colon tissue and thus could impair monocyte recruitment 
as confirmed reduced CD68 and CD14 mRNAs, both markers of macrophages. Besides, both 
butyrate-based compounds, as mentioned above, down-regulated AnxA1, Fpr1 and Fpr2 mRNA 
levels reducing so PMN infiltration. Productive phase of inflammation is characterized by release of 
pro-inflammatory cytokine and enzymes from immune cells [639]. In our experimental model, 
establishment of inflammation and tissue injury in DSS-treated mice was confirmed by increase in 
colon tissue of nitric oxide synthase-2 (NOS2), TNF-α, IL-6 [597] and by reduction in colonic 
mRNA levels of IL-10 and in serum adiponectin. 
IL-10 plays an important role in preventing colitis pathology. In fact, IL-10 knock out are 
prone to develop spontaneous colitis [608]. Anti-inflammatory effect of preventive and curative 
treatments with Butyrate and FBA was also evident in reducing pro-inflammatory mediators and in 
restoring anti-inflammatory ones. In spite of its clinically beneficial effects for patients suffering 
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from IBD [640], there is a lack of understanding of how SCFAs exert their anti-inflammatory 
effects. Recent studies of Chang et al. demonstrate that the short chain fatty acid n-butyrate, which 
is secreted in high amounts by commensal bacterial as Clostridiales species, can modulate the 
function of intestinal macrophages, the most abundant immune cell type in the lamina propria 
[641]. In fact, treatment of macrophages with n-butyrate led to the downregulation of 
lipopolysaccharide-induced proinflammatory mediators, including nitric oxide, IL-6, and IL-12 but 
did not affect levels of TNF-α or MCP-1. The authors attribute these effects to inhibition of HDAC 
activity in macrophages, as it is known that SCFAs inhibit HDAC activity in many cell types 
[642,643]. Furthermore, several studies demonstrate that inhibition of HDAC9 increases T 
regulatory cell (T-reg cells) function preventing and ameliorating colitis in mice [644,645]. Butyrate 
is well known to regulate gene expression epigenetically by inhibiting histone deacetylases 
(HDACs) [413,642], specifically class IIA and I of the four HDAC classes identified in mammals. 
Because class IIA HDAC has been reported to suppress T-reg cell expansion [644,646], butyrate 
may influence histone acetylation of gut CD4+ T cells to regulate epigenetically the transcription of 
the genes responsible for T-reg cell induction [647]. These findings not only link butyrate to 
commensal microbe-mediated induction of functional T-reg cells in the colonic mucosa, but also 
provide molecular insight into the therapeutic application of butyrate and how a metabolite 
produced by colonic microbial fermentation mediates host–microbial crosstalk for establishment of 
gut immune homeostasis [648]. Taken together these observations we sought to assess HDAC9 
trascriptional levels in colonic mucosa since this enzyme is a member of class IIA of HDAC family. 
As reported in Fig. 8.8C, in DSS-challenged mice we observed a significant up-regulation of 
HDAC9 mRNA levels while Butyrate and FBA were able to normalize these levels. In fact, 
butyrate has a role as an anti-inflammatory agent, primarily via inhibition of nuclear factor κB (NF-
κB) activation in human colonic epithelial cells [419], which may result from the inhibition of 
HDAC. NF-κB regulates many cellular genes involved in early immune inflammatory responses, 
including IL-1β, TNF-α, IL-2, IL-6, IL-8, IL-12, iNOS (or NOS2), COX-2, ICAM-1, VCAM-1, 
TCR-α, and MHC class Ⅱ molecules [420]. The activity of NF-κB is frequently dysregulated in 
colon cancer [421] and in IBDs, such as ulcerative colitis and Crohn’s disease [422,423]. So, we 
can suppose that one of possible mechanism of action for its anti-inflammatory effects is due to 
Butyrate and FBA ability in preventing or reducing NF-κB activation by HDAC9 inhibition. 
Numerous studies have reported that butyrate metabolism is impaired in intestinal inflamed mucosa 
of patients with IBD. Recent data show that butyrate deficiency results from the reduction of 
butyrate uptake by the inflamed mucosa through downregulation of MCT1 [428]. Butyrate transport 
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deficiency is expected to have clinical consequences. Particularly, the reduction of the intracellular 
availability of butyrate in colonocytes may decrease its protective effects toward cancer in IBD 
patients [649]. So in our model we observed a strong reduction of this transporter in colonic mucosa 
of DSS mice confirming an impairment of butyrate utilization, and oxidative stress, in colonocytes. 
Both Butyrate and FBA, only when applied alongside a curative protocol, prevented this down-
regulation bringing back MCT1 transcriptional levels to physiology. Aside from inhibition of NF-
kB activation, butyrate may exert an anti-inflammatory activity through the upregulation of PPAR-γ 
[650,651]. This nuclear receptor is a ligand-activated transcription factor highly expressed in 
colonic epithelial cells and its activation exerts anti-inflammatory effects [652]. Genetic ablation of 
PPAR-γ resulted in increased susceptibility to experimental colitis in rodents [652]. Furthermore, 
PPAR-γ protein expression is 60% lower in the inflamed colonic mucosa of UC patients compared 
with that in controls [152]. Modulation of PPAR-γ protein expression in UC may prove to be an 
interesting treatment for UC. Recent studies have shown that the nuclear receptor PPAR-γ can 
inhibit NF-kB activation and cytokine expression in monocytes [653] and in murine and human 
colonic epithelial cells [654,655]. Our hypothesis is that butyrate up-regulates PPAR-γ in epithelial 
cells, where this acts in a negative feedback loop, uncoupling NF-kB –dependent target genes that 
are important for inflammatory responses [656]. In fact, Butyrate and FBA restored PPAR-γ mRNA 
levels in colonic mucosa reducing cytokines release and inflammatory status, and improving 
intestinal homeostasis. 
 
8.5 Conclusions 
In conclusions these data show that Butyrate and FBA are able to improve gut permeability 
avoiding bacterial translocation and impairing immune cell recruitment. These anti-inflammatory 
effects are visible as reduction in neutrophil infiltration and reduced HDAC9 transcription in 
colonic mucosa. These events improve intestinal immune homeostasis and tolerance vs. commensal 
bacteria. In addition, butyrate-based compounds restored colonocyte ability to up-take butyrate after 
fiber digestion: this occurred with unaltered PPAR-γ levels but blocking NF-kB activation, all 
leading to colonocyte protection fom the inflammatory condition. Efficacy of Butyrate to limit early 
molecular events underlying inflammatory process linked to intestinal damage, suggests its 
potential clinical utility as a preventive and therapeutic strategy for UC. Since FBA does not have 
the characteristic odor of rancid cheese, this derivative may represent a viable therapeutic 
alternative to Butyrate, favoring a better compliance and a greater effectiveness. 
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GENERAL CONCLUSIONS 
 
The study of intestinal microbiota composition and its role in different pathological conditions 
has greatly helped our understanding on the potential use of probiotics in liver (from simple 
steatosis to steatohepatitis), and in gut disease. It is now clear that not all probiotics may have the 
same effects. High-quality preclinical studies and few randomized controlled trials support the 
therapeutic use of probiotics in gastrointestinal diseases. Unfortunately, these data could not be 
extrapolated for all probiotic compounds now available on the market. The rationale of the use of 
mixtures of bacteria is based on the possible combination of different mechanisms of action of 
individual strains. Additional carefully designed, mechanistic-based laboratory and clinical studies 
need to be undertaken to provide scientific evidence for the efficacy in NAFLD and ulcerative 
colitis therapy of probiotics alone or in appropriate synergistic combination between strains or with 
some prebiotics. Keeping in mind “primum non nocere,” in the future, nutrients containing pre-
probiotics will very likely be considered a new nutritional approach in these patients. 
Short-chain fatty acids are important end-products of probiotic fermentation and so they 
should be considered as “postbiotics”. Among the SCFAs produced in the human intestine, 
butyrate has been widely studied and has been shown to play an important role in the maintenance 
of colonic health. Increased butyrate production in the large intestine seems to be responsible for at 
least some of the protective effects of fermentable dietary fibre. However, it should be taken into 
account that the effects of increased butyrate production may be connected with other effects of 
dietary fibres and their fermentation, such as changes in the composition of the intestinal microbiota 
and increased faecal bulking. The effects of butyrate are diverse and complex and involve several 
distinct mechanisms that go beyond the classical impact as an energy source for the intestinal 
epithelial cells. Frequently described are the effect on gene expression because of the inhibition of 
histone deacetylase and the suppression of NF-kB activation. Hence, butyrate exerts multiple effects 
such as the inhibition of colonic carcinogenesis, inflammation and oxidative stress, the 
improvement of the colonic defence barrier function and the promotion of satiety. These effects are 
not only at intestinal but also at extraintestinal level. In fact butyrate is able to prevent the main 
events which underline NAFLD pathogenesis like liver inflammation, insulin-resistance and tissue 
adipose disfunction. 
In the last decade, several new insights into possible mechanisms and effects revealed that 
butyrate is a pivotal metabolite produced within the large intestine. However, these new insights are 
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mainly based on in vitro data, animal models and some clinical intervention studies. More emphasis 
should be placed on clinical studies to elucidate the role of butyrate in health and disease.  
In these three years our aim was to confirm probiotics and postbiotic efficacy in 
gastrointestinal diseases. Considering the strength anatomical correlation between liver and gut, we 
wanted to observe if microorganisms present in gut like probiotics and their postbiotic derivate 
(SCFAs), were able to prevent or cure not only local intestinal disease but also to limit systemic 
pathologies like liver steatosis and insulin-resistance. Our results show a protective and curative 
effect of probiotics and SCFAs in limiting the onset and the progression of these gastrointestinal 
tract affections. We propose some mechanisms of action for these effects but other studies are 
necessary to clarify the exact mechanism/s by which probiotics and postbiotics could mediate their 
efficacy. Surely the first step is represented by restoring gut microflora environment. In fact, 
probiotics can compete with pathogen bacteria avoiding them to attach intestinal epithelium and so 
to stimulate immune response. Probiotics can act also indirectly by enhancing postbiotics 
production which in turn, lowering pH create a unfavorable environment for bacteria overgrowth. 
Furthermore, both probiotics and SCFAs are able to influence directly colonic functions improving 
innate immune defense mechanisms. In fact, from our data it appears evident that Lactobacillus 
paracasei B21060 and butyrate-based compounds improved not only tight-junction structure, 
reducing so intestinal permeability but also mucin and defensine production stmulating in this way 
antimicrobial properties of intestinal epithelial cells. Alteration of tight-junctions or mucin 
production together with changes in microbiota composition, can be considered as predisposing 
factors to development of gastrointestinal disease. Specially in western life style, bad alimentary 
habits taken together with smoke or alchol consumption, represent a favourable situation for the 
onset of these conditions. In this context, daily assumption of probiotics or directly of their derivate 
compounds as butyrate, could be considered a valid approach for prevention or treatment of 
gastrointestinal pathologies. For example, in our model of NAFLD and UC both Flortec and 
butyrate prevented the beginning of the principal events which underlie progression of these 
conditions such as insulin-resistance (for NAFLD) and weight loss (for UC). 
Many literature data propose one or more possible mechanisms of action for these agents. The 
question is how probiotics or small molecules as short chain fatty acids, can mediate systemic 
effects like insulin-resistance, obesity or liver steatosis. We suggest a mechanism based on 
restoration of intestinal “good” microflora and gut barrier function, avoiding bacterial traslocation 
which, via portal vein circulation, could join liver and here induce inflammation preceding steatosis 
and IR. In fact in our experimental condition we discovered that treatment with probiotic and 
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SCFAs was able to restore TLRs pathway in liver tissue. These receptors link bacterial derived 
products and resulted incresead by high fat diet assumption. How is it possible that PAMPs or 
DAMPs which normally induce TLRs activation in gut epithelium, carry out their actions also in 
another tissue? And especially, how is it realizable that probiotics and short chain fatty acids which 
are produced in gastrointestanl tract, are able to influence metabolic process in liver and adipose 
tissue? Our results confirmed that modulation of microbiota can improve functionality of other 
tissues and contribute to host health. Besides, beneficial effects of pro- and postbiotic are 
principally local. In-fact during inflammatory conditions, due to ulcerogenic agents or intestinal 
dysbiosis, these compounds restore altered microflora and reduce inflammatory mediators 
production. To this regard, in our experimendal protocol of sodium dextran sulphate induced colitis, 
we observed not only preventive but also curative proprieties of Flortec and both butyrate 
compounds. In fact, our pharmacological treatments exhibited a strong efficacy in reduce colonic 
inflammation, immune cells recruitment and tissue damage. Furthermore about macroscopic 
aspects, animals treated with pro- and postbiotics were protected by colitis symptoms such as 
weight loss, rectal bleeding and diarrhea. These data suggest a potential utility of these compounds 
not only during acute phase of pathology but also in preventing relapse of disease. About the 
pathogenesis of colitis, many experimental works underlie the presence of a deregulated microflora 
and an abnormal immune response against it. In addition to this issue, genetic mutations in TLRs or 
NOD receptors pathway should play an important role in the onset of this condition. It is well 
known that Lactobacillus paracasei B21060 has immunomodulatory abilities and that butyrate is 
able to influence T-reg activity in colonic lamina propria, so it is possible the use of these agents as 
adjuvant therapy for treatment of mild to moderate colitis. In fact our results confirme an useful 
clinical application for Flortec, sodium butyrate and FBA as curative or preventive protocol. 
Regarding obesity is well known that high fat diet is responsable for establishment of an 
“high fat microbiota”. This altered microflora extracts from dietary assumption an excessive 
quantity of calories and this issue could aggravate obesity condition. So maintenance of a good 
microflora homeostasis, associated with correct dietary habits, contribute to body healthy condition. 
Nowadays is too difficult specially among paediatric population to obtain respect of healthy dietary 
habits and correct lifestyle. Furthermore actual therapeutic strategies for treatment of NAFLD and 
UC are represented by TZDs or metformin and salicylate or corticosteroids, respectively. All these 
drugs are linked to many collateral effects and could be considerate inappropriate for paediatric 
patients. So probiotics and butyrate represent a valid therapeutic possibility alone or in combination 
with traditional drugs for prevention or treatment of NAFLD and mild to moderate ulcerative 
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colitis. In fact, our data show that Flortec, sodium butyrate and FBA were able to prevent and limit 
the onset and the progression of NAFLD and ulcerative colitis, improving hepatic steatosis together 
with insulin-resistance and liver damage, and reducing colonic inflammation and intestinal injury. 
Furthermore, we obtained a new chemical derivate (FBA) of sodium butyrate which lose bad odour 
of rancid cheese, and so it could represent a good therapeutical alternative to butyrate, showing a 
more favorable compliance an a better efficacy in intestinal and extraintestinal diseases. 
175 
 
ABBREVIATIONS: 
 
4-HNE, 4-Hydroxynonenal 
4-PBA, Sodium phenylbutyrate 4 
5-ASA, 5-Aminosalicylic acid 
5-HT, 5-Hydroxytryptamine 
AhR, Aryl hydrocarbon receptor 
ALT, Alanine transaminase 
AMPK, Adenosin monophosphate kinase 
AnxA1, Annexin A1 
AP1, Activator protein 1 
ASC, Apoptosis-associated speck-like protein 
AST, Aspartate aminotransferase 
ATG16L1, Autophagy-related protein 16-1 
BDNF, Brain-derived neurotrophic factor 
BLG, β-lactoglobulin 
BLIS, Bacteriocin-like inhibitory substances 
BrdU, Bromo-2’-deoxyuridine 
c-Cbl, Casitas B-lineage Lymphoma 
CD, Crohn’s disease  
CD14, Cluster of differentiation 14 
CDH1, Cadherin-1 
CFTR, Cystic fibrosis transmembrane conductance regulator 
ChAT, Choline acetyltransferase 
ChREBP, Carbohydrate response element-binding protein 
CLD, Congenital Chloride Diarrhea 
CMA, Cow’s milk allergy 
COX-2, Cyclooxygenase-2 
CREB, Phospho-cAMP response element-binding protein 
CRP, C-reactive protein  
DAI, Disease activity index 
DAMPs, Damage-associated molecular patterns 
DAP, Diaminopimelic acid  
DCs, Dendritic cells 
Defb1, β-defensin 1 
DGAT1/2, Diacylglycerol acyltransferase 1 and 2 
DIO, Diet inducing obesity 
DNL, de novo hepatic lipogenesis 
DSS, Sodium dextran sulphate 
ENS, Enteric nervous system 
ERK, Extracellular receptor kinase 
FBA, Phenylalanine-butyramide 
FDA, Food and Drug Administration 
FFAR, Free fatty acid receptor 
FFAs, Free fatty acids 
FGF21, Fibroblast growth factor 
Fiaf, Fasting-induced adipocyte factor 
FOS, Fructooligosaccharides 
Fpr1, Formyl peptide receptor 1 
Fpr2, Formyl peptide receptor 2 
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase 
GBF, Germinated barley foodstuff 
GLP-1, Glucagon-like peptide 1  
GLUT4, glucose transporter 4 
GM-CSF, Granulocyte-macrophage colony-stimulating factor 
GOSs, Galactooligosaccharides  
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Gpr41 and Gpr43, G protein–coupled receptors 41 and 43 
GSTs, glutathione-S-transferases 
HbF, Fetal hemoglobin 
HCV, Hepatitis C virus  
HDAC, Histone deacetylase 
HFD, High-fat diet 
HLA-DR, MHC class II cell surface receptor 
HMGB1, High mobility group box 1 
HNF4A, Hepatocyte nuclear factor 4 
HOMA, Homeostasis model assessment 
HSPs, Heat shock proteins 
IBD, Inflammatory bowel disease 
IBS, Irritable bowel syndrome 
ICAM-1, Intercellular adhesion molecule-1 
IECs, Intestinal epithelial cells 
IFN-γ, Interferon gamma 
IKK β, Nuclear factor-kB kinase-β 
IL-18R, Interleukin 18 receptor 
IL-6, Interleukin-6 
iNOS, Inducible nitric oxide synthase 
IPAA, Ileal pouch–anal anastomosis 
IR, Insulin resistance  
IRF5, Interferon regulatory factor 5 
IRGM, Immunity-related GTPase family M protein 
IRS-1, Insulin receptor substrate 
ITF or TFF3, Intestinal trefoil factors 
JAK2, Janus kinase 2 
JNK1, c-Jun N-terminal kinases 
LAB, Lactic acid bacteria  
LAMB1, Laminin beta 1  
LCPT1, Carnitine palmitoyl transferase I 
LDL-C, Low density lipoprotein- cholesterol 
LPL, Lipoprotein lipase inhibitor  
LPS, Lipopolysaccharide 
MALT, Mucosa-associated lymphoid tissue 
MAMPs, Microbe-associated molecular patterns 
MAPK, Mitogen-activated protein kinase 
MCD, Methionine choline-deficient 
MCP-1, Monocyte chemoattractant protein 1 
MCT1, Monocarboxylate transporter isoform 1 
MDA, Malonyl dialdehyde 
MMPs, Metalloproteinases 
MSU, Monosodium urate crystals 
MUC2, Mucin-2 
MyD88, Myeloid differentiation primary response 88 
NAFLD, Non-alcoholic fatty liver disease 
NASH, Nonalcoholic steatohepatitis  
NE, Neutrophil Elastase 
NEFA, Nonesterified fatty acids 
NF-kB, Nuclear factor-kB 
NKT, Natural killer T cell 
NKX2-3, NK2 homeobox 3 
NLRP, NOD-LRR- and pyrin domain-containing 
NLRs, Nucleotide binding oligomerization-domain protein-like receptors 
nNOS, Neuronal nitric oxide synthase 
NOD2, Nucleotide-binding oligomerization domain-containing protein 2 
NOS2, Nitric oxide synthase-2 
NRP-1, Neuropilin-1 
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p38 MAPK, p38 mitogen-activated protein kinase 
PAMPs, pathogen-associated molecular patterns 
pANCA, Perinuclear antineutrophilic cytoplasmic antibodies 
PGC-1α, Peroxisome proliferator-activated receptor (PPAR) coactivator-1α 
PKA, Protein kinase A 
PLC, phospholipase C 
PPAR- , peroxisome proliferator-activated receptors  
PPAR- , peroxisome proliferator-activated receptor  
PRDM1, PR domain containing 1 
PTP1B, Tyrosine phosphatase 1B 
PTPN2, Tyrosine-protein phosphatase non-receptor type 2  
PYY, Peptide YY 
RegIIIγ, Regenerating islet derived 3-gamma 
RIP, Receptor interacting protein 
ROI, Reactive oxygen intermediates 
ROS, Reactive oxygen species 
SCFAs, Short chain fatty acids 
Sirt1, Sirtuin 1 
SLC26A3, Solute-linked carrier family 26-member A3 
S-NO, S-nitrosothiols  
SOCS3, Suppressor of cytokine signalling 3 
SREBP, Sterol regulatory element- binding protein 
STAS, Anti-sigma factor antagonist 
STAT, Signal transducer and activator of transcription 
T2DM, Type 2 diabetes 
TCDD, 2,3,7,8-tetrachlorodibenzodioxin  
TCR-α, T cell receptor-α 
TFAs, Trans fatty acids 
TG, Triglyceride 
TGF, Transforming growth factor 
TJs, Tight junctions  
TL1A, Tumor necrosis factor–like ligand 1 
TLRs, Toll-like receptors 
TNBS, 2,4,6-trinitrobenzenesulfonic acid 
TNF- , tumor necrosis factor  
TRADD, TNF receptor-1 associated death domain protein 
TRAF2, TNF receptor-associated factor 2;  
Treg, Regulatory T cells 
TZDs, Thiazolidinediones 
Ub, Ubiquitin mediated 
UC, Ulcerative colitis  
UCP-2, Uncoupling protein-2 
UPR, Unfolded protein response  
VCAM-1, Vascular cellular adhesion molecule-1 
VEGF, Vascular endothelial growth factor 
X-ALD, X-linked Adrenoleukodystrophy 
XBP1, X-box binding protein 1 
ZO-1, Zonula occludens-1 
α-SMA, Alpha smooth muscle actin 
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